Engineering rFVIIa-loaded platelets; a novel approach to treating acute bleeding by Mookerjee, Souradip
Engineering rFVIIa-loaded platelets; 






St Catharine’s College 
 
This thesis is submitted on November 2020 for the degree of Doctor 
of Philosophy 





This dissertation is the result of my own work and includes nothing which is the 
outcome of work done in collaboration except as declared in the Preface and 
specified in the text. It is not substantially the same as any that I have submitted, 
or am concurrently submitting, for a degree or diploma or other qualification at the 
University of Cambridge or any other University or similar institution except as 
declared in the Preface and specified in the text. 
I further state that no substantial part of my dissertation has already been 
submitted, or is being concurrently submitted, for any such degree, diploma or 
other qualification at the University of Cambridge or any other University or similar 
institution except as declared in the Preface and specified in the text. This 








The copyright of this thesis rests with the author. Unless otherwise indicated, its 
contents are licensed under a Creative Commons Attribution 4.0 International 
Licence (CC BY). 
Under this licence, you may copy and redistribute the material in any medium or 
format for both commercial and non-commercial purposes. You may also create 
and distribute modified versions of the work. This on the condition that you credit 
the author. 
When reusing or sharing this work, ensure you make the licence terms clear to 
others by naming the licence and linking to the licence text. Where a work has 
been adapted, you should indicate that the work has been changed and describe 
those changes. 
Please seek permission from the copyright holder for uses of this work that are 
not included in this licence or permitted under UK Copyright Law. 





Engineering rFVIIa-loaded platelets; a novel approach to 
treating acute bleeding 
Souradip Mookerjee, St Catharine’s College 
Haemorrhage remains a leading cause of mortality around the world, resulting 
from both trauma and surgery. Current treatments for acute haemorrhage include 
blood products such as fresh frozen plasma, as well as platelet transfusion and 
recombinant clotting factors such as rFVIIa. However, the use of recombinant 
clotting factors is limited due to cost and adverse side effects resulting from 
increased thrombosis, such as increased rate of myocardial infarction and 
cerebrovascular accidents. 
Platelets are small anucleate cells that exist in very large quantities in our blood 
and, along with cross-linked fibrin from the coagulation cascade, are involved in 
forming a haemostatic plug upon exposure to damaged endothelium in a wound. 
They are metabolically active and undergo a process of platelet activation when 
stimulated by pro-thrombotic agonists such as thrombin resulting from the 
coagulation cascade. This then triggers a process whereby the contents of their 
granules are released locally to facilitate coagulation. 
This thesis explores the possibility of loading these platelet granules with 
recombinant clotting factors, in this case rFVIIa which has already been shown in 
clinical trials to result in a significant decrease in mortality from acute 
haemorrhage. The targeted delivery of this drug is explored, both through 
endocytosis and genetic engineering of megakaryocytes differentiated in vitro 
from induced pluripotent stem cells (iPSCs). These are evaluated with in vitro 
assays to model the process of clot formation, as well as an in vivo model of 
haemostasis to compare their efficacy to conventional treatments. Overall, this 
serves as a proof of concept of the engineering of platelet granules as a novel 
drug delivery system. 
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1  INTRODUCTION 




1.1 An introduction to platelets 
Platelets are anucleate, discoid cells with a radius of 2.6µm-2.9µm (Figure 1.1). 
They are the smallest cells circulating in human blood at an average 
concentration of 150-400x109 per litre. They last for around ten days in the 
circulation meaning that daily, megakaryocytes release 1/10th of the platelet mass 
into the circulation and that 1/10th of the circulating platelets are cleared in the 
spleen and the liver (Kaplan and Saba, 1978). Their primary physiological function 
is in haemostasis where they can sense damaged endothelium and accumulate 
at the site of injury, initiating blood clot formation to block the circulatory leak 
although recent work has shown them to be important in many immunological 
functions (Semple, Italiano and Freedman, 2011). Although they lack a nucleus, 
platelets remain metabolically active and can sustain de novo translation from 
remnant mRNAs (Weyrich et al., 2004). 
 
 
Figure 1.1. Schematic and real electron micrograph of the ultrastructure of platelets. 
(A) A schematic of platelet ultrastructure in the equatorial plane (upper image) and 
in cross section (lower image). Reprinted under the CC BY license from 
Transmission Electron Microscopy of Platelets From Apheresis and Buffy-Coat-
Derived Platelet Concentrates (Neumüller, Ellinger and Wagner, 2015) (B) An 
electron micrograph of a platelet showing some of these features highlighted in real 
platelets. (Reprinted by permission from Springer Customer Service Centre GmbH: 
Springer Nature, Nature Reviews Immunology: Platelets and the Immune 
Continuum. Semple, Italiano and Freedman © 2011; permission conveyed through 
Copyright Clearance Center, Inc) 
Abbreviations: DTS = dense tubular system, Gly = glycogen, α = α-granules, δ = δ-
granules or dense bodies, λ = λ-granules or lysosomes, GR = Golgi remnants, MF 
= microfilaments, Mit = Mitochondria, OCS = open canalicular system, P = pores of 
the OCS, Pin = pinocytosis, Rib = ribosomes, MTC = microtubular coil. 
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1.2 Megakaryopoiesis and thrombopoiesis in vivo 
Platelets arise from larger (10-65µm) polyploid cells known as megakaryocytes 
(MKs) that are, in turn, derived from haematopoietic stem cells (HSCs) in the bone 
marrow (Levine, Hazzard and Lamberg, 1982). The process of these stem cells 
differentiating to form megakaryocytes is known as megakaryopoiesis, while the 
process by which these polyploid multinucleate megakaryocytes fragment to form 




Figure 1.2. An overview of differentiation from HSCs to megakaryocytes in vivo, 
followed by thrombopoiesis to give rise to platelets in the circulation. (Figure by 
Thomas Moreau, unpublished, reproduced with permission). 
 An introduction to stem cells 
A stem cell is defined as a cell that has the properties of being able to self-renew 
and to differentiate to produce more specialised cells, leading to a loss of some 
of the stem cell’s development potential. Pioneering work in the 20th century 
defined the power of a single cell to fully regenerate tissues destroyed by radiation 
(Weissman, 2014). This idea arose originally from studies in the haematopoietic 
system, after the atom bomb was deployed, it became clear in animal models that 
the lowest lethal dose effectively eliminated the blood-forming system, resulting 
in death within two weeks (Weissman, 2014). At the height of the cold war, there 
was much research on how to counteract these effects through bone marrow 
transplantation. The dominant theory of the day was that a transplant from an 
unirradiated donor released factors that drove the repair of the irradiated host 
cells (Jacobson et al., 1951). Two important papers reversed this notion, using 




either mice bearing a chromosome marker or rats with their own histochemically-
trackable chromosomes as a bone marrow donor to show that at least early post-
treatment survival was driven by the regeneration of blood-formation by the donor 
cells rather than by host cells repaired by the postulated factors  (Ford et al., 1956; 
Nowell et al., 1956). 
Type of Stem Cell Differentiates into Example of cell: 




Pluripotent All embryonic tissues Embryonic stem cell 
(ESC), induced 
pluripotent stem cell 
(iPSC) 
Multipotent All lineages of a 
tissue/organ 
Haematopoietic stem 
cell (HSC), neural 
stem cell (NSC) 






Bipotent Two different lineages  Megakaryocyte 
erythroid progenitor 
(MEP) 
Unipotent/Progenitor cell One lineage  Macrophage 
progenitor 
Table 1.1. A summary of the different types of stem cells identified in vivo, categorised by 
their potential for differentiation. 
McCulloch and Till gave bone marrow transplants to heavily irradiated mice and 
showed that these cells migrated to the spleen and were able to form nodules 
there that reconstituted the haematopoietic system of these animals (McCulloch 
and Till, 1960; Becker, McCulloch and Till, 1963). Within each nodule, they 
identified donor cells of several different lineages (erythrocyte-forming, platelet-
forming and leukocyte-forming) and used abnormal chromosome marker studies 
to establish the clonal nature of these nodules. This, combined with the direct 
linear relationship between the number of cells transplanted and number of 
nodules formed, led to the conclusion that each nodule represented the progeny 
of a single transplanted bone marrow cell. They also demonstrated that cells 
within the colony could give rise to additional colonies after serial transplantation 
into a second recipient (the now classic assay of self-renewal potential). Based 
around the numbers of bone marrow cells required for a successful transplant, 
they also concluded that this cell capable of both self-renewal and differentiation 
was rare in the bulk population. Furthermore, these nodules (that they named 




‘colony forming units in the spleen’, or ‘CFU-S’), were noted to have a variable 
capacity for self-renewal, giving rise to the idea of functional heterogeneity and 
that not all stem cells are created equal (Siminovitch, McCulloch and Till, 1963). 
Subsequent work over the decades established that the zygote itself was a 
‘totipotent’ stem cell, and as these cells divided and specialised into various bodily 
tissues, they became more restricted to only forming cells within each lineage 
(Zakrzewski et al., 2019) and that regulation of clonal expansion may be 
stochastic (Wiesner et al., 2018). Eventually, the cell giving rise to all the lineages 
of the blood system became known as a haematopoietic stem cell, and other 
identified stem cell types are outlined in Table 1.1. 
 HSC maintenance in bone marrow 
Stromal co-cultures were used to maintain HSC cultures in vitro, and it became 
clear that in vivo HSC survival was also dependent upon support from populations 
of non-haematopoietic cells in the bone marrow (Dexter, Allen and Lajtha, 1977). 
Functional colony forming assays made clear that these HSCs were not randomly 
distributed in the bone marrow, but existed within a well-defined spatial 
organisation in the endosteal region of the bone marrow (Lord, Testa and Hendry, 
1975). Combined with observations that recovery of CFU-S in the recipient 
proceeded differently depending upon the cytotoxic regime used to bring about 
the depletion, and that the theoretical ‘immortality’ a stem cell should possess 
was at odds with experimental findings suggesting an ‘age-structure’, the 
existence of a ‘stem cell niche’ was hypothesised, drawing parallels with the field 
of ecology (Schofield, 1978). Schofield’s theory outlined that these stem cells 
were in a defined anatomical location and that removal of stem cells from this 
niche resulted in differentiation, and that this specialised microenvironment had 
additional functions, such as the ability to impose a stem-like state onto 
differentiated cells, and a mechanism to limit the accumulation of genetic mutation 
in stem cells by restricting their cell cycle until necessary. 
HSCs were identified by flow cytometry through a combination of antibodies and 
fluorophores too complex to replicate with immunofluorescence (Spangrude, 
Heimfeld and Weissman, 1988; Morrison and Scadden, 2014). The development 
of tools required to directly image HSC localisation with confidence in 
haematopoietic tissues took over 25 years. A simplified cell surface marker 
selection and the identification of genetic markers made it possible to generate 
GFP-tagged mice (Nombela-Arrieta et al., 2013; Morrison and Scadden, 2014; 
Acar et al., 2015; Chen et al., 2016). Analysis of the localisation of these cells in 
tissue sections showed that most HSCs reside in areas adjacent to the sinusoidal 




blood vessels in the bone marrow and spleen, leading to the proposal of a 
perivascular niche for HSCs (Kiel et al., 2005). 
Soluble factors that are non-cell-autonomously required to maintain HSC 
populations were discovered through conditional genetic deletion studies of the 
factor receptor in HSCs. These include SCF (that binds to its receptor KIT, 
expressed by HSCs) (Barker, 1994), CXCL12 (through binding to its receptor 
CXCR4) (Nagasawa et al., 1996) and TPO (binding to c-Mpl) (Kimura et al., 
1998). Many other factors have also been identified that do not appear to be 
required for HSC maintenance under steady state conditions but can promote 
HSC regeneration after injury, including angiogenin (Goncalves et al., 2016), 
angiopoietin-like protein 3 (Zheng et al., 2011), FGF1 (Zhao et al., 2012), FGF2 
(Itkin et al., 2012), IL-6 (Bernad et al., 1994), Notch-2 (Varnum-Finney et al., 2011) 
and pleiotropin (Himburg et al., 2014).  
Cell ablation studies were used to identify other cell types involved in maintaining 
this microenvironment. This identified many stromal cell populations, including 
osteoblasts (Visnjic et al., 2004), CXCL12-adundant reticular (CAR, also 
described as perivascular stromal) cells (Omatsu et al., 2010), leptin receptor-
expressing (LEPR+) cells (Zhou et al., 2014), Nes-CreER+ (Nestin+) cells 
(Méndez-Ferrer et al., 2010)  and Ng2-CreER+ cells (Kunisaki et al., 2013), as 
well as differentiated haematopoietic cells themselves such as megakaryocytes 
(Bruns et al., 2014) and macrophages (Chow et al., 2011). In each case, HSCs 
entered the cell cycle and/or became depleted after the ablation of the respective 
cell populations, suggesting a loss of the niche environment. 
These studies remain controversial; some have commented upon how there has 
been no cell type that has yet been ablated and not shown to induce HSC 
activation or depletion (Crane, Jeffery and Morrison, 2017). This has led to 
speculation that there is widespread cross-talk where many cells indirectly 
regulate other cells in the bone marrow. This is apparent when vascular cells are 
ablated, leading to a disruption of blood flow through the bone marrow (e.g. Nes-
CreER is expressed by bone marrow endothelial cells (Ono et al., 2014)). In one 
case, HSCs were only depleted weeks after osteoblast ablation when the entire 
bone marrow became pancytopenic (Visnjic et al., 2004). Observations through 
immunofluorescence show that few HSCs reside close to bone surfaces where 
osteoblasts are located and that osteoblasts do not even express the crucial niche 
factor SCF (Ding et al., 2012). 




There is evidence for MKs having a direct role on HSC maintenance by inhibiting 
HSC cell division through several redundant signalling factors. Megakaryocytes 
are situated physically close to HSCs in the perivascular region and produce 
TGFb which has been shown to inhibit HSCs in vivo (Zhao et al., 2014). 
Conditional deletion of TGFb from MKs also increase HSC proliferation in vivo. 
They are also a source of CXCL4 (also known as platelet factor 4, PF4) and 
Cxcl4-deficient mice have increased HSC numbers and proliferation (Bruns et al., 
2014). The administration of recombinant CXCL4 or TGFβ reduces the 
proliferation that is otherwise seen. 
Overall, HSCs exist in the bone marrow predominantly in well-defined anatomical 
locations in the perivascular or perisinusoidal regions and depend upon many 
non-cell-autonomous factors. SCF and CXCL12 appear the most important and 
well-studied, along with cell-cell interactions; especially with cells that produce the 
mentioned factors, including the perivascular stromal cells. These HSCs exist in 
a dynamic equilibrium between factors pulling them towards division to undergo 
haematopoiesis and quiescence in order to maintain their stem-cell-like properties 
in equal measure. The maintenance of HSCs in culture in vitro indefinitely as they 
exist in vivo remains, as of yet, impossible. 
 HSC differentiation of megakaryocyte precursor cells 
 
Figure 1.3. Waddington’s landscape, illustrating the idea that acquisition of cell fate 
can occur unidirectionally, from an immature (pluripotent) to a mature (differentiated) 
state, depicted as a ball rolling down from the top of a 'mountain' to the bottom of a 
'valley'. (Reprinted by permission from Springer Customer Service Centre GmbH: 
Springer Nature, Nature Reviews Molecular Cell Biology: A decade of transcription 
factor-mediated reprogramming to pluripotency. Takahashi and Yamanaka © 2016; 
permission conveyed through Copyright Clearance Center, Inc) 




During differentiation, HSCs progressively become more restricted in their 
lineage. In 1957, Waddington described how mammalian development is 
unidirectional, akin to a ball rolling down a mountain to the bottom of various 
valleys to represent the potential differentiation trajectories of multipotent cells 
(Waddington, 1957). Over time, a series of landmark experiments have also 
shown that cell fate is both flexible and reversible, for example, the cloning of a 
sheep from the nucleus of a differentiated cell (Wilmut et al., 1997) and the 
discovery of induced pluripotent stem cells (iPSCs), where differentiated cells can 
be induced to return to a state of pluripotency (Takahashi and Yamanaka, 2006). 
Nonetheless, bearing these caveats in mind, this still serves as a useful model to 
describe the differentiation pathway of pluripotent stem cells into 
megakaryocytes, with each valley the ball passes down representing the various 
epigenetic programming the cell acquires through this process (see Figure 1.3). 
Many groups have used lineage tracing techniques to investigate how the 
differentiation potential of HSCs become progressively restricted (Figure 1.4). Cell 
surface markers of discrete subpopulations of developing blood cells are 
analysed by flow cytometry and fluorescence-assisted cell sorting (FACS) and 
various functional assays (including in vitro colony assays and in vivo 
transplantation assays) are used to characterise their differentiation potential, 
giving rise to the classical idea of a ‘haematopoietic tree’, a highly ordered and 
deterministic process (Figure 1.4). HSCs lose their ability to self-renew while 
retaining full lineage potential in the form of multipotent progenitors (MPPs) 
(Morrison and Weissman, 1994). Eventually, they appear to form bipotent 
megakaryocyte-erythroid progenitors (MEPs) either directly or through a common 
myeloid progenitor (CMP), followed by megakaryocyte progenitors (MkPs) 
(Nakorn, Miyamoto and Weissman, 2003).  
The success of these marker-based approaches is dependent upon the existence 
of cell-surface markers specific for distinct progenitors, and that captured cell 
populations are not perturbed during functional assays; both assumptions are 
coming under scrutiny (Sun et al., 2014). Despite the unequivocal evidence for 
the hierarchical and branching nature of haematopoietic differentiation, recent 
single cell transcriptomic approaches have revealed unexpected, considerable 
heterogeneity in the classically sorted populations from Figure 1.4 (Paul et al., 
2015). This study combined massively parallel single cell RNA-seq (MARS-Seq) 
with indexed FACS and further functional assays and found that FACS markers 
were poor predictors for the single-cell-based transcriptomic clustering of cells. 
Rather than being a simple deterministic organised process, single cell data 
suggests these intermediate cells exist along a gradient with transplantation 




experiments suggesting a high degree of plasticity. For example, CD41+ MK 
progenitors in transplantation assays demonstrated the ability to still form 
erythrocyte lineages.  
 
 
Figure 1.4. Model of the hematopoietic hierarchy. The HSC resides at the top of the 
hierarchy and is defined as the cell that has both the self‐renewal capacity and the 
potential to give rise to all hematopoietic cell types (multipotency). HSCs first lose self‐
renewal capacity, then lineage potential step‐by‐step as it commits to a certain lineage. 
The cell surface phenotype of each population is shown for the mouse and human 
systems. In the mouse, evidence suggests that some of MPPs directly give rise to MEP 
without passing through CMP (dashed arrow). CLP, common lymphoid progenitor; 
CMP, common myeloid progenitor; DC, dendritic cell; EP, erythrocyte progenitor; GMP, 
granulocyte/macrophage progenitor; GP, granulocyte progenitor; HSC, hematopoietic 
stem cell; MacP, macrophage progenitor; MEP, megakaryocyte/erythrocyte progenitor; 
MkP, megakaryocyte progenitor; NK, natural killer; Lin, lineage markers. © 2010 John 
Wiley & Sons, Inc. Reprinted from Seita and Weissman, 2010 by permission conveyed 
through Copyright Clearance Center, Inc. 
Complicating matters, MKs and HSCs share many features in common, including 
dependence upon TPO signalling through the c-Mpl receptor, as well as sharing 
many surface markers between them, including CD41, CD150 and CD9 and 
mRNA transcripts of proteins such as von Willebrand Factor (VWF). There are of 
course, important differences; CD42b is only expressed by mature 
megakaryocytes and not in any progenitor (Nishikii, Kurita and Chiba, 2017). 
There may be important physiological reasons for these similarities; TPO is the 
major physiological regulator of platelet homeostasis, and in vitro can directly 
instruct HSC precursors to differentiate towards a megakaryocytic lineage (Choi 




et al., 1995; Stoffel, Wiestner and Skoda, 1996). When the platelet count is low, 
an increase in TPO levels triggers an increase in HSC differentiation towards 
megakaryocytes and platelet formation (Bartley et al., 1994). Although c-Mpl 
deficient mice have an 85% reduction in their platelet count, they are still able to 
produce platelets, suggesting redundancy and a role for other mediators in this 
process (Gurney et al., 1994). 
As the differentiation process is thought to be largely mediated by the 
transcriptional state in the cell, three groups of the driving transcription factors 
involved in megakaryopoiesis have also been identified; the GATA family, core 
binding factor (CBF) and ETS transcription factors. The presence of binding sites 
for the GATA family of zinc-finger transcription factors is a canonical feature of 
megakaryocytic promoters. GATA1 and its binding partner FOG1 have both 
shown to be important as a central broker in megakaryopoiesis and erythropoiesis 
(Stachura, Chou and Weiss, 2006). Mutations in GATA1 lead to an X-linked 
thrombocytopaenia, and as many as four distinct biochemical classes of mutation 
have been described in X-linked disorders of megakaryocyte development 
(Nichols et al., 2000). Distinct structural elements of GATA1 appear to contribute 
to different parts of megakaryopoiesis as evidenced through ex vivo rescue 
assays (Kuhl et al., 2005). 
Several megakaryocytic promoters contain CBF (also known as RUNX) sites. The 
CBF family of transcription factors consists of the three homologous DNA-binding 
proteins RUNX1-3 and a non-DNA binding component, CBFβ. Mature 
megakaryocytes express high levels of RUNX1 and low levels of RUNX3 
(Levanon et al., 2001), while inducible inactivation of either RUNX1 or its binding 
partner CBFβ in mice causes a rapid and profound disruption in 
megakaryopoiesis with limited effects on erythropoiesis (Ichikawa et al., 2004). 
This is likely mediated through its effects on expression and signalling of c-Mpl. 
ETS transcription factor binding sites occur next to most megakaryocytic gene 
promoters, often adjacent to GATA sites (Bastian et al., 1999). Three transcription 
factors in the ETS family are known to be involved in driving megakaryopoiesis, 
FLI1, GAPBα and TEL1. In mouse models, depletion of any of these three 
transcription factors leads to a specific drop in platelet counts with no effect on 
haemoglobin levels (Hart et al., 2000; Hock et al., 2004; Pang et al., 2006). FLI1 
was also discovered from mutations in humans that lead to a thrombocytopaenia 
and a characterisation of megakaryopoiesis from CD34+ HSCs derived from 
patients showed a deficiency in differentiation, recapitulated when a mouse model 




was created and rescue experiments showed that this phenotype was dependent 
upon FLI1 expression (Raslova et al., 2004). 
As well as positive regulators of megakaryopoiesis, antagonists have also been 
discovered. Through a random chemical mutagenesis screen in mice, the 
transcription factor c-Myb was identified as a potent negative modulator of 
megakaryopoiesis, acting through the recruitment of the p300 coactivator; 
mutations in either lead to the same marked elevation in platelet count and tissue 
megakaryocytes. It is likely that this acts at the level of the MEP; wild-type cultured 
MEPs gave rise to predominantly erythroid cells, c-Myb-/- MEPs gave rise to 
predominantly megakaryocytes, an effect reversed by retroviral transduction of 
functional c-Myb (Mukai et al., 2006). 
 MK production, endomitosis and cytoplasmic maturation 
Once committed to the megakaryocytic lineage, MK progenitors differentiate into 
immature megakaryocytes with a limited capacity for self-renewal and must 
undergo a series of characteristic maturation steps to become terminally 
differentiated. Interestingly, the mere translocation of megakaryocyte progenitors 
to the vicinity of bone marrow vascular sinusoids is sufficient to induce maturation, 
with the cytokines SDF-1 and FGF-4 implicated in this process (Avecilla et al., 
2004). 
Endomitosis is the first maturation step that takes place. This is a primarily TPO-
driven process through which MKs become polyploid through cycles of DNA 
replication without cell division (Ebbe, 1976; Gurney et al., 1994). The study of 
this process was facilitated through the use of in vitro culture systems using TPO. 
During their life cycle, MKs first undergo a proliferative mitotic (2n) stage in which 
their progression through the cell cycle is identical to other haematopoietic cells. 
Subsequently, during endomitosis, MKs can acquire a DNA content of 4n, 8n, 
16n, 32n, 64n and even 128n in a single polylobulated nucleus (Zimmet and 
Ravid, 2000). 
This polyploidy is likely required to produce the large quantities of mRNA and 
protein to be packaged into platelets, but the relationship between high polyploidy 
and efficient platelet production is highly debated (Zimmet and Ravid, 2000). For 
example, nicotinamide is often used to increase ploidy of human and mouse MKs 
in culture (Giammona et al., 2006), but administration of this to mice does not 
increase their platelet counts (Konieczna et al., 2013). Overexpression of cell 
cycle regulators such as cyclin D3 have been also shown to enhance MK ploidy 




in vivo without any increase in platelet count (Zimmet et al., 1997), affecting the 
G1 phase of the cell cycle (see Figure 1.5). 
There is evidence to suggest that endomitosis is due to an inhibition of late 
cytokinesis. During normal mitosis, cytokinesis occurs through the formation of a 
cleavage furrow, a contractile ring comprising of myosin II and F-actin, that 
generates the mechanical forces necessary for cell separation (Lordier et al., 
2008). RhoA, a small GTPase regulating the actin cytoskeleton, is required to 
generate this contractile force and the microtubule-associated GEF-H1 activates 
RhoA at the cleavage furrow (Birkenfeld et al., 2007), while ECT2 is involved in 
RhoA localisation and activation (Petronczki et al., 2007). 
Studies in primary MKs reveals that RUNX1 downregulates MYH10 (myosin IIB 
heavy chain) (Lordier et al., 2012), and that both GEF-H1 and ECT are 
downregulated at the mRNA and protein level during polyploidization (Gao et al., 
2012). Interestingly, GEF-H1 downregulation appears to be required for 2n cells 
to become 4n, while ECT downregulation appears to be necessary for 
polyploidization beyond 4n, suggesting different mechanisms are involved in the 
initial 2n to 4n transition and subsequent endomitotic events. 
 
Figure 1.5. Cyclin–CDK regulation of the mammalian cell cycle. The cell cycle consists 
of a DNA synthesis (S) phase and a mitotic (M) phase, separated by two gap (G1 and 
G2) phases. In mammalian cells different cyclin–CDK complexes regulate progression 
of cells through the different phases of the cell cycle. Republished with permission of 
Portland Press Ltd, from Control of cell cycle progression by phosphorylation of cyclin- 
dependent kinase (CDK) substrates, Suryadinata, Sadowski and Sarcevic, Bioscience 
Reports 30(4) © 2010; permission conveyed through Copyright Clearance Center, Inc. 
Although inhibition of cleavage furrow formation physically prevents MKs from 
dividing, there may be a separate process that regulates the repeated cycles of 
DNA replication and limits their exit from mitosis. Studies in megakaryocytic 
transformed cell lines show that this switch to polyploidization may also be 
mediated through degradation of cyclin B and consequent reduced activity of the 




cyclin B-dependent Cdc2 kinase (Datta et al., 1996). Many studies have identified 
roles for G1/S phase regulators, such as cyclins D and E, supporting the 
hypothesis that up-regulation of G1 phase components may be important in 
promoting endomitotic DNA replication for the development of high ploidy MKs 
(see Figure 1.5) (Muntean et al., 2007; Eliades, Papadantonakis and Ravid, 
2010).  
The other main maturation phase MKs must undergo is cytoplasmic maturation. 
This process describes the development of a highly invaginated membrane 
reservoir system throughout the MK cytoplasm continuous with the plasma 
membrane known as the invaginated membrane system (IMS) or the demarcation 
membrane (DMS). This requires a high amount of protein and lipid synthesis and 
so only occurs after endomitosis has taken place. The IMS is thought to act as a 
membrane reservoir for the surface area required for proplatelet formation, as 
demonstrated by direct labelling to observe membrane dynamics in vitro (Schulze 
et al., 2006). The IMS also requires cytoskeletal support; spectrin, a protein that 
forms the plasma membrane skeleton in many cell types has been shown to form 
a 2D lattice that stabilises and underlies the IMS in MKs, and MKs expressing a 
spectrin tetramer disrupting construct have an underdeveloped IMS with 
insufficient membrane to form proplatelets (Patel-Hett et al., 2011). 
Other major hallmarks of MK maturation include the formation of structures that 
are not important to the MK itself, but are crucial to the function of the resultant 
platelets from the MK. These include the formation of a dense tubular system, 
found to be the site of prostaglandin synthesis in platelets (Gerrard, White and 
Peterson, 1978), the open canalicular system, a surface-connected channelled 
system important as a conduit for discharge of granule products during platelet 
activation (Escolar and White, 1991), and the formation and loading of these 
granules with proteins and other substances. 
 Platelet granules and their biogenesis 
There are three main types of granules in platelets, α-granules, dense (or δ-
granules) and lysosomal granules, of which the α-granules are the most 
abundant, numbering between 50 and 80 per platelet and comprising about 10% 
of the platelet volume  (Harrison and Cramer-Martin, 1993). The contents of these 
α-granules are heterogeneous, containing substances that are either membrane-
bound proteins that become exposed onto the surface of platelets (e.g. P-selectin) 
or proteins that are released into the interstitial space (Figure 1.8). In many ways, 
they are analogous to the Weibel-Palade bodies found in endothelial cells, 




containing many similar proteins as cargo, such as vWF (Heijnen, 2019). The 
dense granules contain ADP, serotonin and other small-molecule, non-protein 
mediators of platelet-platelet signalling. 
α–granules have four distinct morphological zones identified by electron 
microscopy.  From the outside in they are the peripheral membrane, tubular and 
vesicular structures, an electron-lucent area and an electron-dense nucleoid. 
Mass spectrometry experiments to probe the proteome of these α-granules has 
identified over 280 different proteins with many whose physiological role is not yet 
clear (Maynard et al., 2007). These proteins include those that are important for 
haemostasis (such as von Willebrand Factor, factor V and thrombospondin) as 
well as innate immunity (such as CXCL1, platelet factor 4 [PF4] and RANTES), 
perhaps reflecting the dual role of platelets in haemostasis and as an immune cell 
(Thomas and Storey, 2015). 
Platelet granule formation begins in the MK but continues in the circulating 
platelet. Platelet α-granules contain proteins that arrive broadly from one of two 
sources (see Figure 1.6); from biosynthesis, predominantly at the MK level (such 
as PF4), through the trans-Golgi network, with some vestigial synthesis in 
platelets and through endocytosis and pinocytosis at both the MK and platelet 
levels (for proteins such as fibrinogen and IgG) (Harrison and Cramer-Martin, 
1993).  





Figure 1.6. α–Granule cargo derives from budding of the trans-Golgi network (TGN) 
and endocytosis of the plasma membrane. MVB - multivesicular bodies  (Blair and 
Flaumenhaft, 2009)1 
In the megakaryocyte, α–granules appear to be derived in part from the budding 
of small vesicles from the trans-Golgi network as seen through immunogold 
staining for α–granules proteins such as PF4 in rat megakaryocytes and studies 
of various α–granule cargo proteins have suggested different mechanisms for the 
targeting and retention of different granule proteins (Hegyi, Heilbrun and Nakeff, 
1990). Studies of PF4 led to the identification of a four amino acid signal sequence 
in an exposed hydrophilic loop required for the sorting of PF4 into α–granules, 
with analogous sequences identified in other platelet chemokines such as 
RANTES and NAP-2 (El Golli et al., 2005). Mice lacking the dominant platelet 
glycosaminoglycan, serglycin, fail to store soluble proteins containing basically 
charged regions, such as PF4, PDGF or NAP-2, suggesting serglycin may serve 
to retain chemokines containing an exposed cationic region (Blair and 
Flaumenhaft, 2009). 
Another mechanism suggested for the incorporation of larger soluble proteins into 
α–granules is through the aggregation of protein monomers. Large multimeric 
 
1 Reprinted from Blood Reviews 23(4), Blair and Flaumenhaft, Platelet α-granules: Basic 
biology and clinical correlates, 177-189, Copyright 2009, with permission from Elsevier. 




self-assembling proteins such as multimerin, a factor V binding protein found in 
platelet α–granules, have been proposed to sort to immature vesicles through 
homoaggregation (Hayward et al., 1999). In MKs, VWF also self-assembles into 
large multimeric structures and is packaged into a discrete tubular structure within 
α–granules. The expression of vWF in cell lines possessing a regulated secretory 
pathway (e.g. RIN 5F or 293T cells) can also drive the de novo formation of α–
granule-like structures complete with recruitment of membrane proteins such as 
P-selectin, but this does not occur in cell lines lacking such a secretory pathway 
(e.g. CHO or 3T3 cells) (Blagoveshchenskaya et al., 2002). One group took 
advantage of this biosynthesis route by fusing the signalling domain of VWF (the 
SPD2 domain) with FVIII and introduced this as a lentiviral gene therapy in 
haemophilic dogs to restore haemostasis (Du et al., 2013). 
Evidence for endocytosis as a mechanism for granule biogenesis was discovered 
through observations that these granules contain large amounts of proteins that 
are unlikely to be synthesised by megakaryocytes. For example, immunoglobulins 
(e.g. IgG) are well-known to be produced by B cells as part of the adaptive 
immune system through complex processes of recombination and hypermutation 
that simply do not occur in megakaryocytes. Guinea pigs injected with 
horseradish peroxidase (HRP) were studied and their MKs and subsequent 
platelets were found to contain HRP inside of the α–granules. This HRP was able 
to be released from these platelets upon stimulation with thrombin, showing that 
proteins could be endocytosed, packaged into α–granules and released upon 
exposure to a platelet agonist (Handagama, George, et al., 1987). Studies in dogs 
evaluating the accumulation of fibrinogen and immunoglobulin show that the 
levels of endocytosed but not endogenous proteins increase as platelets age, 
suggesting that constitutive trafficking to platelet α–granules continues throughout 
the lifespan of the platelet (Heilmann et al., 1994). 
There has also been evidence to show this may also work for other proteins that 
are not usually present in granules, including Factor VII. MEG-01 
megakaryoblastic cells were incubated with recombinant activated Factor VII and 
flow cytometry combined with immunofluorescence was used to show this 
becomes taken up into the granules of these cells, as well as the subsequently 
produced platelets. The authors suggest this could explain the prolongation of the 
beneficial effects of this clinical drug beyond its usual two hour half-life in the 
blood (Schut et al., 2017). 
In many other cell models, vesicle trafficking and maturation is mediated through 
an orchestrated assemblage of coat proteins (e.g. clathrin, COPII), adapter 




proteins (e.g. AP1, AP2, AP3), fusion machinery (e.g. SNAREs) and monomeric 
GTPases (e.g. Rabs) and it is thought that similar processes take place in MKs. 
Vesicles budding from either the trans-Golgi network or the plasma membrane 
from endocytosis are subsequently directed towards multivesicular bodies 
(MVBs). MVBs appear to be a key megakaryocyte-platelet storage and sorting 
compartment, that are abundant in early megakaryocytes and decline with cellular 
maturation, serving as an intermediate stage of granule formation. Kinetic studies 
in MKs demonstrate the transport of endocytosed proteins proceeds from 
endosomes to immature MVBs (MVB I, with internal vesicles alone) to mature 
MVBs (MVB II, with internal vesicles and an electron dense matrix) to α–granules 
(Heijnen et al., 1998). 
Recent data also suggests there are two distinct sub-types of α–granules; 
broadly, one containing pro-angiogenic proteins, such as VEGF, and the other 
containing anti-angiogenic proteins, such as endostatin. Proteins appear to be 
differentially packaged into one and not the other, with no overlap of proteins 
existing in both (Sehgal and Storrie, 2007; Italiano et al., 2008). The physiological 
role of the differential packaging of α–granules remains unclear, as well as 
whether further subtypes exist. Furthermore, other studies, have disputed the 
existence of separate specialised granule subtypes, favouring the explanation 
that this observation is due to stochastic protein sorting to α-granules. This is 
backed by immunofluorescence data showing that VEGF and endostatin co-
localise 41% of the time, suggesting these observations are possibly microscope-
setting-dependent (Kamykowski et al., 2011). 
Other approaches to studying granule formation are through the studies of 
diseases that lead to a lack of α-granules in platelets. Some of these studies led 
to the discovery of VPS33B, VPS16B and NBEAL2 being essential to granule 
biogenesis, though the precise mechanisms remain unclear (Chen et al., 2017). 
Overall, there appear to be many different redundant mechanisms and processes 
responsible for granule formation in platelets, some of which are similar to other 
cell types studied and others that appear unique to MKs.  
 Platelet assembly and release 
Proplatelets are long (up to millimetres in length), thin cytoplasmic processes 
emanating from megakaryocytes, characterised by multiple platelet-sized 
swellings linked together by thin cytoplasmic bridges. Developing platelets were 
assumed to be encased in plasma membrane only as proplatelets are formed, 
supported by the observation that platelet membrane antigenicity and structure 




more closely resembles those of the IMS than of the surface of the MK. Direct 
visualisation with GFP-tagged proteins further demonstrated the IMS to be the 
origin of proplatelet and platelet membranes (Schulze et al., 2006b).  
The classical theory suggested that the megakaryocyte fragment into platelets, 
with the IMS serving the function of subdividing the MK cytoplasm into platelet 
areas (Becker and De Bruyn, 1976) but the evidence for these subdivisions 
remained elusive. This was later supplanted by the ‘flow model’, postulating that 
platelets derived exclusively from the interconnected platelet-sized beads along 
proplatelets, and that the IMS did not function to divide platelet fields, but to act 
as a reservoir of surface membrane to be evaginated during proplatelet formation 
(Radley and Haller, 1982).  
Proplatelets have been observed (1) in vivo (Schmitt et al., 2001), (2) in a wide 
range of mammalian species including mice, rats, guinea pigs, humans and 
others (Handagama, Feldman, et al., 1987; Tablin, Castro and Leven, 1990; Choi 
et al., 1995), (3) extending from megakaryocytes in the bone marrow through 
junctions in the endothelial lining of blood sinuses, hypothesised to subsequently 
be released into the circulation and undergo further fragmentation into platelets 
(Lichtman et al., 1978), and (4) to be absent in mice lacking two distinct 
haematopoietic transcription factors, failing to produce proplatelets in culture and 
leading to a severe thrombocytopaenia in vivo (Shivdasani et al., 1997; Lecine et 
al., 1998). 
Through the discovery of TPO, in vitro megakaryocyte culture systems have been 
developed that have successfully reconstituted the platelet formation process 
allowing this process to be directly visualised as it takes place. Counter-intuitively, 
TPO appears to also inhibit proplatelet formation by mature human 
megakaryocytes in vitro (Ito et al., 1996). Mice containing fluorescent markers in 
their megakaryocytes combined with intravital microscopy have allowed these 
processes to also be visualised directly in the cranial bone marrow in living mice, 
showing that proplatelets extend through the endothelium into capillaries and 
these megakaryocytic fragments are released into the circulation, exceeding the 
size typically expected for platelets, suggesting these undergo further 
fragmentation later on, which is the modification in the ‘modified’ flow model 
(Patel, Hartwig and Italiano, 2005). 
Proplatelet formation appears dependent upon microtubule formation; drugs that 
depolymerise microtubules such as nocodazole or vincristine also block 
proplatelet formation in vitro. The microtubule cytoskeleton of megakaryocytes 




undergoes a dramatic rearrangement. Studies of murine megakaryocytes 
transduced with EB3-GFP (end binding protein 3, to mark growing microtubules) 
have revealed that immature MKs lacking proplatelets show a centrosomal-
coupled microtubule nucleation/assembly reaction where microtubules assemble 
only from centrosomes and grow outwards to the cell cortex (Patel et al., 2005). 
Just before proplatelet formation however, as observed through fluorescence 
time-lapse microscopy, centrosomal assembly ceases, microtubules begin to 
consolidate into the cortex and microtubule assembly occurs continuously 
throughout the entire proplatelet structure. Organelles, including platelet 
granules, are transported along these microtubule bundles into the proplatelets, 
powered by microtubule motor proteins. They appear to be captured in developing 
platelets by microtubule coils, which persist in mature platelets. 
In recent years, evidence for the classical fragmentation model of platelet 
formation (termed MK rupture) has emerged as an alternative to the proplatelet 
model in the context of IL-1a-dependent emergency platelet release in response 
the administration of an inflammatory stimulus to mice (Nishimura et al., 2015). 
This process appears to be independent of serum TPO levels, and entails rapid 
cytoplasmic fragmentation followed by the release of much larger numbers of 
platelets than would be expected under normal homeostasis, primarily into blood 
vessels. 
Still controversial in the field is the primary location of platelet production. 
Although megakaryocytes arise in the bone marrow, they have been documented 
to migrate into the blood and therefore platelet production may also occur at non-
marrow sites (Michelson, 2007). In the developing foetus, thrombopoiesis occurs 
from megakaryocytes resident in first the yolk sac and then the foetal liver, 
suggesting that the bone marrow microenvironment, although sufficient, is not 
necessary for platelet release (Brouard et al., 2017). The two main alternative 
locations of platelet formation are in the blood and in the lungs.  
Behnke and Forer have suggested that the final stage of platelet formation takes 
place in the blood (Behnke and Forer, 1998). In this model, megakaryocyte 
fragments that are released from the bone marrow into the blood become 
transformed into platelets while in circulation. This theory is supported by the 
presence of megakaryocytes as well as megakaryocyte fragments that are 
sometimes beaded (and can represent between 5-20% of the circulating platelet 
mass in plasma) in the blood, and reports that these megakaryocyte fragments, 
when isolated from platelet-rich plasma taken from rats, elongate and undergo 




curving and bending motions, eventually fragmenting to form disc-shaped 
structures resembling platelets. 
Aschoff first described pulmonary megakaryocytes in 1893, suggesting they 
arose in the bone marrow, migrated into the blood and because of their massive 
size, were lodged in the capillary bed of the lung where they fragmented and 
released platelets (Aschoff, 1893). This was supported by data showing (1) the 
presence of MKs in the lungs, and (2) there were more MKs in the blood entering 
the lungs than the blood exiting, while there were more platelets in blood exiting 
the lungs than entering. More recently, Lefrançais et al used 2-photon microscopy 
in GFP reporter mice to show similar results, as well as video footage of the 
process of proplatelet formation taking place from MKs in the capillary bed of the 
lungs, but the calculations for what percentage of the total platelet production of 
the body this represents is debated (Lefrançais et al., 2017). 
Overall, it is likely that all three sites, bone marrow, blood and the lungs play roles 
in platelet formation. At present, it appears that megakaryocytes in the bone 
marrow produce the majority of proplatelets which later undergo fragmentation 
further in the circulation, perhaps due to shear forces. This is likely supplemented 
by some platelet production also taking place in the lungs. 
 Platelets and their physiology; activation to thrombus formation 
In vivo observations show that flowing blood segregates into an RBC-rich core 
and an RBC-depleted near-wall region (Figure 1.7), which is where the majority 
of the platelets are located (Tangelder et al., 1985). This margination effect is 
greater in arterioles than in venules, suggesting that this effect is due to high shear 
rates. This margination is thought to have an important physiological function, 
allowing platelets to react quickly when the vessel wall and endothelium is 
damaged. 





Figure 1.7. Generalised frequency distribution of platelets in a blood vessel (solid line) 
with 95% confidence intervals (dashed lines) as calculated from 15 measurements in 13 
vessels in 10 animals (total platelet number 6,571) demonstrating that platelets are 
pushed to the outer parts of the blood vessel in contact with endothelium. Distribution 
expected in the case of a uniform distribution is indicated by dotted line. Reprinted by 
permission from The American Physiological Society © 1985 Tangelder et al., 
Distribution of blood platelets flowing in arterioles, Am J Physiol. 1985 Mar;248(3 Pt 
2):H318-23. 
Under resting physiological conditions, the endothelium of blood vessels release 
nitric oxide and prostacyclin, inhibiting platelet activation and preventing 
aggregation (Lüscher, 1993). Upon vessel injury and damage to the endothelium, 
platelets can interact with subendothelial components that have become 
exposed, such as collagen. This leads to a sequence of tightly controlled 
processes; tethering, rolling, activation and firm adhesion, resulting in the 
formation of stable platelet adhesion and thrombus formation (Michelson, 2007). 
The mechanisms for these processes vary between vessels of low shear rate 
(veins and arteries) compared with high shear rates in the microvasculature. In 
vessels with a low shear rate, the exposure of platelets to collagen, laminin and 
fibronectin appear to play the predominant role in tethering and recruiting flowing 
platelets; exposed collagen can directly bind to the platelet glycoprotein (GP) 
Ia/IIa and GPVI receptors (Savage, Saldívar and Ruggeri, 1996). In vessels with 
a high shear rate, von Willebrand Factor (vWF) can form a bridge between 
exposed collagen and the GP Ib/V/IX complex on the platelet membrane 
(Andrews and Berndt, 2004) to tether platelets. This tethering is insufficient to 
produce stable binding, but it acts to decelerate platelets, allowing them to roll in 
the direction of blood flow. This rolling process puts non-activated platelets into 
close and continuous contact with the exposed extracellular matrix, allowing 
further platelet-matrix interactions to stabilise the adhesion. 




Collagen type I and II are particularly potent adhesion molecules exposed by the 
subendothelial extracellular matrix. The subsequent binding of these collagens to 
platelet GPVI receptors induces their activation. Other mediators from 
neighbouring activated platelets additionally can trigger further activation of 
platelets, such as ADP, serotonin (both released from platelet dense granules) 
and thrombin (from the coagulation cascade) by binding to G-protein coupled 
receptors (GPCRs) on platelet membranes such as PAR1/4 for thrombin, and 
P2Y12 for ADP (Figure 1.8A) (Thomas and Storey, 2015). 
These various signals converge on an intracellular messenger, calcium. Platelet 
activation causes an increase in intracellular Ca2+, in turn resulting in a physical 
shape change and causing activated platelets to flatten and spread. Calcium 
signalling also causes the activation of integrins on the membrane surface that 
promote strong aggregation and adhesion by the formation of fibrinogen bridges. 
Finally upon activation, platelets also release their granules through mechanisms 
similar to what has been described in the release of synaptic vesicles at neuronal 
junctions, through the binding of v-SNAREs on granule membranes with t-
SNAREs on platelet plasma membranes driving the fusion of these lipid 
membranes in a controlled manner, releasing the contents of the granules into 
the extracellular space (Blair and Flaumenhaft, 2009). 
The primary v-SNARE mediating platelet α–granule secretion is VAMP-8, with 
VAMP-3 and with VAMP-2 serving subordinate functions (Ren et al., 2007). 
Platelet t-SNAREs include syntaxins and SNAP-23. Syntaxins 2 and 4 have been 
shown to participate in α–granule release. Coiled-coil domains within v-SNAREs 
and t-SNAREs interact, forming a twisted 4-helical bundle, bringing the opposing 
negatively charged membranes of the granule and target membrane into close 
apposition, generating the energy required for membrane fusion. Pore formation 
with a subsequent release of granule content follows, with an expansion of the 
total platelet membrane surface area (Figure 1.8B) (Ren, Ye and Whiteheart, 
2008). 






Figure 1.8. Diagram of the triggers and receptors involved in platelet activation and the 
subsequent release of the contents of α-granules. (A) Thrombin from the coagulation 
cascade, as well as collagen and ADP all trigger platelet activation, resulting in several 
key morphological changes including degranulation. Redrawn based on Thomas and 
Storey, 2015. (B) Granules are normally prevented from being released in a resting 
platelet by repulsion between the negatively charged vesicle membrane and negatively 
charged plasma membrane. Upon activation, the v-SNARES and t-SNARES interact 
to physically overcome these repulsive forces. The lipid membrane of the granule fuses 
with the surface membrane, releasing the contents of the granule into the OCS while 
delivering the membrane components of the granule into the surface of the platelet 
(e.g. P-selectin). Adapted from Blair and Flaumenhaft, 20092. 
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Ultimately this signalling results in an ‘inside-out’ signalling cascade that leads to 
the priming of integrin IIbβ3 (also known as the CD41/61 complex). Platelet surface 
membranes express several integrins, including αIIbβ3 (fibrinogen receptor), αvβ3 
(vitronectin receptor), α2β1 (collagen receptor), α5β1 (fibronectin receptor) and 
α6β1 (laminin receptor) that all share similar signal transduction mechanisms. The 
most abundant of these is αIIbβ3, which is normally kept in a low-affinity resting 
state in circulating platelets. Activation of the Ca2+ signalling cascade, through 
CalDEG-GEF1 and its downstream target Rap1, results in the binding of talins 
and kindlins to the cytoplasmic domain of this integrin, inducing changes in its 
extracellular domain to an activated state (Crittenden et al., 2004). Ligand binding 
to this activated form of αIIbβ3 not only mediates further platelet adhesion and 
aggregation but also results in a second ‘outside-in’ signalling pathway that has 
similar effects to the GPCR-mediated signalling pathway described earlier.  There 
is much cross-talk between these pathways, and the end result is further platelet 
spreading, granule secretion, as well as stable adhesion and eventually clot 
retraction (Shattil and Newman, 2004). 
1.3 Induced pluripotent stem cells, in vitro megakaryopoiesis 
and bioreactors 
 Induced pluripotent stem cells for regenerative medicine 
As previously described in Table 1.1, pluripotent stem cells have the property of 
being able to differentiate into any tissue type in the body and hold great potential 
in regenerative medicine. Mouse and human embryonic stem cells are 
undifferentiated, pluripotent stem cells that can be maintained indefinitely in 
culture. However, for many decades the field had been fraught with ethical issues, 
as these stem cells were once only obtainable from embryonic tissues from 
aborted foetuses. 
Gurdon et al demonstrated that all differentiated, somatic cells retain the 
necessary information to regenerate an entire organism (Gurdon, Elsdale and 
Fischberg, 1958). This culminated with experiments in the 1990s where a whole 
sheep was cloned from a skin fibroblast from an adult, demonstrating that even 
somatic cells might be manipulated to return to a stem-like state (Wilmut et al., 
1997). This would be far more desirable than obtaining these stem cells from 
embryonic sources, both from an ethical standpoint and from a histocompatibility 
standpoint if these were to be used to regenerate tissues for eventual transplant 
or transfusion. Unlike other stem cell therapies, platelets have no nucleus and 
cannot divide, so risks classically associated with these therapies like 








To tackle the many issues that remain with donor-derived platelet products and 
in order to better study megakaryocyte biology there have been several different 
attempts at recreating megakaryopoiesis in vitro. Although in vivo HSCs appear 
to be able to self-renew without limit, once they are removed from their niche they 
do not appear to maintain their stem-like state indefinitely. There remain many 
unknowns about the factors that maintain this niche in vivo, and this can only be 
partially replicated through complex combinations of cytokines in tissue culture 
and so only survive for several days in tissue culture at present (Frisch and Calvi, 
2014). 
Much more recently, induced pluripotent stem cells (iPSCs) have shown great 
promise as a more practical source of stem cells, being derived through driving 
the expression of four specific transcription factors (Oct3/4, Sox2, Klf4 and c-Myc) 
in easily-acquired skin fibroblasts to induce a pluripotent-like cell state (Takahashi 
and Yamanaka, 2006). These transcription factors are highly expressed in 
embryonic stem (ES) cells, and driving their over-expression appears to be able 
to induce pluripotency in both mouse and human somatic cells, indicating they 
likely regulate a key switch in the developmental signalling network necessary for 
pluripotency. 
In recent years, much attention has turned to the possibility of guiding iPS cells 
(which can be maintained indefinitely in tissue culture) through haematopoietic 
differentiation and megakaryopoiesis. Simultaneously, there has been much work 
in designing bioreactors for these megakaryocytes to recreate the shear forces 
thought to be necessary for thrombopoiesis in vitro. 
 Recreating MK differentiation in vitro from iPS cells 
The classical approach to creating megakaryocytes from iPS cells has been 
‘directed differentiation’, to recreate the process of paracrine signalling that occurs 
in vivo to differentiate iPS cells through sequential changes in the culture media. 
Much of this early work was done with mouse and human embryonic stem cells, 
and this has in more recent years been translated into iPSC cultures. Each new 
culture media contains different combinations of cytokines to guide the iPS cells 
through a process modelled after embryogenesis (Lu et al., 2011).  
In mice and humans, two distinct haematopoietic programs, designated primitive 
haematopoiesis and definitive haematopoiesis, occur during embryonic/foetal 
development and both give rise to megakaryocytes. These programs can be 
distinguished by the subtype of globin expressed in erythroid cells. The first, 
primitive wave of haematopoiesis develops from an extra-embryonic mesoderm 




population in the yolk sac. These yolk sac progenitors give rise to nucleated 
erythrocytes, macrophages and primitive megakaryocytes. Towards the end of 
the primitive wave, definitive erythro-myeloid progenitors emerge from the yolk 
sac and colonise the foetal liver, where they act as the major source of 
haematopoiesis prior to the emergence of HSCs. Another wave, this time of 
definitive haematopoiesis, occurs in the aorto-gonads-mesonephros region and 
this is responsible for the generation of long-term HSCs having multi-lineage 
potential as well as enucleated erythrocytes, myeloid cells, lymphocytes and 
crucially, definitive megakaryocytes. These HSCs then colonise the foetal liver, 
before transitioning to the bone marrow where they reside for the remainder of 
adult life (Mikkola and Orkin, 2006). 
While megakaryocytes are generated in both waves, functional differences 
between them have been well-documented. Primitive megakaryocytes are less 
proliferative, display a lower ploidy and each megakaryocyte releases a relatively 
small number of platelets. By contrast, definitive megakaryocytes undergo more 
rounds of endomitosis and give rise to on the order of 103-104 platelets per MK 
(Wang and Zheng, 2016). There is recent evidence to suggest that Wnt signalling 
(Sturgeon et al., 2014) and IGF2BP3 (Elagib et al., 2017) acts as a master switch 
driving immature foetal haematopoiesis to the adult form. 
The first attempts to differentiate human ES cells through haematopoiesis was 
through co-culture with certain mouse stromal cell lines derived from 
haematopoietic tissue (Kaufman et al., 2001). In particular, co-culture with the 
OP9 stromal cell line was able to differentiate up to 25% of the human ES cells 
into CD34+ HSCs within 8-9 days of culture, displaying the phenotype of primitive 
haematopoietic progenitors and going on to produce lymphoid and myeloid cells 
when subsequently co-cultured with the MS-5 stromal cell line (Vodyanik et al., 
2005). Kinetic studies have shown the differentiating populations progress 
through a primitive streak stage defined by either BRACHYURY or MIXL1 
expression, then to KDR+ (Flk-1+) or PDGFR+ mesoderm, and subsequently to 
a yolk sac haematopoietic program (Zambidis et al., 2005). Studies comparing 
these MKs to those from adult bone marrow have found iPSC-derived primitive 
megakaryocytes are smaller, have lower ploidy and release fewer platelets when 
infused into mice (Wang et al., 2015).  
This was followed by studies aiming to eliminate the use of both serum and 
stromal cells, barriers in translation to clinical contexts. BMP4 was discovered as 
a crucial signal to induce the formation of the primitive streak-like population 
required for the subsequent development of haematopoietic mesoderm, and 




when supplemented with recombinant VEGF, FGF2, TPO and SCF were able to 
differentiate these hESCs to megakaryocytes as observed by functional assays 
and were able to produce functional platelet-like particles (Pick et al., 2007). Much 
of this work has been directly translated to iPSC culture. 
In more recent years, this process has been refined further and differentiation 
protocols driving definitive haematopoiesis have been developed through the 
timed modulation of the Wnt pathway (Sturgeon et al., 2014). Both 
haematopoietic programs transition through a hemogenic endothelial 
intermediate and develop from KDR+ mesoderm progenitors that are 
distinguishable by CD235a expression. Generation of the primitive progenitors 
(KDR+CD235a+) depends on stage-specific activin-nodal signalling and inhibition 
of the Wnt pathway, while specification of the definitive progenitors 
(KDR+CD235a-) required Wnt signalling in the same timeframe. 
However, one of the key issues with directed differentiation has been the yield 
and number of generated megakaryocytes and the quantity of platelets produced. 
The process of directed differentiation involves recreating the whole of 
haematopoiesis, and so cells that have differentiated down a non-megakaryocytic 
route are generated at each stage, resulting in a relatively low yield of 
megakaryocytes per input iPSC (Gaur et al., 2006). 
 Improving the purity of the differentiation process with ‘forward-
programming’ 
One approach developed by Eto et al to improve the number of MKs produced 
through directed differentiation has been the immortalisation of MK progenitors 
obtained through directed differentiation, through overexpression of BMI1 and 
BCL-XL to suppress senescence and apoptosis and c-Myc to promote 
proliferation (Nakamura et al., 2014). This has proven successful in scaling up the 
production of megakaryocytes to enable animal model experiments but it also 
raises several clinical safety concerns with regards to the safety of potentially 
infusing immunocompatible immortalised cells into a patient; primarily due to the 
risk of tumorigenicity and lack of an immune response against these cells. This 
technique also requires very precise control over Myc expression levels and 
subsequent silencing of all three exogenous genes to achieve full MK maturation. 
The complex nature of the genetic modifications involved and the manual 
screening and clonal selection resulting in a limited success rate for this 
immortalisation technique have proven barriers to this being widely adopted. 




An alternative approach was developed by Moreau et al that can give rise to a far 
greater purity and yield of megakaryocytes compared with directed differentiation, 
known as ‘forward-programming’ (Moreau et al., 2016). MK-specific transcription 
factors (TFs) forming complexes able to interact with chromatin modelers were 
hypothesised to be able to rewire the hiPSC gene regulatory network to induce 
differentiation. This came out of RNAseq experiments comparing the transcription 
factor expression between iPSCs and cord blood-derived megakaryocytes, 
followed by overexpressing combinations of these factors in iPSCs through 
lentiviral vectors. This had been following discoveries on the plasticity of cell 
identity controlled by limited sets of transcription factors altering the epigenetic 
landscape (Cherry and Daley, 2012). 
iPSCs were then maintained in iPSC medium (containing FGF2 and Activin A) for 
two days, followed by a MK medium (containing TPO and SCF) for a further five 
days, requiring no mesoderm induction. Crucially, these culture conditions after 
transduction with a GFP control showed no evidence for megakaryocytes in the 
culture, demonstrating these culture conditions alone were not capable of 
inducing differentiation. 
Overexpression of a combination of GATA1, FLI1 and TAL1 was uniquely able to 
produce CD41+CD42+ megakaryocytes from iPSCs in a highly efficient manner, 
maturing into platelet-producing cells that could be cryopreserved, maintained, 
and amplified in vitro for over 90 days. The culture was further optimised by 
introducing a mesoderm induction step with FGF2 and BMP4 and embryoid body 
culture instead of a 2D iPSC culture. 
There remain issues with these differentiation systems. Functional, qPCR and 
more recently, scRNAseq data suggests that forward programming appears to 
produce primitive megakaryocytes rather than the definitive MKs found in adult 
bone marrow. Gene expression profiles were compiled from iPSCs, fetal liver 
MKs and cbMKs to create a ‘trajectory’ of MK development and to examine the 
genes most differentially expressed between these cultures. When compared to 
the gene expression profile in FoP-MKs, although many of these differentially 
expressed genes appeared to be similarly expressed to cbMKs, some key MK 
genes appeared to either be unchanged from the levels expected in iPSCs or in 
between the levels expressed by iPSCs and cbMKs (e.g. vWF). It remains an 
ongoing area of research in the lab to find factors that may help further mature 
the MKs produced. This controversy is not unique to the field of iPSC-derived 
MKs, but to many other fields attempting to derive adult tissues from iPSCs, such 
as with cardiomyocytes (Karakikes et al., 2015). 
 
 




 Stem cell editing to produce better megakaryocytes and platelets 
The potential for platelets derived from standardised iPSC lines raise the 
possibility of improving upon them using genome editing techniques. Such 
modifications could include the addition or removal of TFPI to promote or reduce 
clotting, combinations of growth factors (difficult to currently deliver together at 
high doses to specific tissues using traditional pharmacokinetics) to promote 
cardiac regeneration in myocardial infarction or rFVIIa to promote clotting in areas 
of bleeding. Evidence supporting the modulation of TFPI come from monoclonal 
antibodies inhibiting it currently undergoing development as a procoagulant 
(Lauritzen et al., 2019). Evidence for growth factors promoting cardiac 
regeneration come from studies on thymosin-β4 in cell culture (Smart et al., 
2007). Recombinant factor VIIa was chosen here due to its proven efficacy in 
clinical practice as a low-hanging fruit to investigate the principle of delivering 
proteins in a targeted manner using platelets. If proven successful, this would 
open the possibility for other proteins with currently more speculative benefits to 
be delivered in this way. 
Technology to perform targeted gene replacement (or gene insertion) in both 
yeast and mouse ES cells has been available since 1979, utilising homologous 
recombination for gene replacement and powerful selection procedures (often 
requiring both positive selection to maintain the cells that have taken up the 
modification and negative selection against the common products of random 
integration) (Scherer and Davis, 1979; Gordon and Ruddle, 1981; Capecchi, 
2005). The absolute frequency of homologous recombination has always been 
low, on the order of one in every 104-107 cells, limiting its utility in other 
experimental systems. The challenge in extending gene targeting can therefore 
be largely viewed as one of increasing the frequency of recombination. 
In recent years, several new techniques have emerged that have made this 
process fast and accurate, inspired by discoveries that natural recombination 
events are initiated through the formation of double strand breaks (DSBs) (Rudin, 
Sugarman and Haber, 1989). In the absence of a replacement template, a 
targeted DSB can introduce targeted mutagenesis. When two double strand 
breaks are introduced ‘bracketing’ a genomic locus, the entire locus can be 
knocked out in a targeted manner. 
The first advancement in this field came from the development of zinc finger 
nucleases (ZFNs); synthetic proteins based around zinc finger proteins (a family 
of transcription factors) fused to the endonuclease Fok1. These originated from 
observations that natural type IIS restriction enzyme Fok1 has physically 




separable domains for binding and cleavage, that the cleavage domain has no 
apparent sequence specificity, and when this cleavage domain was fused to 
alternative recognition domains constructed from novel assemblies of zinc fingers 
(where each finger binds primarily 3bp of DNA in a remarkably modular fashion), 
that this cleavage activity could be redirected to specific targets (Kim, Cha and 
Chandrasegaran, 1996). 
The design of combinations of zinc finger assemblies to target specific regions of 
interest remained complex for many years however, and new technologies that 
could make this targeting process easier emerged. Transcription activator-like 
effector nucleases (TALENs) were developed as an alternative to ZFNs for 
genome editing and DSB introduction, based around the same cleavage domain 
of Fok1. However, instead of using zinc finger assemblies for gene targeting, it 
was fused to a novel DNA binding domain composed of highly conserved repeats 
derived from transcription activator-like effector (TALEs), proteins secreted by 
Xanthomonas bacteria. Crucially, these DNA binding domains could be designed 
easily and rapidly with a simple ‘protein-DNA code’ that relates modular DNA-
binding TALE repeat domains to individual bases in a target-binding site (Li et al., 
2011). 
Both above-mentioned technologies require the expression of custom-designed 
proteins, each of which act as specific endonucleases to a target DNA sequence. 
A recent breakthrough has been the development of endonucleases designed 
around clustered regularly interspaced short palindromic repeats (CRISPR), 
where a single endonuclease (Cas9 and others) can be introduced with a short 
guide RNA to target its activity to a desired location (Jinek et al., 2012; Cong et 
al., 2013). Originally this was discovered as part of a bacterial immune system, 
allowing for the same endonuclease to be retargeted using only fragments of 
RNA. There are many advantages to this approach over designing a novel protein 
assembly for each modification; oligonucleotide synthesis is comparatively faster, 
more straightforward to perform and far less expensive, paving the way for much 
a greater scale of modifications to be made. CRISPR technology has been 
expanded to include the possibility of not only introducing double stranded breaks 
(and so perform gene knockout, mutagenesis and replacement), but also as a 
targetable activatory/inhibitory transcription factor, and at scale for large-scale 
CRISPR knockout screens (Bikard et al., 2013; Hart et al., 2015). 





Figure 1.9. Schematic view of the inducible expression cassette and genomic integration 
sites in the inducible MKFoP system. Reproduced with permission from Thomas Moreau, 
unpublished. 
Use of lentivirus has proven to be a barrier towards clinical translation of these 
technologies. One use of genome editing in our lab was to reduce the need for 
lentivirus to overexpress TFs. This was done by inserting a doxycycline-inducible 
cassette inserted by Dr Amanda Dalby to the genomic safe harbour site AAVS1 
to protect it from being epigenetically silenced (Figure 1.9). This allows expression 
of the three transgenes necessary for differentiating the iPS cells to 
megakaryocytes along with a reporter GFP upon exposure to doxycycline and 
allows for differentiation to occur without exposure to lentiviruses, rendering it 
more suitable for GMP-grade manufacturing. 
The dominant cause of alloimmune platelet transfusion refractoriness (observed 
in 5-15% of patients) is due to the production of alloantibodies against HLA class 
I. Knockout of HLA Class I expression by using CRISPR to delete β2-
microglobulin, a protein required to stabilise HLA-A, B, C and E, on the surface of 
platelets could result in universal platelets suitable for any transfusion. Suzuki et 
al have shown that this is not only possible but that the resultant PLPs are also 
inert to NK cell mediated immunity, the normal immune process to remove cells 
not expressing HLA Class I (Suzuki et al., 2020). The HLA-matching of donor 
platelets may be one day supplemented with a supply of universally immuno-
compatible platelets, especially for patients that show a high refractoriness to 
transfusion.  
Taken together, genome editing has been used successfully in iPSC-derived MK 
culture to simplify protocols and to introduce clinically desirable modifications to 
the megakaryocyte. There has even been some work in using these technologies 
to introduce mutations to study genetic diseases of megakaryopoiesis that have 
proven difficult to study in MKs from patients due to the rarity of megakaryocytes 
in bone marrow aspirates and the complex nature of many of these genetic 
diseases that previous technologies have been unable to replicate (Albers et al., 
2012). The potential for off-target effects of CRISPR and other gene editing tools 
in MKs demands caution and further work however, and the study of genome-




wide changes introduced through these techniques has become possible only 
recently through the advent of next-generation sequencing technologies. 
 Replicating thrombopoiesis in vitro through bioreactor design 
Although the precise location of platelet formation in vivo remains controversial, 
it has been widely accepted that each adult MK can give rise to 103 platelets. A 
resting culture of cbMK or FoP-MKs can give rise to proplatelets and subsequent 
PLPs but is comparatively far less efficient; it has been estimated that the yields 
are between 1-2 PLPs per MK from a static culture. This is thought to be due to 
the importance of mechanical factors (e.g. shear forces) that physically separate 
PLPs from MKs, as well as soluble factors produced by the niche that stimulate 
platelet release. However, the complex interactions within the 3D 
microenvironments regulating thrombopoiesis remain poorly understood. 
Bioreactors attempt to recreate some of these mechanical factors to more closely 
simulate the bone marrow microenvironment and niche in which these MKs 
normally live and thrive and have proven important in scaling up the production 
of platelets from these in vitro MK culture systems. There have been several 
complementary approaches to their design. 
Thon et al developed a microfluidic device that was biologically-inspired to 
recapitulate a simplified 2D version of the dimensions of human venules in the 
bone marrow and provide a physiological shear stress to extract viable platelets 
from iPSC-derived MKs (Thon et al., 2014). A two-channel design was used to 
recreate this shear stress; the two channels sit on top of one another, separated 
by a membrane containing small holes. They were able to show that adult mouse 
MKs seeded into the upper channel were retained in the membrane through video 
light microscopy. Differential flow in both chambers was able to provide shear 
stress to stimulate proplatelet formation and this allowed their device to siphon off 
the platelets from these proplatelet extrusions. They showed that shear stress-
induced proplatelet formation was driven by the cytoskeleton using a GFP-tagged 
tubulin marker, and that this process also occurred in iPSC-derived 
megakaryocytes obtained through directed differentiation, to obtain a yield of 
around 14 PLPs per input MK. 
One approach suggested by Ito et al is to use a turbulent flow-based bioreactor. 
They hypothesised that shear forces alone could not explain the discrepancy 
between the order of magnitude differences between those produced by shear 
forces in bioreactors similar to Thon et al. Through observations made in vivo, 
they suggested that turbulence could also induce thrombopoiesis and designed a 




bioreactor based on this principle, a vertical reciprocal motion liquid culture 
bioreactor (Ito et al., 2018). They describe a liquid culture containing two oval 
shaped mixing blades fixed at right angles to each other, repeating an up-down 
reciprocal motion to generate turbulent flow, and showed it was possible to 
generate between 70-80 PLPs per input MK compared with the 14 seen with the 
Thon bioreactor. 
There have been attempts seeking to recreate a 3D structure to mimic the bone 
microenvironment, as opposed to the 2D microfluidic devices develop by Thon et 
al. One such approach used a two-layer collagen scaffold (extensively cross-
linked collagen type I, which has been widely used as a 3D scaffold structure for 
other tissue regeneration projects). This follows on from previous work showing 
that carbodiimide crosslinking of collagen leads to the ablation of integrin-
dependent cell stimulation while adding stability and strength. The two-layer 
collagen scaffolds were integrated into a twin chamber culture system, where one 
side allowed for seeding of MKs into the scaffold and retention of MKs within its 
porous structure, while cross-flow subjected them to shear forces to induce 
platelet release (Shepherd et al., 2018). 
Another distinct approach is that of the SilkFusion project, an EU-wide 
collaboration using silk fibroin protein to assemble 3D scaffolds mimicking the 
bone marrow niche architecture and functionalise this material with proteins to 
recreate the extracellular matrix (ECM) composition found in vivo (Di Buduo et al., 
2015). They were able to show that the silk is a similar stiffness to the in vivo 
microenvironment and can direct human MK behaviour, functionalisation with 
ECM proteins could support MK development and that co-culture with endothelial 
cells increases proplatelet formation and platelet release.  
Individually, these approaches have paved way for a much higher yield of 
platelets from iPSC-derived MKs, and insights into their mechanisms of platelet 
release combined with an appraisal of their relative strengths and limitations will 
no doubt lead to improvements in these technologies in the near future towards 
reaching a 103 platelet per MK yield as is possible in vivo. 
1.4 An introduction to coagulation 
 The classical ‘waterfall’ model of haemostasis 
As well as platelets, another important factor for haemostasis is the central role 
that the vast amounts of proenzymes produced by the liver play in the role of 
maintaining haemostasis. The classical waterfall model was introduced by Davie, 




Ratnoff and Macfarlane describing the cascade of enzyme-mediated amplification 
of the clotting process, based upon in vitro experiments with human donor blood 
(Davie and Ratnoff, 1964; Macfarlane, 1964). Initially, the molecular identity of 
many of the factors involved with procoagulant activity were unknown and were 
labelled in roman numbers from Factor I to XII in order of their discovery. Other 
proteins were also discovered that showed an anticoagulant activity, such as 
protein C, S and Z. 
Further studies have revealed the identities of these factors (see Table 1.2). 
These circulate as zymogens in the blood, and once activated are suffixed with 
‘a’ to indicate their activation. Most of these factors are proteins produced by the 
liver, apart from factors III (tissue factor) and IV (calcium). Factors II, VII, IX, and 
X as well as protein C, S and Z are dependent upon a post-translational 
modification (vitamin K dependent gamma carboxylation of glutamic acid 
residues) that enables them to bind calcium and other divalent cations and thus 
participate in this coagulation cascade (Vermeer, 1984).  
  










I Fibrinogen Clot formation 
II Prothrombin Activation of I, V, VII, VIII, XI, XIII, protein C, 
platelets 
III Tissue Factor Co-factor of VIIa 




Cofactor of X-prothrombinase complex 
VI Unassigned  
VII Proconvertin, 
stable factor 
Activates factor IX, X 
VIII Antihaemophilic 
factor A 
Cofactor of IX-tenase complex 
IX Antihaemophilic 
factor B or 
Christmas factor 




Thrombinase complex with factor V; 




Activates factor IX 
XII Hageman 
Factor 




Table 1.2. A table of the clotting factors that have been assigned Roman numerals. 
(Based upon Wright, 1962) 
Knowledge of this coagulation cascade has led to the development of many drugs 
to modulate its various components to promote an anticoagulated state for 
patients at risk of thrombosis. Drugs such as warfarin antagonise the production 
of vitamin K dependent clotting factors, by competing with vitamin K for binding 
sites on vitamin K epoxide reductase (VKOR), competitively inhibiting the post-
translational modifications necessary for these factors to function (Czogalla et al., 
2017). The factor VII and anticoagulant protein C has a much shorter half-life than 




the procoagulant factors II, IX and X in blood (Stirling, 1995). The loss of protein 
C leads to a lack of inhibition of coagulation, while the loss of Factor VII inactivates 
the extrinsic pathway (but the intrinsic pathway is left undisturbed). Thus, warfarin 
initially causes a brief pro-coagulant state followed by a prolonged anti-coagulant 
state when the rest of the vitamin K-dependent factors are removed from 
circulation. For this reason and to over the delay between initiation of warfarin 
therapy and depletion of vitamin K-dependent factors, clinically it is often 
supplemented with heparin initially, which acts as an anticoagulant through 
activating the enzyme inhibitor antithrombin III (ATIII), which then inactivates 
thrombin, Factor Xa and other proteases (Hirsh et al., 2001). 
The extrinsic pathway described here has been shown to be vital in initiation of 
clotting. In this model, FVII is activated to FVIIa through contact with tissue factor 
(factor III) and forms a complex of FVIIa-TF. This complex goes on to activate 
Factor X to Xa. Both extrinsic and intrinsic pathways converge on Factor X (Figure 
1.10), the steps after which are called the common pathway. Factor Xa, in 
combination with Factor Va, converts prothrombin to thrombin, and subsequently 
thrombin converts fibrinogen to fibrin, forming a fibrin clot. The intrinsic pathway 
described acts as an amplification loop, being both initiated by either thrombin 
activating FXI or contact activation of FXII from negatively charged surfaces and 
resulting in the formation of more thrombin, through a cascade of FXII, FXI, IX, 
VIII resulting in activation of Factor X (Macfarlane, 1964). Clinically, the extrinsic 
and common pathways are measured through the prothrombin time (PT), while 
activation of the intrinsic and common pathways are measured through the 
activated partial thromboplastin time (aPTT) and the understanding of the calcium 
dependence of this process led to the use of calcium chelators for blood collection 
(Erban, Kinman and Schwartz, 1989).  
This model has also helped to understand genetic defects in coagulation. For 
example, haemophilia A and B are caused by a lack of Factor VIII and IX 
respectively, which affects the same intrinsic pathway (Castaman and Matino, 
2019). Clinically, the missing factors are replaced (through factor concentrates or 
recombinant factors) or the intrinsic pathway is bypassed by supplementing the 
extrinsic pathway with further FVIIa (although the mechanism through which this 
may work remains controversial for reasons described in more detail in section 
1.4.2). Clinical samples showing defects in coagulation can also be mixed with 
known normal plasma; a correction of the PT or aPTT implies the defect is due to 
a lack of a coagulation factor, while a continuation of abnormal test results implies 
the presence of inhibitors, which can develop as an immune response to repeated 
transfusions of factor concentrates (Miller, 2019). 





Figure 1.10. The classical waterfall model of coagulation, redrawn based on 
information from (Peters and Harris, 2018). Circled is the central activation of Factor 
VII to Factor VIIa of the extrinsic pathway, vital in the initiation of clotting. PL = 
phospholipids. 
The two cascades of extrinsic and intrinsic cascades (Figure 1.10) may suggest 
that they operate as independent and redundant pathways, but clinical 
manifestations of individual factor deficiencies demonstrate that this is not the 
case. Further evidence for the intrinsic pathway acting as a signal amplification 
loop comes from studies of mutations in its component enzymes. Deficiencies of 
the initial parts of the intrinsic pathway (FXII, HMWK or PK) cause a marked 
elongation of aPTT but are not associated with a tendency for bleeding in humans 
or mice (Cheng et al., 2010). Deficiencies of the next downstream enzyme, FXI, 
is associated with variable haemostatic deficits in humans (because the extrinsic 
pathway can bypass its requirement through the direct activation of FIX by FVIIa), 
while deficiencies in FIX or FVIII is universally associated with serious bleeding 
tendencies, suggesting that the cascading nature of this system is crucial for 
signal amplification (Wang et al., 2005; Grover and Mackman, 2019). Each 




molecule upstream can activate multiple molecules of the downstream 
component, and in turn each of these can activate multiple molecules of their 
downstream component. This pattern continues throughout the cascade; thus 
defects in the more downstream components are more apparent in the 
phenotype. 
Platelets are notably absent from this model of coagulation, not fitting with the 
observations that thrombocytopenic patients bleed considerably regardless of the 
correct functioning of all enzymes described in the waterfall model, and we know 
that thrombi in vivo consist not just of fibrin but also a mesh of platelets and red 
blood cells. This waterfall model was developed through studying coagulation in 
vitro and has proven vital for understanding and measuring coagulation defects 
in a clinical laboratory setting, but it has become clear over many decades that 
this does not accurately represent the processes that lead to coagulation in vivo. 
 A more modern cell-based model highlights the synergy between 
the clotting factors and platelets 
In recent years, there have been attempts to combine the understanding of 
platelet biology with the coagulation cascade. The more recent modern cell-based 
model of coagulation proposed by Hoffman and Monroe suggests that the 
described coagulation cascade occurs on the surface of platelets and endothelial 
cells, progressing in three overlapping stages; (1) initiation which takes place on 
a tissue-factor bearing cell, (2) amplification in which platelets and cofactors are 
activated to set the stage for large scale thrombin generation, and (3) 
propagation, in which large amounts of thrombin are generated on the surface of 
platelets as seen in Figure 1.11 (Hoffman and Monroe, 2001).  
The initiation of clotting takes place after the injury of vascular endothelium, 
exposing tissue factor to circulating FVII. The endothelial membrane acts as a 
place for the activation of FVII, FV and FX, leading to the production of thrombin 
(and subsequently, fibrin) as described in the extrinsic pathway in the classical 
model (Hoffman and Monroe, 2001). During amplification, platelets adhere to the 
collagen-vWF complex initiating their aggregation. Activated platelets then bind 
FIXa and FVIIIa and promote the release of FV which is subsequently activated 
by thrombin and FXa, similar to the intrinsic pathway in the classical model. During 
the propagation phase, the FIXa-FVIIIa complex adhering to the surface of 
platelets activates FX and binds to FVa. The FVa-FXa complex then converts 
prothrombin into thrombin, initiating the conversion of fibrinogen to fibrin, resulting 




in a fibrin burst with subsequent clot formation. Many of these mentioned factors 
feed back to continue this process until a suitable haemostatic plug has formed.  
 
Figure 1.11. A cell-based model of coagulation. (Hoffman and Monroe, 2001; Bezinover 
et al., 2018). Reprinted by permission from Wolters Kluwer Health, Inc: Perioperative 
Coagulation Management in Liver Transplant Recipients, Transplantation 102(4) © 
2018. 
This cell-centric model of haemostasis may help explain some clinical features 
that an enzyme-centric model does not (Hoffman and Monroe, 2001). For 
example, in haemophilia, the classical model cannot explain why the extrinsic 
pathway cannot produce enough FXa to (at least partially) compensate for a lack 
of factor VIII/IX. TFPI has been hypothesised to shut off the FVIIa/TF pathway 
before it can make enough FXa to support generation of haemostatic amounts of 
thrombin (Wood et al., 2014). While this may play a role, the cell-based model 
suggests another intriguing possibility; that the bleeding tendency in haemophilia 
is caused not because of a lack of production of FXa, but because it is produced 
on the wrong cell surface. FXa produced on the surface of a TF-bearing cell is 
unlikely to reach the platelet surface without being inhibited by ATIII or TFPI. 
These two inhibitors at their normal plasma levels inhibit FXa so efficiently that it 
has a half-life of a minute or less in solution (Jesty et al., 1996). By contrast, FIXa 
is inhibited much less rapidly by ATIII and not at all by TFPI and so it can migrate 
from the TF-bearing cell to the platelet surface to form the platelet tenase complex 
(Hoffman and Monroe, 2001). This model suggests therefore that the bleeding 




tendency in haemophilia is a failure specifically of platelet-surface FX activation 
and thrombin generation. 
Furthermore, there is evidence that TF can become expressed on the surface of 
monocytes within minutes when stimulated by activated platelets through the 
action of P-selectin (Ivanov et al., 2019). There is also indication that this TF can 
end up on the surface of these platelets through microparticles produced by these 
monocytes (Siddiqui et al., 2002). Flow cytometry data also suggest that platelets 
have an inactive form of TF on their surface that becomes functional upon release. 
However, the relevance of this in health and disease remains somewhat 
unexplored. 
1.5 Current therapies for the treatment of haemorrhage 
The causes of thrombosis, pathological clot formation in the absence of bleeding, 
are well-structured by Virchow’s triad, which relies on the pillars of 
hypercoagulability, endothelial damage and blood flow stasis. The induction of 
haemostasis for the treatment of haemorrhage also relies on exacerbating one or 
more of these pillars, either surgically through using substances to promote blood 
flow stasis, or medically through augmenting blood to be hypercoagulable. The 
choice of therapy often depends heavily on the cause of the haemorrhage. 
Surgically, blood flow stasis is often treated through compression, sutures and 
electro-cauterisation as well as topical haemostatic agents ranging from physical 
substrates such as bone wax, gelatine foams, mineral zeolite and cyanoacrylate, 
through to absorbable agents containing oxidised cellulose, microfibrillar 
collagen, chitosan and biologic agents such as thrombin and fibrin (Achneck et 
al., 2010).  
Therapies used to promote hypercoagulability of blood focus around blood-
derived sources of replacement coagulation factors. Fresh frozen plasma (FFP) 
is transfused to replace coagulation factors lost during massive haemorrhage 
(Dickneite and Pragst, 2009). Cryoprecipitate is another blood product derived 
from repeated freeze-thawing of FFP to produce a source of more concentrated 
clotting factors including Factor VIII, vWF and fibrinogen. It is most commonly 
used to replenish fibrinogen levels in acquired coagulopathy in the context of 
cardiac surgery, trauma, obstetric haemorrhage and liver transplantation 
(Nascimento, Goodnough and Levy, 2014). Prothrombin complex concentrates 
(PCC) are blood products enriched in the vitamin K-dependent clotting factors II, 
VII, IX and X. FFP, cryoprecipitate and PCC all serve to replace lost coagulation 
factors and so have their use during massive ongoing perioperative or post-




partum haemorrhage, and in reversal of warfarin therapy by replacing the vitamin 
K-dependent factors back into the blood (Sarode et al., 2013; Ghadimi, Levy and 
Welsby, 2016). 
As well as factors to promote the clotting cascade, tranexamic acid (TXA), a 
synthetic lysine analogue, is a widely used treatment used to inhibit plasmin 
generation and thus the process of fibrinolysis. Patients with polytrauma and 
those undergoing surgical procedures on organs rich in plasminogen activators 
(e.g. liver, kidney, pancreas) are at a high risk of hyperfibrinolysis and in these 
cases, antifibrinolytics such as TXA can be used for prophylaxis and treatment of 
bleeding (Pabinger et al., 2017). 
For patients with haemophilia disorders, factor replacement therapy with FVIII or 
FIX as required is often standard therapy. Upon the development of inhibitory 
antibodies, patients may also be trialled on Factor Eight Inhibitor Bypass Activity 
(FEIBA), a blood product containing zymogen Factors II, IX and X as well as 
activated factor VII, often considered to be an activated form of PCC (Turecek et 
al., 2004; Dager, Roberts and Nishijima, 2019). Recombinant activated FVII is 
also used as an alternative to this blood product to achieve a similar effect, and 
both can be used off-license in severe haemorrhage in non-haemophiliacs 
(described in further detail in section 1.5.4). 
Finally, as mentioned in previous sections, haemostasis requires both coagulation 
factors and platelets and thus platelet transfusion is a hugely successful therapy 
for patients suffering from thrombocytopenia due to chemotherapy, leukaemia, or 
massive blood loss. 
 Transfusion of platelets as a therapy for bleeding 
Pioneering work by W. Duke in 1910 first established that it was possible to 
reverse the risk of bleeding with a case series of thrombocytopenic patients 
transfused with fresh whole blood, whose bleeding ceased and platelet counts 
increased (Duke, 1910). It took another fifty years to confirm the role of 
thrombocytopaenia as the key cause of bleeding in the haemorrhagic disorders 
of leukaemia and to show that selective platelet transfusion could relieve these. 
An autopsy series compared deaths retrospectively in acute leukaemia patients 
before and after 1959 when platelet transfusion became available, and found that 
strikingly, haemorrhage was the second leading cause of death after infection and 
that this dropped from 67% (1953-1959) to 37% (1960-63) (Hersh et al., 1965). 
By the end of the 1960s, platelet transfusion had become a routine procedure in 




haematology departments and had also moved from only treating acute bleeding 
to also being used prophylactically to prevent them. Along with antibiotics for 
infections, this both directly extended patient survival and gave their physicians 
more time to try new chemotherapies to treat the underlying leukaemia. 
Over the next several decades evidence emerged that these platelets could be 
stored for up to 3 days at 22°C with no loss of haemostatic function and 
subsequent advances made it possible to extend this to 5 and then 7 days 
(Murphy and Gardner, 1971). As well as platelets extracted from pooled donated 
whole blood (the buffy coat procedure that requires four pooled blood units), new 
technologies such as automated apheresis allowed the possibility of more 
frequent donations from single platelet donors and thus a way to meet the 
inventory needs of transfusion services supporting increasing numbers of 
chemotherapy patients (Simon, 1994). 
Platelet concentrates also became widely adopted for treating other causes of 
haemorrhage, such as that due to trauma (e.g. on the battlefield), postpartum and 
during surgery (especially cardiac surgery). Although widely practiced, there is 
still a lack of consensus in the literature upon the evidence for perioperative 
platelet transfusion to maintain haemostasis (Levy et al., 2017). 
 Modern platelet transfusion practices around the world 
Presently, up to 2.9 million transfusions of platelets take place each year in 
Europe (Stroncek and Rebulla, 2007). Platelet transfusion strategies are driven 
by either the need to stop active bleeding (therapeutic) or to prevent its 
occurrence in at-risk groups (prophylactic). The most common situations are for 
patients receiving chemotherapy, requiring surgery (especially cardiac surgery) 
or having experienced severe haemorrhage (e.g. from pregnancy or childbirth, 
trauma, largely from road traffic accidents, or severe anaemia in the young, often 
caused by malaria), often being combined with other blood products such as fresh 
frozen plasma and red blood cells (RBCs) in a massive transfusion protocol. 
Just like other blood products, platelets must be tested for immuno-compatibility 
between donors and hosts. A mismatch can quite quickly lead to hyperacute 
rejection and other suboptimal clinical outcomes. Until the turn of the 20th century, 
blood transfusions were a dangerous and unsafe practice, outlawed in many parts 
of the world. Landsteiner’s pioneering work in 1900 laid the foundation for 
transfusion medicine with the discovery of the ABO blood type system which 
made these procedures much safer (Landsteiner, 1900). As well as the ABO 
blood groups common to RBCs and platelets, platelets also have other specific 




antigens that must be matched that are not required for RBC transfusions, such 
as human leukocyte antigens (HLA) and human neutrophil antigens (HNA) and 
human platelet antigens (HPA)  (Estcourt et al., 2017). Often these are not as 
important in a patient receiving their first platelet transfusion, but this becomes 
more important if they begin to receive repeated transfusions and post-pregnancy 
due to the development of alloimmunisation. 
In most high-income countries, there is an adequate supply of blood with its use 
largely pre-planned and predictable, with most blood transfusions (79%) taking 
place in the over 60 group (WHO, 2016). Blood donors and their donated blood 
are rigorously screened, and so the frequency of disease transmission through 
transfusion is low, although tragically marred by recent scandals in the 1980s with 
the large-scale infection of patients with HIV and Hepatitis B when strict screening 
and testing for infectious agents was less common. However, many of these 
factors that are no longer as prevalent in higher-income countries remain major 
ongoing issues in lower-income countries, where most blood transfusions (67%) 
are given to children below the age of 5. This reflecting the different demands on 
medical care in different parts of the world. In sub-Saharan Africa, blood 
shortages (the leading cause of maternal mortality due to post-partum 
haemorrhage) and unsafe blood (leading to many instances of transmission of 
HIV and hepatitis) represent major challenges in transfusion medicine (WHO, 
2015). These are thought to be due to the result of a relative paucity of donors 
(combined with a free market, quickly leading to blood products becoming 
unaffordable for many), the unwillingness of relatives to donate due to cultural 
differences as well as inadequate supply chains, storage and transport 
infrastructure (Bates et al., 2008).  
 Current limitations of platelet transfusion 
In recent years with advances in chemotherapy and increases in trauma surgery, 
demand for platelet products is steadily increasing while at the same time, the 
supply from donors has remained largely constant (see Figure 1.12) (Cowan, 
2017). Many countries rely on voluntary non-remunerated donors, as commercial 
blood donation has been demonstrated to result in blood with a higher prevalence 
of both HIV and Hepatitis B antigen (Ahmed, Ibrahim and Hassan, 2007; Ala et 
al., 2012). 
There have been no major advances to improve the storage of platelets beyond 
7 days, compared with 35-40 days for red blood cells, making these a 
comparatively highly perishable blood product (Smethurst, 2016; García-Roa et 




al., 2017). Due to their short shelf life, it can be difficult for their supply to keep up 
with their demand, especially over holiday periods when fewer donors are 
available, after natural events such as snowstorms, and maintaining the logistics 
of a blood supply chain is difficult in remote areas (American Red Cross, 2019). 
Platelet concentrates are kept at room temperature, increasing risk of bacterial 
contamination, and their haemostatic and metabolic function is known to 
deteriorate over time in storage, in a process named platelet storage lesion (Thon, 
Schubert and Devine, 2008; Védy et al., 2009). Furthermore, the prophylactic use 
of platelets requires the use of repeated transfusions that increases the risk of 
more allo-immunity against these products. This requires progressively stricter 
HLA matching, which reduces the pool of potential donors and it can very quickly 
become difficult to obtain compatible blood (Levy and Woodfield, 1984). 
 
 
Figure 1.12. Demand for platelet units increasing over time in the UK, replotted with 
data from Strategies to reduce inappropriate use of platelet transfusions (Cowan, 
2017) under CC BY. NHSBT = National Health Service Blood and Transplant. 
 NovoSeven (a recombinant FVIIa) as a clinical treatment for 
bleeding 
The above-mentioned cell-based theory of haemostasis also may explain some 
features of the efficiency of high dose recombinant FVIIa in promoting 
haemostasis in haemophiliacs. Recombinant factor VIIa (eptacog alfa or its brand 
name, NovoSeven), was originally developed as a ‘bypass factor’ to treat bleeding 
tendencies in haemophiliacs that had developed inhibitors to exogenous FVIII and 
FIX (Hedner and Kisiel, 1983). 
Factor VII, a serine protease, is encoded in chromosome 13q34, by a sequence 
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1987) located 2.8kb upstream from the Factor X gene (Miao et al., 1992). 
Alternative splicing leads to the expression of two isoforms, A and B. Isoform B is 
the prevailing form in the liver and does not include exon 1b, thus encoding a 
shorter signal peptide than isoform A (O’Hara et al., 1987). Both isoforms encode 
for the same mature protein of a single-chain peptide with 406 amino acids, with 
a molecular weight of 50kDa (Mirzaahmadi et al., 2011). This zymogen protein is 
converted into its active form by the cleavage of a peptide bond between Arg152-
Ile153, physiologically triggered by exposure to tissue factor as described in 
Figure 1.13, while both resultant peptides, the heavy and the light chain, are held 
together by two disulphide bonds. The zymogen undergoes a conformational 
change to expose the active site of the enzyme (Figure 1.13). Eptacog alfa is 
produced in Chinese Hamster Ovary (CHO) cells through expressing the 
recombinant form of zymogen Factor VII. It is activated to FVIIa as a consequence 
of the purification process (Jurlander et al., 2001). 
 
Figure 1.13. The structure of human Factor VII, taken from (Jurlander et al., 2001). * 
indicates glycosylation sites, γ indicates gamma-carboxyglutamic acid, bold circles 
indicate catalytic site residues, arrow indicates the cleavage site for activation after 
Arg152. © Georg Thieme Verlag KG. 




The doses of rFVIIa required for a clinical effect in haemophiliacs produce plasma 
levels that are several orders of magnitude greater than the Kd for FVIIa binding 
to TF, leading many to conclude that it is unlikely that rFVIIa works through this 
classical extrinsic pathway TF-dependent mechanism (Augustsson and Persson, 
2014). In the literature, it is well-documented that FVIIa has very little (although 
not zero) proteolytic activity in the absence of its co-factor. In the cell-based model 
of haemostasis, the platelet surface may behave as a phosphotidylserine (PS)-
containing lipid surface in supporting the activity of FVIIa. FVIIa has been 
demonstrated to bind to activated, but not unactivated platelets with an affinity 
similar to that for synthetic PS-containing lipid vesicles, and that once bound to 
the surface of an activated platelet, it can activate FX (Rao and Rapaport, 1990). 
The amount of FXa generated through this mechanism is thought to be sufficient 
to support near-normal levels of thrombin generation in an experimental model of 
FVIII and FIX deficiency. This is consistent with a model of coagulation in which 
platelet surface FXa generation is necessary to support platelet prothrombinase 
assembly (Ivanciu, Krishnaswamy and Camire, 2014). 
As the cell-based model of haemostasis suggests the haemostatic defects in 
haemophilia is due to a failure of platelet surface thrombin generation, restoration 
of platelet surface thrombin generation by high dose FVIIa through this 
mechanism is plausible. In support of this, it has been found the levels of rFVIIa 
that must be obtained in vivo correlate well with the levels needed for restoration 
of platelet surface thrombin generation in vitro. This platelet surface mechanism 
would also explain why high dose FVIIa is effective in establishing haemostasis 
in non-haemophilic patients with thrombocytopenia or other platelet function 
defects (Hoffman and Monroe, 2001). In models of these conditions, the addition 
of high levels of FVIIa enhances the amount of thrombin generated by each 
platelet. 
Tissue Factor Pathway Inhibitor (TFPI) is also a known potent negative regulator 
of the extrinsic pathway of coagulation by forming a complex with FXa; the 
FVIIa:TF complex generated from the extrinsic pathway forms a quaternary 
complex, FVIIa:TF:FXa:TFPI, which feeds back to inhibit the firm step of the 
extrinsic pathway (Hedner and Erhardtsen, 2000). Two isoforms are known, with 
platelets containing TFPIα and endothelial cells containing TFPIβ. Platelet TFPI 
has been shown to play a physiological role in limiting thrombus growth in 
chimeric mouse studies (Maroney et al., 2011). One theory suggests that the high 
dose of rFVIIa required for clinical efficacy is to overcome this initial negative 
feedback loop. Evidence for this idea has been mixed, with a recent study 
showing that in the presence of concizumab, a monoclonal antibody that inhibits 




TFPI, where we might expect the potency of rFVIIa to increase if the above 
hypothesis were true. The potency of rFVIIa increased when measured on human 
blood with in vitro assays, but not when measured in vivo in rabbits when 
measuring blood loss as a primary endpoint (Lauritzen et al., 2019).  
In summary, the mechanism of action of rFVIIa is thought not to be due to 
augmentation of the extrinsic pathway or by binding to tissue factor in a manner 
similar to endogenous FVII activation, but instead through increasing FXa on the 
surface of activated platelets. This allows for the bypass of deficiencies in factors 
that mediate signal transduction between tissue-factor-bearing cells and platelets 
in haemophilia as well as the augmentation of platelet thrombin generation in 
thrombocytopenia. It is this latter point has led to the use of rFVIIa off-license as 
a treatment for severe bleeding after massive haemorrhage. 
Bleeding after cardiac surgery is a serious complication, and excessive blood loss 
necessitates transfusion of allogeneic blood products as described earlier as well 
as surgical re-exploration. Between 5-7% of patients lose greater than 2L of blood 
within the first 24 hours after surgery and up to 5% require re-operation to treat 
this bleeding (Clifford and Kor, 2016). Both transfusion and re-operation are 
associated with prolonged intensive care and hospital stays as well as reduced 
survival rates. Retrospective studies have also shown that alternatives, such as 
PCC and FEIBA do not provide any advantage over rFVIIa, in terms of blood loss, 
incidence of re-exploration and thromboembolic events (Rao et al., 2014; 
Mehringer et al., 2018). 





Figure 1.14. Randomised controlled trial of NovoSeven in patients undergoing cardiac 
surgery.  (A) Percentage of patients requiring reoperations because of bleeding. 
Percentages are based on the number of patients randomized and dosed (placebo, n=68 
patients; 40 μg/kg rFVIIa, n=35 patients; 80 μg/kg rFVIIa, n=69 patients). P values were 
determined in comparison to placebo treatment values with χ2 tests. (B) Percentage of 
patients avoiding transfusions after administration of trial drug. Percentages are based 
on the number of patients randomized and dosed (placebo, n=68 patients; 40 μg/kg 
rFVIIa, n=35 patients; 80 μg/kg rFVIIa, n=69 patients).(Gill et al., 2009). Reprinted by 
permission from Wolters Kluwer Health, Inc: Safety and Efficacy of Recombinant 
Activated Factor VII, Circulation 120(1) © 2009. 
Clinical randomised controlled trials of rFVIIa have been undertaken to determine 
whether rFVIIa used off-license may be able to improve outcomes in these 
situations (Figure 1.14). In one such trial, patients who had undergone cardiac 
surgery and were bleeding were randomised to either a placebo or rFVIIa at two 
doses (40µg/kg and 80µg/kg) (Gill et al., 2009). Primary end-points were to 
measure the number of adverse events and secondary end-points were to 
measure rates of re-operation, amounts of blood loss and the rates of transfusion 
being used as a therapy. Outcomes from this trial showed a statistically significant 




difference in the secondary end-points; significantly fewer patients in the rFVIIa 
group underwent a re-operation in a dose-dependent manner and significantly 
fewer required allogeneic transfusions. There were more serious adverse events 
reported (including strokes) in the groups that received rFVIIa compared with 
placebo, although these results did not reach statistical significance. The study 
concluded that it may be beneficial but must be used with caution. 
Apart from the potential adverse side-effects, other barriers to the use of rFVIIa 
in preventing bleeding include cost. With an average adult male of 70kg, a 
80µg/kg dose would be 5.6mg, which costs around $11,700.00 per injection 
(NICE, 2020). As recombinant protein drugs have a short half-life (in this case, of 
1-2 hours), it is likely that repeated injections would be required. Lowering the 
cost of using rFVIIa clinically would add to the market case for the use of this 
therapy, however there may be numerous other advantages including an 
improved safety profile and the ability to use the same technology to deliver 
combinations of multiple proteins such as growth factors in the future. 
  




1.6 Project aims 
The aims of my PhD are to investigate the possibility of using platelet α–granules 
as a delivery vehicle for rFVIIa, which might lead to a reduction in the number of 
platelets needed for a transfusion, as well as the amount of rFVIIa required to 
achieve haemostasis. 
In order to do this using the forward-programming system, I will modify the 
zymogen FVII gene to become self-activating and fused this with a vWF SPD2 
motif to direct the protein sorting machinery of megakaryocytes to package this 
into α–granules. I will investigate whether through transduction of in vitro-derived 
megakaryocytes, if it is possible to create a non-immortalised cell culture of 
human megakaryocytes that produce platelets loaded with rFVIIa. I will further 
characterised the functionality of this rFVIIa to demonstrate it shows efficacy 
despite the modifications made and characterised the haemostatic effect of the 
resultant platelets through in vitro assays. 
In turn, I will use endocytosis to demonstrate it is possible for both 
megakaryocytes and platelets to passively take up rFVIIa into their granules and 
release it upon activation. 
Finally, I will also develop a mouse model for human platelet transfusion and 
haemostasis with thrombocytopaenic immunodeficient NRG/J mice, establish the 
controls and test the efficacy of both donor derived-platelets and donor-derived 
platelets loaded with rFVIIa to investigate the additional benefit that this might 
provide. 
  




2  MATERIALS AND METHODS 




2.1 Molecular Biology 
 Buffers 









2.1.1.2 TAE buffer (50x stock) 
Compound Concentration 
Tris base 2M 
Glacial acetic acid 1M 
0.5M EDTA (pH 8.0) 50mM 




Make up to 1L in PBS 
2.1.1.4 TAP lysis buffer 
Compound Concentration 
Tris-HCl (pH 8.0) 10mM 
NaCl 150mM 
NP-40 0.1% 
Make up to 100mL in deionised water 




2.1.1.5 4% PFA 
Compound Concentration 
16% Formaldehyde solution (no 
methanol) (28908, Thermo) 
10ml 
Make up to 40mL with PBS 
2.1.1.6 Acid-citrate dextrose (ACD) 
Compound Concentration 
Sodium citrate 37mM 
Citric acid 25mM 
Dextrose 82mM 
Make up to 100mL in deionised water 
2.1.1.7 AHD-575 (Haemoglobin lysis reagent) 
Compound Concentration 
Triton X-100 2.5% 
NaOH 10mM 
Make up to 100mL in deionised water 
2.1.1.8 0.1M Carbonate/Bicarbonate antibody adsorption buffer (pH 9.6) 
Compound Concentration 
Sodium bicarbonate 12.5mM 
Sodium carbonate (anhydrous) 87.5mM 
Make up to 500mL in deionised water 
2.1.1.9 ELISA Wash Buffer 
Compound Concentration 
Tween-20 0.05% 
Make up to 500mL in PBS 




2.1.1.10 Immunofluorescence permeabilization buffer 
Compound Concentration 
BSA (A9418-5G, Sigma-Aldrich) 1% 




PBS-Tween 20 0.1% 
2.1.1.11 Immunofluorescence primary antibody buffer 
 Compound Concentration 
BSA (A9418-5G, Sigma-Aldrich) 1% 
PBS-Tween 20 0.1% 
Antibody 1:1000 
2.1.1.12 ACK buffer 




2.1.1.13 LB Broth 
 Compound Amount 
Tryptone 10g 
NaCl 10g 
Yeast extract 5g 
Made up to 1L with distilled water 
2.1.1.14 Ampicillin LB-Agar Plates 
 Compound Amount 
Bacto agar 15g 
LB Broth 1L 




100mg/ml ampicillin 0.5mL 
2.1.1.15 TBS-Tween, pH 8.0 
 Compound Concentration 




2.1.1.16 AE6 media 
 Compound Concentration 
DMEM/F12 (Life Technologies) 500mL 
NaHCO3 0.054% 
L-Ascorbic Acid (Thermo Fisher 
Scientific) 
64mg/L 
Insulin (Life Technologies) 20mg/L 
Transferrin (Life Technologies) 11mg/L 
Selenium (Life Technologies) 0.0134mg/L 
 Antibodies 
Clone Host species Antigen  Dilution Used for  Company Cat no. 






acids 209 and 
444 (heavy 
chain only) 
1:1000 IF Abcam ab97614 








acids 39 and 
444 (both light 
and heavy 
chains) 
1:1000 IF R&D AF2338 




HIP8 Mouse anti-CD41a-H7 1:100 FC BDPharmingen 561422 
HIP1 Mouse anti-CD42b-
APC 
1:100 FC BDPharmingen 551061 
HIP1 Mouse anti-CD235a-PE 1:100 FC BDPharmingen 555570 
MOPC-21 Mouse Isotype H7 1:100 FC BDPharmingen 555749 
MOPC-21 Mouse Isotype APC 1:100 FC BDPharmingen 555751 
MOPC-21 Mouse Isotype PE 1:100 FC BDPharmingen 560167 
polyclonal Goat anti-rabbit-
Alexa488 
1:1000 FC Invitrogen A11034 
polyclonal Donkey anti-goat-HRP 
conjugate 
1:10000 WB Signalway 
Antibody 
L3042-2 




polyclonal Goat anti-rabbit-HRP 
conjugate 
1:10000 WB Southern 
Biotech 
4030-05 
polyclonal Rabbit GAPDH 1:1000 WB Abcam ab9485 
1C2 Hamster Anti-CD42d 
PerCy5.5 
1:100 FC BioLegend 148507 
ALMA.16 
(RUO) 
Mouse Anti-CD42-APC 1:100 FC BDPharmingen 558819 
HTK888 Hamster Isotype 
PerCy5.5 
1:100 FC BioLegend 400931 




Cedarlane Lab CLA31440 
Monoclon
al 




Emfret Analytics R300 
Polyclonal Rabbit Anti-Factor VII 1:100 FC Abcam ab197656 
polyclonal Rabbit Anti-Factor VII 1:100 FC Abcam ab97614 






Mouse Anti-endostatin 1:1000 IF Santa Cruz 
Biotechnology 
sc-514355 
Polyclonal Goat Anti-Mouse-488 
Secondary 
1:1000 IF Thermo Fisher A21121 
Polyclonal Goat Anti-Rabbit-647 1:1000 IF Thermo Fisher A21244 






1:1000 IF Abcam ab1823 
 PCR Primers 
All primers were ordered from Sigma-Aldrich, UK. See specific methods and 
results sections for details on their use. 
Name Purpose Sequence 
LC_FO 
















Thrombin_LC_FO Amplification of F7 light 
chain with added 
thrombin cleavage 


















_Fo Gibson assembly 













































Primers for lentiviral 





Table 2.1. A list of PCR primers used in the project, containing their label, function and 
DNA sequence. 
 PCR 
Human foetal liver cDNA was obtained (kind gift from Dr Ludovic Vallier) from 
which the F7 gene was amplified by Dr Annett Mueller.  
Preparative PCR for cloning used the high fidelity Phusion (M0530, New England 
BioLabs) or Platinum Taq (11304-011, Invitrogen) polymerases. Both were 
utilised using the optimal annealing temperature (Tm) for each given primer pair 
and a maximum of 35 amplification cycles. Each reaction was set up as follows: 




Polymerase (as described above) 0.1µL (2U/reaction) 
10X Buffer (provided with polymerase) 5µL 
50mM MgCl2 (provided with 
polymerase) 
1.5µL 
10mM dNTP mix (18427-088, 
Invitrogen) 
1µL 
Water, nuclease-free To 50µL 
This was followed by thermal cycling as described below: 
Step Temperature, ºC Time Cycles 
Initial 
denaturation 
94 2mins 1 
Denaturation 94 30s  
25-35 Annealing Tm-5 30s 
Extension 72 1min/kb 
Hold 4 Indefinitely 1 
For all PCR colony screening, 2x PCR Master Mix (K0171, Thermo Scientific) was 
used. Each PCR reaction was set up as follows: 
PCR Master Mix (2x) 25µL 
Forward primer 1µM 
Reverse primer 1µM 
Template DNA Pipette tip used to extract small 
amount from colony 
Water, nuclease-free To 50µL 
Samples were then amplified by thermal cycling as follows: 




Step Temperature, ºC Time Cycles 
Initial 
denaturation 
95 3mins 1 
Denaturation 95 30s  
25-40 Annealing Tm-5 30s 
Extension 72 1min/kb 
Final extension 72 10mins 1 
After which they were analysed on a 1% TAE agarose gel with a Kb+ ladder 
(10787018, Invitrogen), running at 80V and 400mA for 30mins. DNA fragments in 
gels were visualised through adding 1X SYBR safe DNA Gel stain (stock 
concentration at 1:10,000) (S33102, Thermo Fisher Scientific) and subsequent 
use of a UV light box. 
 Cloning 
Restriction cloning was performed on the plasmid pcDNA4/TO/Myc-His B 
(V103020, Thermo Scientific) using BamHI (R0136, NEB) and NotI (R0189, NEB) 
for double digestion. DNA was incubated with restriction enzymes in NEBuffer 3.1 
(B7203, NEB) and incubated at 37°C for 1 hr. Purification was performed using a 
1% agarose gel in TAE buffer with a Kb+ ladder (10787018, Invitrogen), running 
at 80V and 400mA for 30mins. 
DNA was extracted from gels and purified through gel melting and a column spin 
preparation (28704, Qiagen) and PCR products were purified with a column spin 
preparation (28104, Qiagen). DNA fragments in gels were visualised through 
SYBR safe DNA Gel stain (S33102, Thermo Fisher Scientific) and subsequent 
use of a UV light box. Relevant DNA fragments were excised with a scalpel and 
weighed. Gel slices were combined with buffer QG at a ratio of 3:1, followed by 
incubation at 50ºC for 10 minutes to dissolve the gel slice. One gel slice volume 
equivalent of isopropanol was added to the sample and was centrifuged (17,900g 
for 1 minute) with the provided QIAquick spin column to bind DNA into the 
embedded silicon membrane. The flow-through was discarded, and the DNA 
bound to the column was washed with buffer PE and centrifuged (17,900g for 1 
minute) again. Subsequently, DNA was redissolved from the column with 
nuclease-free water and eluted into a clean microcentrifuge tube. DNA 
concentration and purity were quantified using a NanoDrop Spectrophotometer 
ND-1000 (Thermo Scientific). 
Ligation was performed by incubation of DNA purified from PCR products and 
excised gels with the T4 ligase (M0202, NEB). This was performed by incubating 




2µl of 10X T4 DNA Ligase buffer, 1µl of 200,000 units/ml T4 ligase, 50ng of 
vector DNA, insert DNA at a molar ratio of 3:1 and nuclease-free water to make 
the volume up to 20µl. The reaction was incubated for 16 hours at 4°C.The 
required mass of insert was calculated as follows: 




Transformation was performed with the TOP10 bacterial strain (C404010, 
Thermo Scientific). A vial of cells was thawed for transformation and 5µL of a 
ligation reaction was gently pipetted into the vial. Vials were incubated on ice for 
30 minutes, followed by a heat shock at 42ºC in a pre-warmed water bath for 30 
seconds. Vials were place immediately on ice and  250µL of SOC media was 
added. Vials were shaken at 37ºC for 1 hour at 225rpm in a shaking incubator. 
20µL of the vial was transferred onto ampicillin LB-agar plates (for recipe see 
2.1.1.14) and grown overnight to isolate transformant colonies. Individual 
bacterial clones were then grown in liquid culture with LB broth (for recipe see 
2.1.1.13) (Media Lab, CIMR) supplemented with 100µg/ml ampicillin 
(10835242001, Sigma-Aldrich) for 16 hours at 37°C and 250rpm shaking in 
aerobic conditions. 
The pWPT-VWF lentiviral plasmid was a kind gift from Dr Wilcox, Wisconsin USA. 
The single fragment assembly proceeded with double restriction digestion of the 
plasmid with MluI (R0198) and SalI (R0138) in NEBuffer 3.1 (B7203) (New 
England BioLabs). The two-fragment assembly proceeded with a sequential 
digest of BlpI (R0585) for 1hr at 37°C, followed by adjustment of the salt 
concentration to 100mM by addition of NaCl, and addition of SalI (R0138) with 
subsequent incubation for 1hr at 37°C. Gibson cloning was then performed as per 
manufacturer instructions with 2x Gibson Assembly Master Mix (E2611S, New 
England BioLabs). 
Cloning steps and primers were designed on SnapGene v4.2.2 (GSL Biotech) 
which was also used to align sequencing data and produce plasmid maps. 
Sequencing was performed through capillary-read Sanger sequencing by Source 
Biosciences, UK. 
2.2 Cell culture techniques 
 Cell lines and storage 
All mammalian cell culture was performed under sterile conditions, in the absence 
of antibiotics and in standard humidified incubators kept at 37°C and 5% CO2 
normoxic atmosphere. 
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Transfection of plasmid DNA was performed using TurboFect reagent (R0532, 
Thermo Scientific) as per manufacturer instructions. 1µg of plasmid DNA was 
diluted in 100µL of serum-free RPMI 1640 media (12633-012, Gibco), before 
being mixed with 2µL of TurboFect reagent and vortexed. Turbofect/DNA 
complexes were allowed to form for 15 minutes. HEK293T cells were seeded into 
a 6 well plate and the Turbofect/DNA mixture was introduced when the cells were 
at 80-90% confluency and gently rocked to spread evenly across the cells.  
 Sample collection and cell lysis 
The collection of cell supernatants was performed 48 hours after transfection and 
aspirated from the 6 well plates. The cell layers were washed with phosphate-
buffered saline (PBS) and detached using a 5-minute, 37°C incubation with 
TrypLE Select (12563-029, Gibco), washed by dilution with PBS (1:10), taken into 
a 15ml tube and centrifuged to collect the cell pellets after a 300g centrifugation 
for 5 minutes at r.t. The supernatants were aspirated, and the cells lysed in 300µL 
of either M-PER cell lysis buffer (78501, Thermo Fisher) with Pierce Protease 
Inhibitors (88666, Thermo Fisher) or TAP lysis buffer (2.1.1.4), without inhibitors 
by vortexing the mixture and incubating on ice for 5 minutes. This was then 
centrifuged at 14000g for 10 minutes to remove cell debris. 
 Forward Programming of iPSCs to Megakaryocytes 
iPS cells with genomic modifications to contain GATA1, TAL1 and FLI1 under the 
control of a doxycycline-inducible promoter were used for forward programming. 
iBobC and iPBG3 cell lines were received from Dr Amanda Dalby. Forward 
programming is largely similar to as described previously in (Moreau et al., 2016). 
Briefly, iPS cells were seeded onto 0.5µg/cm2 vitronectin-coated plates (A14701, 
Life Technologies) as single cells and cultured with AE6 (500ml of DMEM/F12 
[11330-032, Gibco], 7.5% NaHCO3, 1x 99% LAA [A92902, Sigma-Aldrich], 1x ITS 
(10 µg/ml recombinant human insulin, 5.5 µg/ml human transferrin (substantially 




iron-free), and 5 ng/ml sodium selenite) [I3146, Sigma-Aldrich]), FGF2 (15ng/ml, 
SRP4037, Sigma-Aldrich), Activin A (15ng/ml, A4941, Sigma-Aldrich) and 10mM 
Y-27632 (ROCK inhibitor) (SCM075, Sigma-Aldrich). After 24 hours, cells were 
washed with PBS and switched to mesoderm media (AE6 with FGF2 (20ng/ml) 
and BMP4 (10ng/ml, 314-BP-010, R&D Systems) and 1µg/ml doxycycline added. 
After 48 hours, the medium was changed for MK-supporting culture conditions as 
CellGRO-SCGM (20802-0500, CellGenix) supplemented with rhTPO (288-TP-
025/CF, R&D) at 20ng/ml and rhSCF (PHC2111, Gibco) at 25ng/ml, maintaining 
1µg/ml doxycycline for iBobC and 0.25µg/ml for iPBG3 in order to induce the 
transgenic expression of the three transcription factors instead of lentiviral 
vectors. and refreshing medium component every 3 days. For further details 
regarding the development and detailed phenotyping of forward-programmed 
lines, see Moreau et al., 2016.  
 Flow cytometry for cell culture monitoring 
CHRFs were analysed by flow cytometry by extracting 100µL from culture within 
a T75 flask, combined with 300µl of PBE Flow Buffer (2.1.1.3), 1µg/ml DAPI 
(D9542, Sigma-Aldrich) and count beads (335925, BD Biosciences). Data 
collection was performed on a Gallios Flow Cytometer (Beckman-Coulter) with 
gates set to exclude non-viable cells (DAPI+) and to measure GFP expression 
and count beads. Results were analysed with Kaluza Analysis v1.5 (Beckman 
Coulter). 
Forward Programmed megakaryocytes were stained in the dark for 20mins with 
antibodies (anti-CD41a-H7, anti-CD42b-APC, anti-CD235a-PE) (including 
unstained, single stained and isotype controls) before being diluted in PBS, spun 
down at 300g for 5 minutes and resuspended in flow buffer and 1µg/ml DAPI and 
flow cytometry was performed as described above. Antibody details (catalogue 
numbers, source company, clone type) are available on page 73. 
 Intracellular flow cytometry staining 
Wash steps for all cells were performed by adding 1ml of PBE flow buffer 
(2.1.1.3), spinning at 300g for 5mins and aspirating the supernatant. Wash steps 
for samples containing platelets were performed by adding 750ng/ml 
prostaglandin I2 (PGI2) (P6188, Sigma) and 1ml of PBE flow buffer (2.1.1.3) 
before spinning down at 1500g and aspirating the flow buffer. 
Firstly, samples were incubated with 1:50 (1 unit) of Zombie-Violet (423113, 
BioLegend) for 20mins followed by a wash step. Samples were then fixed with 
4% PFA for 15mins in the dark at room temperature, followed by another wash 
step. Samples were permeabilised with Reagent B in Fix-and-perm kit 
(GAS002S5, Thermo) and incubated with primary antibodies (2.1.1.12) at the 
appropriate dilution for 20mins. After a wash step, samples were incubated with 
Reagent B again along with secondary antibodies (2.1.1.12) in the dark for 
20mins. Samples underwent another wash step, followed by resuspension in PBE 




flow buffer (2.1.1.3) and data was collected using the Gallios Flow Cytometer as 
described above (2.2.5). 
 Lentiviral production and titration 
Lentiviruses were produced as described previously (Moreau et al., 2016). Briefly, 
HEK293T cells were transfected (2.2.2) with the individual pWPT plasmid (12255, 
Addgene) containing the sequences of interest and co-transfected with packaging 
plasmids psPAX2 (12260, Addgene) and pMD2.G (12259, Addgene). Cells were 
washed after 24 hours and supernatants containing virus were collected at 48 
hours and concentrated using Lenti-X Concentrator (631232, Takara Bio). One 
volume of supernatant was combined with three volumes of Lenti-X Concentrator 
and mixed by gentle inversion. The mixture was incubated at 4ºC for 30 minutes, 
and then centrifuged at 1500g for 45 minutes held at 4ºC. The resulting 
supernatant was removed, following careful resuspension of the pellet in 1/100th 
of the original volume in CellGro (20802-0500, CellGenix). qPCR titrations of 
lentiviruses were also performed as described previously by the lab in an 
MX3000P (Stratagene). Briefly, HCT116 cells transduced with various 
multiplicities of infection (MOIs) of GFP-bearing lentivirus was run on a flow 
cytometer and used as a control curve. Then all cell lysates from cells transduced 
with unknown titres of virus and GFP control virus were analysed by qPCR for 
HMBS (hydroxymethylbilane synthase, as a housekeeping gene present in the 
cells) and RRE (Rev-responsive element, to measure the presence of the vector), 
along with known dilutions of a qPCR lentivirus standard. Functional data from 
the flow cytometry was used to create a conversion curve between qPCR ratios 
of viral Rev-response element (RRE) to cellular hydroxymethylbilane synthase 
(HMBS) with GFP expression (in transduction units/ml). A Poisson distribution 
was used to model infection by the lentivirus and calculate the effective 
transduction units present in each viral sample. 
 Transduction of cells with lentivirus 
Cells were counted, and 1x105 cells were resuspended in 300µl of media (2.2.1) 
in a 24 well plate, and the appropriate amount of lentivirus was added (with an 
MOI of between 2 and 10) carefully to transduce the cells along with protamine 
sulfate at a final concentration of 10µg/ml (P3369-10G, Sigma-Aldrich). Cells 
were washed in PBS after 24 hours, and the culture was scaled up over the next 
three splits into a 6 well plate (and in the case for CHRFs but not for FoP-MKs, 
T25 flask and eventually into T75 flasks). 
2.3 Protein experiments 
 Immunofluorescence 
Fibrinogen (F3879-1G, Sigma) (200µg/ml) was adsorbed onto glass cover slips 
for 1hr at r.t. Cells (counted to 1x106) incubated onto these coated cover slips for 
1hr were fixed with 1% formaldehyde at 37°C for 10 mins, and then washed in 




PBS. Permeabilisation buffer (page 72) was added and cover slips were 
incubated at room temperature for 1hr, followed by primary antibody buffer (page 
73) for 1hr at room temperature, and then washed three times in PBS for five 
minutes each. They were then incubated with secondary antibody buffer (1% 
BSA, 1:1000 secondary antibody, goat anti-rabbit-Alexa488) for 1hr at room 
temperature in the dark and washed again 3x (5 mins each) with PBS in the dark. 
The first wash step included 1µg/ml DAPI (D9542, Sigma-Aldrich) to stain nuclei. 
These were fixed onto slides with ProLong Diamond Antifade Mountant (P36961, 
Invitrogen). 
 Western Blotting 
Protein concentrations were analysed via a BCA assay (23225, Thermo 
Scientific). BSA standards were made  through diluting the provided BSA stocks, 
to 2000, 1500, 1000, 750, 500, 250, 125, 25 and 0µg/ml. BCA Working reagent 
was prepared by mixing 50 parts of the provided reagent A with 1 part of the 
provided reagent B. 25µL of each sample or standard was pipetted onto a 
microplate, along with 200µl of working reagent. The plate was covered and left 
in the dark at 37ºC for 30mins. Colour changes were measured at 562nm with a  
SpectraMax M5 spectrophotometer, and the standard curve was used to 
interpolate protein concentrations of the samples. 
Samples were then normalised for protein concentration and were denatured 
using a reducing agent (NP0004, Invitrogen) and sample buffer (NP0007, 
Invitrogen) by incubating this mixture at 90ºC for 10 minutes. Samples loaded into 
a 4-12% Bis-Tris gel (NP0321BOX, Life Technologies) were run at 180V for 1hr 
with 2.5µl of a MagicMark XP Protein Ladder (LC5602, Thermo Scientific) with a 
running buffer containing 50ml of 20x MOPS SDS Running Buffer (NP0001, Life 
Technologies), 1L of dH2O and 500µL of antioxidants (NP0005, Life 
Technologies). Samples were then wet-transferred onto nitrocellulose membrane 
at 30V for 1hr, with transfer buffer containing 50ml of 20x Transfer Buffer 
(NP0006, Life Technologies), 100ml of methanol, 1ml of anti-oxidants (NP0005, 
Life Technologies) and 850ml of dH2O. 
Blocking was performed with 5% skimmed milk (70166-500G, Sigma-Aldrich) in 
TBS-Tween (for recipe see 2.1.1.15) (T9039-10PAK, Sigma-Aldrich) for 2hrs, 
followed by primary antibody in 5% skimmed milk (for concentrations of 
antibodies, see 2.1.1.12) overnight at 4°C on a plate rocker. TBS-Tween (for 
recipe see 2.1.1.15) (T9039-10PAK, Sigma-Aldrich) was then used for washing 
(3x10mins). The appropriate secondary antibody was incubated (see section 
2.1.1.15). Imaging was performed through use of ECL Prime reagent (RPN2232, 
Amersham) by adding a 1:1 mixture of the provided reagent A (luminol) and 
reagent B (peroxide) at r.t. in the dark for 5 minutes followed by imaging using a 
LICOR Odyssey Fc Imaging System. 




After imaging, for additional antibody stainings membranes were stripped with 
stripping buffer (46430, Thermo Scientific) for 15mins at room temperature. 
Membranes were then reblocked, stained and developed with appropriate follow-
up antibodies as described in the previous paragraph. 
 ELISA 
A Factor VII sandwich ELISA (ab190810, Abcam) was performed. Samples and 
standards were incubated with an antibody cocktail solution (supplied with kit) at 
room temperature for 1hr in a plate shaker at 400rpm. TMB Substrate (supplied 
with kit) was added and incubated for 10mins in the dark, before the reaction was 
stopped with 0.16M sulphuric acid. Microplates were read using a SpectraMax 
M5 (Molecular Devices) at 450nm and data was analysed with SoftMax Pro 
v7.0.3. 
 Chromogenic Factor VII Assay 
A chromogenic factor VII assay (ab108830, Abcam) was performed. Monoclonal 
FVII antibody (ab151543) was adsorbed to a 96 well Nunc MaxiSorb microplate 
by incubating 100uL of 0.1M carbonate/bicarbonate buffer (pH 9.6) with a rabbit 
monoclonal anti-FVII antibody (described in 2.1.1.15) per well. Samples and 
standards were allowed to bind on a microplate (either the one provided with the 
kit or the one prepared in the lab) at room temperature for 1hr, and then the plate 
was washed 5x in ELISA wash buffer (page 72). Tissue Factor, chromogenic 
Factor Xa substrate and Factor X (all supplied with kit) were added, and the plate 
was incubated at 37°C for 30mins. The rate of colour change over time was 
measured at 405nm every minute for 60 minutes with plate shaking before each 
reading. Data was analysed with SoftMax Pro v7.0.3. NovoSeven (eptacog alfa) 
(#00169-7201-01, Novo Nordisk) was used as a positive control at the indicated 
serial dilutions. 
 Thrombin generation assay 
The thrombin generation assay (5006010, Technoclone) was performed as 
follows. This assay was performed on black immunostandard 96 well plates for 
fluorescence assays (475515, Thermo Fisher). A thrombin calibration curve was 
generated by adding a 1:2, 1:4, 1:20 and 1:200 dilution of the calibrator in 
duplicate. 40µL of each of these samples was added to the 96 well plate, followed 
by 50µL of the TGA substrate (5006235, Technoclone). Fluorescence was 
measured for 10 minutes in 30 second intervals on a SpectraMax M5 pre-warmed 
to 37ºC with the protocol files provided with the kit. This was then exported onto 
the Excel spreadsheet given with the kit in order to calculate the concentration of 
thrombin in the TGA substrate. Platelet samples were measured by adding 40µL 
of the samples in duplicate to the 96 well plate, followed by 10µL of the RC Low 
buffer (5006212, Technoclone) provided with the kit. Finally, 50µL of TGA 
substrate was added before immediately placing the plate into a SpectraMax M5 
pre-warmed to 37ºC using the given protocol files. Analysis was performed 




according to the Excel spreadsheet provided by the manufacturer to measure all 
relevant parameters of the thrombin generation curve. 
 Whole blood sampling and platelet preparation 
Blood was drawn first using an EDTA vacutainer which was then discarded, and 
then, following this, without a tourniquet over sodium citate by vacutainers with 
full written informed consent given by the donor under local ethics approval (Blood 
donor ethics no: HBREC.2018.13). 
An additional 10% acid citrate dextrose (ACD, Sigma) was added to the blood 
before centrifugation at 100g at room temperature (r.t.) for 20 mins. The platelet 
rich plasma (PRP) layer was collected and supplemented with 750ng/ml PGI2 
(P6188, Sigma) before centrifugation at 1400g at r.t. for 10mins. The supernatant 
was removed and the platelet pellet carefully resuspended in Tyrode’s buffer 
(page 71) supplemented with 10% ACD and 750ng/ml PGI2 (P6188, Sigma). 
Finally, platelets were centrifuged at 1400g at r.t. for 10mins and platelets 
carefully resuspended in a Tyrode’s buffer to the indicated concentration. Platelet 
concentrations were calculated by diluting 10µl of platelets in 10ml of ISOTON 
solution (12754878, Fisher Scientific), and then measured using a Z2 Coulter 
Counter (6605700, Beckman-Coulter). 
 Endocytosis of rFVIIa in MKs and platelets 
Platelets were first prepared as in section 2.3.6. MKs and platelets were incubated 
with 0.01µg/µl rFVIIa for 2 hours at room temperature to allow endocytosis to take 
place. Platelet samples were then inhibited with 750ng/ml PGI2 (P6188, Sigma), 
washed with Tyrode’s and centrifuged (1400g for 10mins), followed by 
resuspension in Tyrodes buffer to wash off any unabsorbed rFVIIa. MKs were 
washed with PBE, spun down at 300g, and resuspended in PBE. These samples 
were then used for further analysis in intracellular flow, releasate assay and 
immunofluorescence staining. 
 Animal housing 
Mice were housed in pathogen free conditions. Animals were kept in a standard 
temperature- and humidity-controlled environment and had free access to water 
at Central Biomedical Services (Cambridge, UK) and cared for by trained staff. 
This research has been regulated under the Animals (Scientific Procedures) Act 
1986 Amendment Regulations 2012 following ethical review by the University of 
Cambridge Animal Welfare and Ethical Review Body (AWERB). Experiments 
were performed under Project Licence P667BD734 by trained, Personal Licence 
(PIL) holders. 




 Tail vein bleed 
Peripheral blood samples were withdrawn from the tail vein (to a maximum 
volume of 20 µL) to measure full blood counts. Mice were heated for 5mins at 
30ºC in a hot box. They were then transferred into a murine restraint stand. A 27G 
needle (BD Microlance 3 needles @ 27G x ½, cat no.:#300635, BD) was used to 
puncture a superficial vessel, and blood was collected into EDTA coated capillary 
tubes (SARSTEDT Microvette CB 300 K2E, ref.: 16.444). Pressure was applied 
to ensure haemostasis, before mice were returned to cages. Blood samples were 
then analysed using a Vet abc Plus+(scil) automatic haemocytometer. 
 IVC bleed 
Mice were terminated by a rising CO2 concentration. They were then moved onto 
a corkboard where they were held in place and a midline incision was made into 
the peritoneum in order to isolate the inferior vena cava (IVC). 1ml of blood was 
withdrawn from the IVC into either 100µL of ACD (as prepared in 2.1.1.6) or 0.1M 
EDTA to ensure anticoagulation. The right femoral artery was transected to 
ensure exsanguination and completion of the schedule 1 protocol. 
 Antibody depletion 
Mice were injected with 0.6µg/g body weight anti-CD42b (#R300, Emfret 
Analytics) in PBS intraperitoneally. Mice were bled from the tail vein at necessary 
timepoints into EDTA-coated capillary tubes (Microvette CB300, Sarstedt) to 
confirm depletion prior to tail transection assay. Platelet counts were determined 
using a Vet abc Plus+(scil) automatic haemocytometer. On one occasion, mice 
were followed up at 1, 4, 24, 48, 96 and 120 hours post depletion in order to 
assess the platelet depletion window. 
 Tail transection assay 
Immunodeficient NRG/J mice were depleted specifically of their platelets using 
0.6µg/g BW anti-CD42b antibody (Emfret Analytics, Germany) a minimum of one 
hour prior to a tail vein bleed both to confirm depletion and give an accurate 
haemoglobin level.  Following confirmation of depletion (by tail vein bleed as in 
2.3.9), mice were injected intraperitoneally using a mixture of ketamine 
(100mg/kg) and xylazine (10mg/kg) and transferred to a chamber set to 
38degrees for 5minutes.  Mice were then immediately intravenously (IV) injected 
in a tail vein with either Tyrode’s buffer, washed donor or in vitro bioreactor 
derived platelets.  Immediately following IV injection, mouse tails were transected 
2mm from the tail tip, and placed into 40ml warmed phosphate buffered saline.  
Every 4 mins tails were moved into fresh 40ml of saline for a total of 20mins.  
Following a maximum 20mins of bleeding time, mice were euthanised and blood 
was collected from the inferior vena cava into 100µl of 0.5M EDTA. 




 Haemoglobin assay 
The haemoglobin assay was based on the modified Triton-X/NaOH method from 
the QuantiChrom Haemoglobin Assay Kit (#DIHB-250, BioAssay Systems).  For 
the standards, 50µL water (blank) and 50µL of calibrator were added in duplicate 
to wells of a 96 well plate. This gives a linear response in the range of 0-200mg/dl 
of haemoglobin. 50µL of each unknown sample was added in duplicate to the 96 
well plate. 200µL of the AHD-575 reagent was added to all wells, this was 
incubated for 5 mins at room temperature to allow for the colour change, and then 
read on a plate reader at 400nm. The diluted calibrator is equivalent to 100mg/dL 





From the Hb concentration values, it is possible to infer the volume of blood loss 
from an animal with the following formula: 
Blood loss =  
[𝐻𝐻𝐻𝐻]𝑓𝑓𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑏𝑏 𝑐𝑐𝑡𝑡𝑏𝑏𝑠𝑠 × 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑓𝑓𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐𝑏𝑏 𝑐𝑐𝑡𝑡𝑏𝑏𝑠𝑠
[𝐻𝐻𝐻𝐻]𝑐𝑐𝑠𝑠𝑐𝑐𝑠𝑠 𝑣𝑣𝑠𝑠𝑐𝑐𝑏𝑏 𝑏𝑏𝑠𝑠𝑠𝑠𝑠𝑠𝑏𝑏
 
Post platelet depletion haemoglobin levels were analysed on a haematology 
analyser (scil Vet abc Plus+, scil animal care company) as a reference baseline 
haemoglobin level for each individual mouse. 
 Mouse MK isolation and culture 
Mouse bone marrow (BM) cells were prepared by extracting femoral and tibial 
bones from mice, with the muscle stripped and bone marrow exposed through 
fracture of the epiphysis. Media (DMEM containing 10% FBS and 5% pen-strep) 
was used to flush out bone marrow with a syringe. Extracted marrow was 
collected in 50ml falcon tubes, which were subsequently centrifuged for 5mins at 
200g held at 4ºC and supernatant aspirated. The cell pellets were resuspended 
in 6ml ACK buffer (2.1.1.12) per mouse, and filtered through a 70µm filter into a 
fresh falcon tube, followed by further centrifugation at 200g for 5mins held at 4ºC. 
Cells were resuspended and subsequently cultured in mouse MK media 
consisting of 5ml CellGro per mouse (Cellgenix, Freiburg, Germany) with 50 
ng/mL recombinant murine thrombopoietin (TPO; PeproTech) at 37°C under 5% 
CO2 for 5 days. 
Mature MKs were purified using a 1.5%/3% bovine serum albumin (BSA) 
gradient. Cells were pooled into a 15ml falcon, washed with PBS and centrifuged 
at 120g for 5 mins held at r.t. BSA gradients were prepared by diluting 30% BSA 
1:10 for a 3% gradient and 1:20 for a 1.5% gradient. Supernatants were poured 
off and cells resuspended in 4ml of PBS. Cells were layered on top of the BSA 
gradient and left to stand for 45 mins. The top 10ml was then transferred (or 




discarded if this was the second BSA gradient for this culture) to a 15ml falcon, 
centrifuged at 200g for 5mins, the supernatant was discarded and cells were 
resuspended in 5ml of MK media (CellGro supplemented with TPO as described 
above). Cells were then incubated at 37ºC for a further three days. For the 
remaining 2ml of the BSA gradient, 20ml of PBS was added, centrifuged at 120g 
for 5mins, the supernatant was poured off and the pellet was resuspended in the 
desired concentration of MK media. 
 Releasate assays 
Releasate assays were performed by incubating donor platelets (prepared as in 
2.3.6) or PLPs with and without agonist (1 unit of thrombin/reaction or 10µM 
TRAP6/10µM MeS-ADP) for 30 minutes at 37ºC. PGI2 (P6188, Sigma) was added 
at 750ng/ml to inhibit any unactivated platelets, samples were spun down at 
1400g for 10mins, and the supernatant was used for other assays. 
 Genomic sequencing and analysis 
Genomic DNA was isolated (DNeasy kit, Qiagen) from each parental cell line, all 
clones and subclones and used for whole-genome sequencing using the Illumina 
HiSeqX10 platform. Fragments of 150bp paired-end trimmed sequencing reads 
were aligned to the GRCh37 reference genome using BWA. Marking of duplicates 
and their removal took place using biobambam, and mutations were then called 
using CaVEMaN. All somatic mutations were then filtered through standardised 
quality control filters (Alexandrov et al., 2013), filtering for Mean Alignment Score 
(ASMD) of reads greater than 130, and no clipped bases were considered, 
identifying SNVs. Annotated SNPs from the general population taken from dbSNP 
were then removed as well as any variants with an allelic frequency less than 0.2. 
For indels, the PINDEL algorithm was used to call these variants, and only those 
with a standard filtering score of >250 and an allelic frequency of >0.2 were 
considered.  
 




3 Genetically engineering a FVII that can 
self-target to α–granules in a FOP-MK 
culture system





 Forward programming as a technique for high purity megakaryocyte 
differentiation from stem cells 
Although there exist many techniques to differentiate megakaryocytes from 
iPSCs, in this project the forward-programming methodology was adopted. With 
an average yield of 200,000 MKs per input iPSC, this is much higher than had 
been previously reported from directed differentiation, reported to be on average 
26.3 and 11.7 times more mature MKs compared to directed differentiation from 
two different cell lines (Moreau et al., 2016). The purity of the culture was also far 
greater on average, the percentage of cells that became CD41+/CD42+ was 
97.7±0.8% for the forward-programming technique compared to 21.3±2.9%. This 
suggests that it is possible to combine the benefits of the large numbers of MKs 
from the immortalisation technique but without similar safety risks. This high 
efficiency of differentiation combined with the serum and stromal cell free culture, 
minimal cell manipulation and low cytokine requirements established this 
technology as a promising platform for both basic biology and clinical applications. 
In a clinical context, the long-term culture expansion allows a cumulative 
production of 2x1011 MKs releasing (without the use of bioreactor technology) 
around 1x1012 platelets, the equivalent of 3 transfusion units, from only 1x106 
iPSCs. 
In culture, these mature FoPMKs produced proplatelet structures containing P-
selectin-positive α–granules. Electron microscopy of the platelets produced from 
these FoPMKs compared to those produced from cbMKs showed that both 
contained the typical platelet ultrastructure, including a high α–granule content. In 
vitro derived platelets from FoPMKs showed surface expression of the main 
thrombocyte receptors, normal mean volume on a blood analyzer and an 
increased immature platelet fraction compared to donor blood. Platelet survival 
was assayed in an in vivo NSG mouse model; the FoPMK platelets were 
detectable for several hours, while showing a shorter half-life than primary donor 
platelets. Finally, functionally the produced platelet-like particles (PLPs) appear 
able to be able to react to thrombin stimulation and take part in clot formation in 
vitro, with visible sequential rolling, binding, and spreading. 
 Preliminary work on targeting proteins to α-granules (performed by 
Dr Annett Mueller) 
Previously, FVIII has been targeted to the α-granules of canine megakaryocytes 
as a gene therapy for haemophilia A through fusion with the vWF signal peptide 




and D2 domain (SPD2), a protein normally present in α-granules (Du et al., 2013). 
vWF is a protein normally expressed in α-granules, and so its signalling domain 
was chosen to direct other proteins to be trafficked in a similar way. The ability to 
target proteins into the α-granules of forward-programmed megakaryocytes has 
been demonstrated by Dr Annett Mueller through the fusion of vWF SPD2 to GFP; 
immunohistochemistry (IHC) data shows good co-localisation of the GFP with a  
marker of α-granules (Figure 3.1). Both constructs were under control of a 
megakaryocyte-specific ITGA2B promoter. The cells are also stained for 
thrombospondin, a marker for α-granules. Figure 3.1A shows transduction with a 
lentivirus containing this ITGA2B promoter fused to eGFP without any targeting 
domain, and this eGFP is mostly located within the cytoplasm. Figure 3.1B shows 
transduction of the same construct, with a vWF-SPD2 domain from Du and 
colleagues inserted between the ITGA2B promoter and the eGFP, demonstrating 
co-localisation of GFP with thrombospondin, suggesting that the protein has been 
targeted to the α-granules.  
 
Figure 3.1. Fluorescence microscopy data taken from forward-programmed 
megakaryocytes transduced with a construct containing the ITGA2B promoter fused to 
either (A) only eGFP or (B) the SPD2 domain of vWF fused to eGFP (data generated by 





















 Previous work on a self-activating FVII 
Previously, the zymogen Factor VII (FVII) cDNA coding sequence had been 
cloned from adult liver tissue by TA cloning into the plasmid pCRII by Dr Annett 
Mueller. This could be used to produce the zymogen form of Factor VII (FVII), but 
for the purpose of loading the granules to be used in a similar way to rFVIIa, the 
factor VII needed to be produced and stored in an activated form into the platelet 
α-granules. 
The zymogen form is converted physiologically to the active form in the blood by 
cleavage of a peptide bond between Arg152-Ile153 (Chaing et al., 1994), located 
between the light and heavy chains, after exposure to tissue factor. In one study, 
this cleavage site was disrupted by the insertion of a specific binding site 
(RKRRKR) for the intracellular protease furin to result in a constitutively activated 
FVIIa (Margaritis et al., 2004). This modified FVII sequence has previously been 
expressed long-term as a gene therapy in vivo in a mouse model to elevate 
plasma rFVIIa levels (Aljamali et al., 2008). 
 Thrombin cleavage sequence for separation of FVII from vWF 
To avoid unwanted effects on FVII enzymatic function and to prevent it from being 
tethered to the activated platelet by the vWF domain, the separation of FVII from 
the vWF peptide upon its release from the α-granules at the site of injury would 
be required (Figure 3.2). 
Thrombin was chosen as a suitable enzyme to cleave off the activated factor VII 
from vWF, as it concentrates in areas of bleeding thus allowing an accurate time 
and space control of protein cleavage specifically at sites of injury. The thrombin 
cleavage sequence (LTPRGWRL) was chosen from a study on the optimal 
cleavage sequence for human thrombin using phage display technology (Gallwitz 
et al., 2012). This was then codon-optimised for H. sapiens to ensure maximal 
protein translation using a tool and codon table available online (Nakamura, 
Gojobori and Ikemura, 2000; Stothard, 2000) and integrated into a PCR primer. 
This was specifically chosen due to being based around human thrombin instead 
of the commonly used sequence (LVPRGS), based on bovine thrombin (Waugh, 
2011). 
 Assays to measure the functional activity of Factor VIIa 
Specific assays to measure the activity of FVIIa activity exist in the literature, 
notably a chromogenic FVII assay (Avvisati et al., 1980). This involves the 
immobilisation of FVII from a sample on a plate with an antibody similar to an 
ELISA, and then uses the addition of Factor X as a substrate for Factor VII, and 




the addition of a chromogenic substrate for Factor Xa that can be read on a plate 
reader to give an enzyme kinetics readout.  
Other clotting assays that can be performed in vitro include the thrombin 
generation assay (TGA). There is somewhat of a gap between the aPTT and PTT 
(that measure ex vivo coagulation) and in vivo coagulation, which involves an 
interplay between the coagulation cascade and platelets; the TGA was developed 
to fill this gap. Coagulation of the test sample (either platelet poor or platelet-rich 
plasma) is activated by a small amount of tissue factor and phospholipids, and 
the reaction of thrombin generation is measured continuously through the means 
of a thrombin-specific fluorogenic substrate (Tripodi, 2016). As such, several 
parameters can be measured of the coagulation reaction at once, including the 
lag time between stimulation with tissue factor and thrombin spike, the peak 
thrombin generation, the area under the curve representing the total thrombin 
generation and the rate of increase of thrombin generation (the velocity index). 
Many of these parameters have correlations to a hyper- or hypo- coagulable state 
in patients (van Veen, Gatt and Makris, 2008). 
In recent years, microfluidic devices have become popular for measuring 
coagulation with very small samples. For example, the in vitro thrombus under 
flow (IVTUF) assay is able to measure incorporation of differentially labelled 
platelet samples and assess their interaction with a collagen-coated substrate 
while under flow, attempting to recapitulate the in vivo environment more closely 
than traditional assays (Provenzale et al., 2019). Other assays using microscopic 
pillars have been used (‘NanoPosts’) to measure the contractile force of individual 
platelets which may change after exposure to a procoagulant environment 
(Feghhi et al., 2016). 





 Cloning strategy 
The aims for modifying the FVII sequence were to (1) ensure the FVII would be 
self-activating without the need for tissue factor, (2) to be directed to the α-
granules by fusion with the vWF SPD2 domain and (3) to be able to cleave off 
this domain in areas of bleeding through the insertion of a thrombin cleavage site 
(summarised in Figure 3.2). Overlapping-extension PCR was used to amplify the 
light and heavy chains independently containing the furin cleavage sequence in 
the amplification primers (Figure 3.3A) before being joined back together. A 
further PCR reaction would be used to extend this combined product to contain a 
thrombin cleavage site (Figure 3.3B) (vWF-F7TF, containing the vWF domain 
fused to FVII modified with a thrombin and furin site). 
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Figure 3.2. Schematic of the intended design of the modified FVII sequence in FoP-MKs. 
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Figure 3.3. Schematic of the overlaying-extension PCR strategy used to (A) insert a 2RKR (furin 
cleavage sequence) between the light and heavy chains of Factor VII, followed by (B) a thrombin 











 Structural assays in transduced CHRFs and FoPMKs 
Next, lentivirus containing the generated construct was transduced into a 
megakaryoblast cell line to discover a suitable antibody, confirm successful 
expression. Assays were established such as intracellular flow cytometry, ELISA, 
Western blot. The lentivirus was then transduced into FoPMKs and the same 
assays were repeated to confirm the successful expression of the vWF-F7TF 
fusion sequence. Immunofluorescence was then used to examine the localisation 
of the fusion protein and compare this to several α-granule markers. 
 Functional assays for FVII in FoPMKs and subsequent platelets 
Next, assays were performed to measure the function of this modified fusion 
protein. The furin and thrombin cleavage sites were experimentally tested through 
addition of exogenous enzyme and analysis by Western blot. A chromogenic 
enzymatic assay was also performed on the lysates of these transduced MKs. 
Platelets produced from these MKs were collected and also analysed for the 
presence of FVII by intracellular flow cytometry, before being analysed by a 
thrombin generation assay to compare their function to platelets from 
untransduced FoPMKs and human donor platelets. 
  




3.3 A furin cleavage site was inserted between the light and 
heavy chains by overlapping-extension PCR 
Replacement of the normal FVII activation cleavage site with a furin cleavage site 
was performed through overlapping-extension PCR. Primers were designed for 
the heavy and light chain separately to amplify out each chain, while adding the 
sequence with the furin cleavage sequence (RKRRKR) in their nucleic acid 5’ and 
3’ ends respectively (details in section 2.1.3 for the primers LC_FO, 
LC_2RKR_RE, 2RKR_HC_FO, HC_RE). BamHI and NotI restriction enzyme 
sites were also added to the primers such that they could allow for later restriction 
cloning before the light chain and after the heavy chain sequence. The resulting 
sequence containing the furin sequence is labelled F7F. 
The plasmid containing zymogen FVII was used as a template to perform the 
independent preparative PCRs for the light and heavy chains so that they could 
then be combined into one sequence (Figure 3.3). The amplification of the heavy 
chain required further optimisation when standard buffer did not allow efficient 
amplification of the heavy chain (Figure 3.4A) – the polymerase was switched to 
a Platinum Taq, the buffer was changed to a HF buffer and a temperature gradient 
was used (Figure 3.4B). The use of a HF buffer or Platinum Taq was sufficient to 
amplify this heavy chain, and the results from the HF buffer were subsequently 
used in an overlapping-extension PCR reaction to join them together (Figure 
3.4C). The final PCR products were sequenced to confirm their integrity to the 
original template; alignment was successful and no frameshifts or point mutations 
were observed (Figure 3.4D). 








Figure 3.4. Amplification of light and heavy chain to insert furin cleavage sequence 
from template Factor VII cloned out of primary adult liver cDNA. (A) Agarose gel (1%) 
was run after the PCR reaction to amplify the light and heavy chains from the template, 
using GC buffer. Arrow indicates the light chain extracted for further cloning.  (B) 
Agarose gel (1%) used to optimise the annealing temperature and buffer conditions 
Bands seen in the GC buffer are artefacts from handling the gel. Indicated is a row of 
bands extracted for further cloning. (C) Agarose gel (1%) after performing the final PCR 
overlaying-extension reaction combining the products from (A) and (B), under three 
different annealing temperatures. Bands from two conditions were excised (indicated) 
and DNA was extracted for further cloning. (D) Sanger sequencing confirmed the 
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3.4 Insertion of a thrombin cleavage site by PCR 
The F7TF sequence was obtained by PCR using the F7F sequence as a template 
and a forward primer containing this thrombin cleavage site (details in section 
2.1.3 for the primers Thrombin_LC_FO and HC_RE). The result was run on a gel 
to separate the different DNA sequences present in the reaction, the expected 
size band for F7TF extracted and sent for sequencing to confirm the insertion of 
the thrombin cleavage sequence (Figure 3.5). The yellow box represents an error 
in the base calling algorithm, and the chromatogram below shows the missing 
base is likely a C, corresponding with the engineered sequence, confirming there 
were no unexpected mutations in the sequence. 
 
Figure 3.5. Sequencing was used to confirm the insertion of the thrombin cleavage 
sequence before the light chain of FVII. 
3.5 Gibson assembly for cloning into pWPT-VWF 
Next a plasmid was created using a vector backbone capable of generating 
lentiviruses, and to transduce cell lines resistant to classical transfection (e.g. 
forward-programmed megakaryocytes) and establish stable clones. A construct 
from the David Wilcox group was chosen (Du et al., 2013) containing a CD41 
promoter fragment to restrict expression to megakaryocytes and the SPD2 
domain from vWF to target proteins to α-granules of megakaryocytes and 
platelets (Figure 3.6). As a control, a version of the plasmid without the vWF 
targeting sequence would be cloned as well. 
The cloning for these constructs was performed using the Gibson assembly 
method of utilising overlapping PCR primers (Gibson et al., 2009). Insertion of the 
F7TF sequence fused to the vWF α-granule targeting (GT) sequence was a one-
fragment insertion (resulting in the fusion sequence vWF-F7TF) (Figure 3.7A and 




Figure 3.7B). For the cloning of a construct without the GT sequence, there were 
no easily accessible restriction sites to extract this targeting sequence without 
also removing part of the ITGA2B promoter fragment so this was performed using 
a two-fragment assembly, where the part of the promoter that would be excised 
was amplified by PCR and assembled back in to the plasmid alongside F7TF 
(Figure 3.7C and Figure 3.7D). 
 
Figure 3.6. The unmodified pWPT plasmid with the VWF targeting sequence attached to 
eGFP under control of a megakaryocyte-specific promoter (CD41, or ITGA2B) (Du et al., 
2013) with the three different unique restriction sites highlighted. 






Figure 3.7. The cloning strategy for inserting modified Factor VII into a pWPT lentiviral plasmid 
using Gibson assembly. (A) Insertion of the F7TF sequence fused to the vWF via a simple one-
fragment assembly (B) Sanger sequencing chromatogram showing the insertion of F7TF into the 
pWPT backbone after the vWF domain. (C) Insertion of the F7TF sequence without the vWF 
sequence via a two-fragment assembly. (D) Sanger sequencing chromatogram showing the 








3.6 Lentivirus was produced and titred from the previously 
described plasmids 
Lentivirus from the plasmids described in Figure 3.7B and Figure 3.7C were 
generated (see section 2.2.7) and titrated by qPCR (Figure 3.8). The average viral 
titre for the pWPT lentivirus containing vWF fused to the modified FVII sequence 
was calculated to be 8.73E+08 ± 5.39E+05 (mean ± SD). The average viral titre 
for the pWPT lentivirus containing the modified FVII sequence without vWF was 
7.16E+08 ± 2.92E+08 (mean ± SD). Cells were transduced with these viral 
samples as described in section 2.2.8. 
3.7 CHRF cells were transduced with the virus to establish FVII 
assays and confirm production of the modified protein 
CHRFs, a cell line derived from megakaryoblasts were cultured and transduced 
with the produced lentiviruses in order to generate large amounts of protein to set 
up assays that could measure FVII. 
The ELISA showed that the lentivirus containing vWF-F7TF was successfully 
expressing this protein, while F7TF showed no evidence for expression of FVII. 
A standard curve was established with known concentrations of FVII (Figure 
3.9A). An ELISA on the lysates was performed, and significant (p<0.001) amounts 
of FVII was detected in the positive control, NovoSeven, and the lysates of cells 
transduced with vWF-F7TF but not the lysates from cells transduced with F7TF 
without the vWF signalling domain (Figure 3.9B). As the amount detected reached 
the upper limit of the ELISA, samples were diluted 1:10 and run again on an 
ELISA to accurately quantify the FVII concentration in the vWF-F7TF lysate 
(Figure 3.9C). Finally, the supernatants from the vWF-F7TF culture also showed 



































F7TF 8.73E+08 5.39E+05 
F7TF 7.16E+08 2.92E+08 
 
Figure 3.8. Linear regression between the qPCR copy number ratio calculated for the GFP virus. 
The GFP was used to control for the transduction efficiency of the cells, to ensure they were responding to 
transduction in an expected way, while the qPCR controls were to establish that the qPCR reaction was working 
as expected. n=1 (A) The linear regression displayed graphically (B) This linear regression was used to calculate 
the equivalent GFP-flow titres in TU for the two types of virus produced. 
A B 




some detectable FVII, suggesting that the vWF-F7TF ended up in the resultant 









































































































































Figure 3.9. ELISA results from CHRF cells transduced with either of the two lentiviruses. 
(A) Concentration curve for ELISA (B) Concentration of FVII from lysates taken from 
untransduced CHRFs, CHRFs transduced with modified FVII lacking the vWF leader 
sequence (FVII) and CHRFs transduced with cells transduced with the vWF-FVII fusion 
protein sequence (vWF-FVII). (C) 1:10 dilution series of all lysate samples. (D) 
Concentration of FVII detected in supernatants from the same cell cultures as (B). 
NovoSeven was used as a positive control. 1x106 cells in each sample were lysed for this 
assay.  *** p<0.001 One-way ANOVA with Tukey’s multiple comparisons test.  n=3 
A B 
C D 

















3.8 An antibody was found to analyse intracellular FVII 
expression by flow cytometry 
A flow cytometry-based assay to detect intracellular FVII was developed. HepG2 
cells (details in section 2.2.1), derived from a hepatocellular carcinoma known to 
produce FVII was used as a positive control and all three antibodies showed some 
positive signal compared to the secondary only control (Figure 3.8). 
From Figure 3.11D, only antibody 2, a rabbit monoclonal raised against FVII, was 
able to differentiate between untransduced CHRFs and CHRFs transduced with 
vWF-F7TF. Antibody 1 (Figure 3.11C) appeared not to be able to differentiate 
between the transduced and untransduced cells, suggesting it may be binding to 
some other protein non-specifically. Antibody 3 (Figure 3.11E) appeared able to 
give differential staining between transduced and untransduced CHRFs, but 
paradoxically it appeared to give a weaker signal in the presence of FVII. 
Antibody 2 was chosen and used to set up a gating strategy, demonstrated in 
Figure 3.12. Three concentrations were trialled for the antibody on untransduced 
and vWF-F7TF transduced cells (Figure 3.12C and D). All three concentrations 
showed a good discrimination between the untransduced and transduced 
samples. A concentration of 1:20 showed an increased percentage positive for 
FVII in both the untransduced and transduced samples, indicating a higher non-
specific binding. A 1:1000 dilution was achieved by first diluting the antibody 1:10 
and subsequently 1:100 in the sample incubation step, to avoid the pipetting of 
very small volumes. It showed increased variability between stains thought to be 
due to issues with fully mixing the pre-dilution solution. A 1:100 concentration was 
therefore chosen from this data for all future intracellular flow experiments as it 
gave a good discrimination between untransduced and transduced cells and low 
variability. 
Figure 3.10. All three antibodies were used to stain HepG2 cells (known to be positive for 
FVII). Shown are the unstained, secondary only controls, and results from the three different 
antibodies (antibody 1, ab197656) (antibody 2, ab151543) (antibody 3, ab97614 
(secondary, A21244) (details in section 2.1.1.15) 





   
Figure 3.11. Flow cytometry data from three different antibodies on untransduced CHRFs 
and CHRFs transduced with vWF-F7TF or F7TF. Representative overlay flow plots 
shown, n=3 for each antibody. (A) Unstained cell control (B) Secondary only control (C) 
Staining for antibody 1 (ab197656) (B) Staining for antibody 2 (ab151543) (C) Staining for 











Figure 3.12. Gating strategy using antibody 2 from the panel in Figure 3.10. (A) Cell 
gating, used subsequently in the other representative flow plots. (B) Unstained and 
secondary only control results from staining untransduced CHRFs (C) Untransduced 
CHRFs with the primary antibody incubated at three concentrations. (D) CHRFs 











3.9 This antibody was further validated by Western blot and 
used to verify the presence of the fusion protein 
This antibody is able to detect FVII at ~52kDa in HepG2 as expected, along with 
a ~90kDa protein in the CHRFs transduced with vWF-FVII (Figure 3.13) showing 
that the full fusion protein with the vWF SPD2 domain is being expressed. No 
band is seen in the CHRFs transduced without the vWF sequence or in 
untransduced CHRFs. A non-specific band is noted in the 50kDa range for 
untransduced forward programmed megakaryocytes (FoP-MKs), but no other 
non-specific bands were noted. 
The presence of the ~90kDa band in the cells transduced with vWF-F7TF is of 
the expected size, containing both the vWF sequence (~40kDa) and the F7TF 
protein (~52kDa) as one fusion protein and no such band is seen in the 
untransduced cell lysates, validating the antibody to be binding to the expected 
protein (both in its native denatured sequence in HepG2 cells and modified 
denatured sequence in CHRFs). 
 
Figure 3.13. Denaturing Western blot showing untransduced FoP-MK and CHRF cell 
lysates as negative controls, HepG2 cell lysates as a positive control, alongside CHRFs 
transduced with either F7TF or vWF-F7TF. Visible bands are highlighted with a red arrow. 
Blots were stripped and restained for GAPDH as a loading control. Western blots were 
repeated for an n=3.  




3.10 A chromogenic assay was established to measure 
functional activity of rFVIIa 
This standard curve (Figure 3.14) established using serial dilutions of NovoSeven 
suggest that the minimum required concentration of rFVIIa to see a statistically 
significant difference lies between 100ng/ml and 1000ng/ml, and below this 
concentration, this functional assay become unreliable and indistinguishable from 
noise. This also established the antibody discovered in Figure 3.11 as being able 
to bind activated rFVIIa (further lending evidence to the results obtained using the 
same antibody in intracellular flow assays and Western blots such as Figure 3.13) 






















Figure 3.14. The antibody found in Figure 3.11 was used to set up a chromogenic FVIIa 
assay (section 2.3.4). NovoSeven was used at 0, 100, 1000 and 10,000ng/ml 
concentrations to establish a dose-response relationship, while measuring the change in 
absorbance over time. n=3, one way ANOVA with multiple comparisons applying 
Bonferroni’s correction. * p < 0.05 *** p < 0.01 Data shown as mean ± SEM. 
 



















































Figure 3.15. Chromogenic assay results from the same samples as in Figure 3.9, on 
untransduced lysates as a negative control, Novoseven as a positive control and the 
supernatants and lysates from cells transduced with vWF-FVII. One-way ANOVA. n=3, 
data shown as mean ± SEM.  
The chromogenic assay in Figure 3.15 showed that although there was a small 
amount of enzymatic activity detected by the assay from both the supernatants 
and lysates, this was not large enough to be statistically significant from the 
untransduced controls. 
  




3.11 Confirmation of the presence of vWF-F7TF in FoPMKs was 
obtained through ELISA, intracellular flow cytometry and 
measured over time 
Megakaryocytes produced from BobC iPSCs through forward programming were 
transduced with the lentiviral constructs from Figure 3.7 (Figure 3.16). They were 
assayed with the intracellular flow cytometry assay established in Figure 3.12 for 
expression of FVII. FoP-MKs transduced with vWF-F7TF showed a significant 
expression of FVII, while those transduced with F7TF showed no signal different 
to the secondary-only or untransduced controls (Figure 3.17). Successful 
production of vWF-F7TF was further confirmed and quantified through ELISA 
(Figure 3.18B). This showed that the vWF-F7TF was detected in the lysates, as 
well as in the supernatants suggesting the platelets given off by this culture may 
contain vWF-F7TF, or that this was somehow otherwise being released into the 
culture. 
Finally, these cultures were assayed over the duration of their cell culture to test 
whether expressed protein levels remained stable over time (Figure 3.18), and 
this confirmed that it remains highly expressed up to 50 days post transduction. 
After this point, the culture lost viability as has been observed in virally transduced 
forward programmed megakaryocytes beyond day 110 (Moreau et al., 2016). 
Cells staining positive for only CD41 are thought to be immature precursors that 
have not fully differentiated. 
 
Figure 3.16. Gating strategy for FoPMKs to ensure they are impermeable to DNA staining 
(DAPI negative, indicating viability) and positive for two common megakaryocyte markers 
(CD41 and CD42) before all experiments were performed. n=3 





Figure 3.17. Intracellular flow cytometry data from FoPMKs untransduced or transduced 
with either F7TF or vWF-F7TF.  (A) Cell gating strategy used to isolate singlets (B) FVII 
staining from unstained untransduced cells and secondary-only stained cells. (C) 
Representative flow plots for untransduced cells, cells transduced with F7TF and vWF-
F7TF (D) Overlay plot of FVII staining. (E) Quantification for n=3, two tailed t-test * p < 














































































Figure 3.18. ELISA evidence of FVII expression in transduced vs untransduced FoPMKs. 
(A) Standard curve for ELISA. (B) ELISA of lysates and supernatants from forward 
programmed MKs transduced and untransduced with lentivirus expressing the modified 



















Figure 3.19. Percentage of cells transduced with vWF-F7TF staining positive for FVII over 
time, overlaid with the DAPI negative (live cell) percentage over the same time period. 
n=3 transductions for 7 timepoints.  
  




3.12 Immunofluorescence reveals that this fusion protein is 
located in the VEGF-containing subpopulation of α–
granules in forward-programmed megakaryocytes 
Having established its presence, immunofluorescence was used to identify 
whether vWF-F7TF correctly localised to the α–granules. Previous work (Figure 
3.1) had established that this vWF leader sequence attached to GFP co-localised 
with thrombospondin, a common α–granule marker. Immunofluorescence data 
from a co-staining of FVII and thrombospondin are shown in Figure 3.20; no co-
localisation was observed between the thrombospondin and vWF-FVII in 
transduced cells. 
As noted by Figure 3.20A, only secondary antibody staining does not result in the 
visualisation of any granular objects. Untransduced FoP-MKs, co-stained for 
thrombospondin and FVII, show green granular objects staining positive for 
thrombospondin but not for FVII (Figure 3.20B). FoP-MKs transduced with vWF-
F7TF (Figure 3.20C) show the presence of granular objects within the cytoplasm 
of these cells staining for either green (thrombospondin) or red (FVII) but not both. 
No co-localisation events were observed. 
Other markers were co-stained with FVII to identify which type of organelle the 
vWF-F7TF had been directed to. A literature review suggested that α–granules 
come in two subtypes, endostatin positive and VEGF positive, and that these two 
subtypes do not overlap with one another (Italiano et al., 2008). A co-stain for FVII 
and endostatin showed similar results to that for thrombospondin with no co-
localisation (Figure 3.19). A co-stain for VEGF showed some co-localisation with 
vWF-F7TF (Figure 3.20).  





Figure 3.20. Immunofluorescence data for localisation of vWF-F7TF and thrombospondin 
(THBS). (A) Secondary antibody only control to establish the background fluorescence 
(B) Untransduced FoP-MKs staining for FVII (red, ab97614, secondary A21244) and 
THBS (green, ab1823, secondary A21121). (C) FoP-MKs transduced with vWF-F7TF 
stained for FVII (red) and THBS (green). Images are representative of n=3 technical 














Figure 3.21. Immunofluorescence data for localisation of vWF-F7TF and endostatin (ENDO). 
(A) Secondary antibody only control to establish the background fluorescence (B) 
Untransduced FoP-MKs staining for FVII (red, ab97614, secondary A21244) and ENDO 
(green, sc-514355, secondary A21121). (C) FoP-MKs transduced with vWF-F7TF stained for 
FVII (red) and ENDO (green). Images are representative of n=3 technical repeats, on a Leica 















Figure 3.22. Immunofluorescence data for localisation of vWF-F7TF and VEGF. (A) 
Secondary antibody only control to establish the background fluorescence (B) 
Untransduced FoP-MKs staining for FVII (red, ab97614, secondary A21244) and VEGF 
(green, NB100664SS, secondary A21121). (C) FoP-MKs transduced with vWF-F7TF 
stained for FVII (red) and VEGF (green). Images are representative of n=3 technical 











3.13 The engineered furin and thrombin sites were functional as 
demonstrated by Western blot and able to reconstitute the 
wild-type rFVIIa upon activation 
From two separate transductions, the full-length protein (Figure 3.21B) can be 
observed at ~95kDa (Figure 3.21A shows the molecular weights of the different 
components of this fusion protein), absent in the untransduced controls. Figure 
3.21C demonstrates that the native tissue factor cleavage site has been replaced 
with a furin cleavage site. Excess furin causes further cleavage of the full-length 
transcript to a band seen at around 60kDa to demonstrate this. 
Addition of thrombin (Figure 3.21C) results in cleavage at the thrombin cleavage 
site, demonstrating its functionality in releasing the heavy and light chains of 
endogenous FVIIa. The shift between these versions of the protein were 
quantified for several western blots and shown in Figure 3.21D, which 
demonstrates how additional furin results in further cleavage of the full-length 
protein, while addition of thrombin alone results in separation of the heavy and 
light chains. 
  









Figure 3.23. Western blot data on vWF-F7TF from FoPMK lysates (A) Schematic of the modifications 
made to the original FVII sequence and molecular weights of the different components (B) Reducing 
blot of untransduced and transduced (with vWF-F7TF) FoP-MKs from two separate cultures with a 
ladder and NovoSeven as a positive control. (C) Reducing blot showing the effect of adding either 
furin or thrombin or both to the lysates of transduced FoPMKs (D) Quantification of the bands with 
ImageStudio at five separate molecular weights from n=3 western blots with lysates from transduced 





























3.14 Functional chromogenic assays were unable to detect 




















































Figure 3.24. Chromogenic assay results for vWF-F7TF produced in FoPMKs. PBS and 
NovoSeven were used as positive and negative controls, followed by lysates from 
untransduced FoP-MKs, lysates from FoPMKs transduced with vWF-F7TF without and 
then with subsequent incubation with either furin or thrombin. All lysate samples came 
from 10x106 cells to normalise protein content.  n=3, data shown as mean ± SEM. 
Chromogenic assays (as established from Figure 3.14) were used to evaluate 
functionality of the fusion protein produced from FoP-MKs (Figure 3.24). Although 
the negative and positive controls worked as expected, no significant differences 
were observed from PBS or untransduced controls. Lysates were also incubated 
with furin or thrombin to increase availability of the native form of FVIIa (as 
observed in Figure 3.21D). A small increase was observed in lysates incubated 
with thrombin, but this was not statistically significant. 
  




3.15 Transduced FopMKs produce platelets loaded with vWF-
F7TF 
Having verified that vWF-F7TF was produced in megakaryocytes transduced with 
the lentivirus, platelets were collected from both untransduced and transduced 
cultures and analysed by intracellular flow cytometry to investigate whether this 
fusion protein was being subsequently packaged into platelets as would be 
expected of a protein in an α–granule (Figure 3.25). Isotype and secondary only 
control stainings were established on platelets from untransduced cultures, 
combining markers for maturity (CD42) and viability (Zombie) to ensure FVII was 
present in platelets and not artefactual remnants of cell culture (Figure 3.25A and 
Figure 3.25B). Combined staining showed a significant whole population shift of 
platelets (Figure 3.25C, Figure 3.25D, Figure 3.26A) in platelets from cultures 
transduced with vWF-F7TF compared to those from untransduced cultures. This 
was quantified and shown to be significant (p < 0.05) (Figure 3.25B). 
  










Figure 3.25. Representative flow plots of intracellular flow experiments on platelets derived from FoPMK 
cultures. (A) Platelets from untransduced cultures were stained for isotypes for maturity (CD42) and viability 
(Zombie) (B) Platelets from untransduced cultures stained for CD42, Zombie and only the secondary antibody 
for FVII. (C) Platelets from untransduced cultures stained for all three markers (D) Platelets from FoPMK 
cultures transduced with vWF-F7TF 
 







Figure 3.26. Summarised flow data for platelets from untransduced and transduced FoPMK cultures.  
After CD42 and Zombie gating (A) Overlay plot of secondary only, untransduced and vWF-F7TF 
cultures. (B) Percentage gating positive for FVII for n=3, data shown as mean ± SEM. Two-tailed t-test, 























3.16 Thrombin generation assays on platelets loaded with this 
fusion protein showed an effect 
All parameters measured for the thrombin generation assay appeared to be 
increased for platelets containing vWF-F7TF compared to both untransduced 
platelets and human donor platelets, for every concentration of platelets tested 
(Figure 3.25A). A representative plot shows that the thrombin generation from in 
vitro-derived platelets differs considerably from that of donor platelets. The 
thrombin generation peak has a reduced lag time, increased peak height and an 
increased area under the curve, indicating higher total thrombin generation. 
Representative plots and subsequent quantification also show in vitro-derived 
platelets loaded with vWF-F7TF had an increased peak height and area under 
the curve when compared with untransduced in vitro platelets. All reactions were 
triggered with the use of RCLow, a solution of a low concentration of phospholipid 
micelles containing rhTF in Tris-Hepes-NaCl buffer. 
There appeared to also be a dose-dependent relationship between the number 
of platelets and a response in peak thrombin generation (Figure 3.25B) and total 
thrombin generation (Figure 3.25C) for each of the conditions. This data shows 
that when modelled as a dose-response curve with non-linear regression, in vitro 
platelets have a higher Vmax for thrombin generation (although this was not 
significant at the p<0.05 level), and that the addition of rFVIIa shifts this curve to 
the left, resulting in a lower EC50. Non-linear regression calculated the EC50 values 
from the area under the curve of the donor, untransduced and vWF-F7TF 
platelets as 3.30 (1.45 to 10.1), 1.91 (0.623 to 4.94), 0.515 (0.281 to 0.937) 
respectively, reported as mean (95% confidence interval) to three significant 
figures. From this, the EC50 of total thrombin generation of vWF-F7TF-loaded in 
vitro platelets was found to be significantly (p<0.05) different to the donor 
platelets, while the untransduced in vitro platelets were not (Figure 3.28). 
  




   














































PMPP + vwf-F7TF ivPLTs


















Figure 3.27. Results from a thrombin generation assay on donor platelets (PLTs), platelets from an 
untransduced culture (ivPLTs) and platelets from a vWF-F7TF culture of FoPMKs (vwf-F7TF ivPLTs) mixed with 
platelet-and-microparticle-free plasma (PMPP) in a volume of 100µl. The reaction was triggered with the addition 
of RCLow (a solution of phospholipid micelles containing rhTF). (A) Shows a representative thrombin generation 
assay for the three conditions carried out for 2x106 platelets. A dose response was plotted for parameters 













































Figure 3.28. Confidence intervals for the EC50 for total thrombin generation, derived from 
non-linear regression applied to the concentration curves in Figure 3.25C. 
3.17 Discussion 
The success of the cloning was confirmed through Sanger sequencing of the 
entire length of the FVII sequence at each stage to confirm no point mutations or 
frameshifts (Figure 3.4D, Figure 3.5, Figure 3.7B and Figure 3.7D). The use of 
overlapping-extension PCR was necessary because of the lack of any suitable 
restriction sites near the tissue factor cleavage site for the insertion of the furin 
cleavage sequence. Gibson assembly was favoured for the insertion to pWPT for 
the ability to insert sequences without leaving restriction site scars that may impair 
function of the plasmid or the resulting protein (Gibson et al., 2009). 
CHRFs were chosen as an intermediate step in order to establish FVII assays 
before transferring these onto FoP-MKs as they are easier to culture and grow in 
large numbers, with the caveat that they do not represent a physiological system 
nor one suitable to generate platelets for human transfusion.  
Using this monoclonal antibody found in Figure 3.11 to set up an intracellular flow 
assay, no appropriate isotype could be found as no details to the concentration 
of this antibody were given. As a substitute, a secondary only staining was used 
instead. This may explain why the untransduced cells appear to cause a shift 
compared to the secondary only control, although not as great a shift as 
transduced samples (Figure 3.17). Other possible reasons for this non-specific 




staining of untransduced cells include the presence of non-specific binding sites 
in FoPMK system as observed in the untransduced FoPMK lane in Figure 3.13. 
Clinically, the most common readout of FVIIa activity is the prothrombin time (PT), 
which measures the activity of the extrinsic pathway of coagulation, as well the 
associated international normalised ratio (INR) (Tripathi et al., 2017). 
Traditionally, the PT is the time taken to form a clot measured in platelet poor 
plasma upon the addition of tissue. Although very useful clinically, this assay has 
some limitations in this context as the effect of FVIIa is measured indirectly and 
other factors can affect the PT. A shortened PT does not necessarily predict 
success of rFVIIa therapy in patients with bleeding, although a correction back to 
a normal range is suggested in the literature to be a better indicator (Pusateri and 
Park, 2005). Furthermore, the quantity of FVIIa required to see a noticeable 
difference is high (Bomken et al., 2009). The quantity of protein produced from a 
small-scale cell culture system may not be sufficient to observe a difference. 
Finally, as the assay takes place in platelet-poor plasma, the effect of platelet-
coagulation pathway synergy as hypothesised by the cell-based model of 
haemostasis is likely to be missed (Hoffman and Monroe, 2001). 
The chromogenic assay in Figure 3.15 showed that although there was a small 
amount of enzymatic activity detected by the assay from both the supernatants 
and lysates, this was not large enough to be statistically significant from the 
untransduced controls. This is likely to be due to concentration of vWF-F7TF 
present in the samples; as seen in Figure 3.14, the minimum concentration 
required for a statistically significant result is at least 1000ng/ml. From Figure 
3.9C, the concentration of vWF-F7TF in the lysates is at most 76ng/ml, far below 
this threshold. Therefore, it is difficult to conclude whether there is or is not any 
functional activity from this data as even the rFVIIa diluted to this level gave a 
statistically insignificant result. 
The FoPMKs were monitored for their maturity (CD41 and CD42) and viability 
(DAPI) routinely to ensure they were live megakaryocytes to remove this as a 
confounding factor from all of the results obtained from these cells. ELISA data 
(Figure 3.18) and intracellular flow data (Figure 3.17) confirmed the presence of 
vWF-F7TF in these cells. Immunofluorescence data showed that the vWF-FVII 
did appear to be in some granular-like object within the cytoplasm (Figure 3.20) 
that did not co-localise with thrombospondin, the granule marker that previously 
co-localised with vWF-eGFP (Figure 3.1); this could be within a lysosome, other 
endosome or another subset of megakaryocyte granule. To rule this out, other 
granule markers were trialled and VEGF was found to co-localise with the vWF-




F7TF to a far greater degree than other granule markers (Figure 3.20). This 
means that the addition of the F7TF sequence has switched trafficking from one 
subtype of α-granule to another. This may be due to the addition specifically of 
the furin cleavage site, as furin is a chaperone protein known to be involved in 
protein trafficking in the secretory pathway (Thomas, 2002). This effect may be 
mediated by other unknown sequences in the endogenous FVII gene or other 
mechanisms, such as through homoaggregation (Hayward et al., 1999). It 
remains unclear whether this will result in different stimuli triggering a differential 
release of rFVIIa-containing granules under certain circumstances and not others. 
The absence of the F7TF protein without the vWF leader sequence was notable, 
as it was intended to be used as a control with the FoP-MKs. This was despite 
the eGFP without the vWF leader sequence being successfully expressed by Dr 
Annett Mueller (Figure 3.1). This could be attributed to a failure of transduction, 
but when measured by qPCR when titrating the lentivirus (Figure 3.8) it appeared 
to be successful. Furthermore, no protein expression was observed across three 
separate attempts at transduction for CHRFs and for FoPMKs. Therefore, 
although a failure of transduction cannot be ruled out it remains unlikely. Another 
reason why no protein was observed is perhaps that the F7TF protein was 
degraded or underwent further post-translational changes hindering the ability for 
binding to the antibody epitope immediately upon production in the cytoplasm. As 
the F7TF portion of the sequence is sufficient to switch trafficking towards a VEGF 
positive granule subpopulation, perhaps lacking the vWF leader sequence it is 
trafficked into lysosomal machinery for degradation. Mutations in the EGF-1 
domain of FVII have been shown to result in clinical deficiencies of FVII due to 
altered sorting mechanics in functional studies (D’Andrea et al., 2004). 
At this point, the vWF-FVII has been detected structurally within the transduced 
FoP-MKs by a variety of techniques and localised into a specific subtype of α–
granule within the FoP-MK. Next, other more functional in vitro assays were used 
to investigate whether the modifications made to the protein sequence were 
functioning as intended, and to test whether the fusion protein was still capable 
of acting as an enzyme. Although the chromogenic assay again returned an 
inconclusive answer (Figure 3.24), likely again due to the protein being present 
at a level orders of magnitude lower than required to observe a difference from 
the control, Western blot data (Figure 3.21) showed that the inserted furin and 
thrombin sequences were functioning as intended, with a shift in protein 
fragments observed upon towards the separated heavy and light chains.  




Figure 3.21D showed a significant shift in profile of the fragments of the fusion 
protein upon the addition of thrombin. Not only were the native light and heavy 
chain produced, but the full-length protein was removed almost entirely with no 
corresponding increase in the zymogen FVII without separation of the heavy and 
light chains as might be expected just from the cleavage of the vWF leader 
sequence. This may suggest some end-product inhibition of furin; the cleavage 
of the thrombin site causing the final conformational change may free 
endogenous furin to further cleave the full-length protein. This may also be due 
to the non-specific antibody binding seen in untransduced samples (Figure 3.13) 
near the same molecular weight of the vWF SPD2+light protein, obscuring the 
true quantity of this form present. 
Although the datasheet for the antibody states that it is a monoclonal antibody 
against one epitope, it is clear from this western blot data that the antibody is able 
to bind to both the heavy chain and the light chain, although the signal is strongest 
from the heavy chain (Figure 3.21B).  
Previous work from the Ghevaert group has established a standardised 
assessment of in vitro-derived platelets through measurement of maturity 
(CD42b) and metabolic viability (Zombie) in anucleate platelets (Shepherd et al., 
2018). This was applied to the in vitro generated platelets from untransduced and 
transduced cultures here in order to establish the identity of these particles not 
purely based on size, in order to exclude as much general cellular debris as 
possible. The metabolic marker here used was Zombie-violet which is an amine-
reactive dye permeable to compromised cell membranes (and so stains dead 
platelets positively); any non-protein debris will stain negatively, the same as a 
live platelet. This was preferable to the other major viability marker in use, Calcein, 
which stains live platelets, as this dye was shown to leak out of permeabilised 
platelets for the intracellular assay (Caillon et al., 2013). 
Intracellular flow data showed that the resultant platelets from these cultures were 
able to produce vWF-FVII containing platelets (Figure 3.26). These platelets were 
combined with functional clotting assays to investigate how this fusion protein 
took part in Figure 3.25. Under the hypothesis of the cell-based model of clotting 
(Figure 1.11), the interplay between the F7TF and platelet membrane would allow 
for a physiologically relevant amplification of any pro-clotting effects that are likely 
to translate to in vivo models more so than the supraphysiological levels of protein 
required for assays looking only at the enzymatic function of FVIIa in isolation, 
e.g. the chromogenic assays. Changes in parameters such as peak height and 
area under the curve have been associated clinically with changes in functional 




haemostasis (van Veen, Gatt and Makris, 2008). Therefore, the data in Figure 
3.25C suggests that the reduction in the EC50 of these vWF-F7TF-loaded platelets 
would result in faster clot formation in vivo compared to unloaded in vitro platelets 
or donor platelets, demonstrating the continued functionality of the fusion protein 
despite the modifications made to it. Note that non-viable cell fragments from 
culture have not been removed from the samples of ivPLTs which may influence 
results obtained. 
There is evidence in the literature that platelets from in vitro megakaryocytes 
retain a more ‘embryonic’ phenotype and are hyperreactive compared to adult 
platelets; this appears to be borne out by the data from untransduced platelets in 
Figure 3.25A showing a tendency towards parameters that suggest a faster rate 
of clot formation, although this was not significantly (p>0.05) different to donor 
platelets from the nonlinear regression confidence intervals (Sim et al., 2016). 
Overall, the FVII gene was modified with a vWF leader sequence, a thrombin 
cleavage site and furin cleavage site. These were expressed successfully in 
FoPMKs and were sorted to their α-granules. The thrombin and furin sequence 
were verified to be functionally active and cleave under the designed 
circumstances to give the native rFVIIa heavy and light chains. These FoPMKs 
were able to produce platelets containing this vWF-F7TF fusion protein and were 
observed to result in an increased haemostatic effect in vitro compared to donor 
platelets and platelets from untransduced cultures.




4 Quantifying the accuracy of genome 
editing with CRISPR with whole-
genome sequencing





CRISPR is a technique to edit genomes through the creation of targeted double 
strand breaks (DSBs) derived from a prokaryotic immune system, providing 
significantly more versatility over older techniques such as ZFNs and TALENs  
(Jinek et al., 2012). The technique has proven successful in a wide range of model 
organisms and systems, including in iPSCs initially for disease modelling (Horii et 
al., 2013). Specificity it is derived from a targeting guide RNA to direct the 
formation of these DSBs. Cas9 scans and unwinds the genomic DNA to create 
an R loop, changing its confirmation to expose the nuclease domain and cleaving 
the DNA (Szczelkun et al., 2014). The specificity of this guide RNA is therefore 
crucial to the avoidance of off-target effects, the formation of DSBs at genomic 
loci not intended by the design of the guide RNA. In applying this technique to 
cells in culture, often large numbers of cells are transfected with a plasmid to 
express both the Cas9 and the guide RNA, and the culture is subcloned and 
screened for the desired mutation. Other techniques have also proven successful, 
including the nucleofection of ribonucleoproteins (RNPs), pre-prepared Cas9 and 
guide RNA complexes directly into cells (Foster et al., 2018). 
The specificity of this technique is critical for ensuring its safety in its translation 
to a clinical setting; off-target mutations have been reported in previous genome 
editing technologies (Grau, Boch and Posch, 2013). These off-target effects can 
impair the fitness or functionality of the edited cells, or more problematically can 
generate oncogenic cell clones. Initially, certain guides (reported as 
‘promiscuous’) were shown to have a high off-target activity while others were not; 
indicating that this question is very guide RNA-dependent (Fu et al., 2013). These 
studies were at first focused on genomic loci predicted computationally to be 
similar to the target sequence, in vitro cleavage assays or high-throughput 
reporter screens (Mali et al., 2013). Later, whole genome sequencing data 
supported the idea that the target specificity of CRISPR is very guide-dependent; 
in one study off-target activity varied widely from zero to as many as 151 off-
targets (Tsai et al., 2015). Other studies have identified DSB hot spots that vary 
between cell types which may contribute to cell-type specific off-target effects 
(Pratto et al., 2014). One study using human iPSCs identified in addition to the 
on-target mutation, only one high frequency off-target not present in the reference 
genome (Yang et al., 2014). 
In response to this data, several techniques have been developed to mitigate the 
potential off-target effects of certain applications of CRISPR, including the double 
nickase system (Ran et al., 2013). Combining two guide RNAs and two Cas9 




enzymes, each tagged to a different fluorescent protein, this technique allows for 
an even higher genome editing specificity, reported to reduce off-target effects by 
50 to 1,500-fold in cell lines without sacrificing on-target efficiency. This is 
reported to occur due to DNA cuts being made only when both nickases are 
binding, which is unlikely to occur in off-target regions of the genomes. 
For the clinical translation of both FoPMK technology and the genetically 
engineered FVII reported in chapter 3, the transition away from a lentivirally 
delivered system to a genome edited system would be favoured to meet clinical 
good manufacturing practice (cGMP) standards. Lentiviral technology has several 
significant barriers for use in the clinic in the context of FoPMK technology. Firstly, 
the production of lentiviral vectors in a cell line must take place alongside any 
iPSC culture to continuously transduce these cells after differentiation in order to 
avoid silencing and with each culture lasting up to 110 days, this process would 
need to be repeated on a consistent basis (Moreau et al., 2016). Secondly, the 
production of lentiviruses requires transient transfection with three to four different 
plasmids in each vector manufacturing batch, introducing significant opportunity 
for variation that is undesirable in a large-scale cGMP manufacturing process 
(Sanber et al., 2015). Thirdly, the integration of the resulting lentivirus is not a 
controlled process. Although integration sites are not completely random, there 
are many reports of lentiviral vector integration inducing alternative splicing and 
aberrant transcript, the consequences of which remain unknown (Moiani et al., 
2012). There remains an element of stochasticity and unpredictability with this 
technique that is undesirable in a cGMP process which may impact the safety of 
the resulting product. 
Ideally, the constructs generated in section 3 would be engineered into a genomic 
safe harbour such as AAVS1 or ROSA26 to prevent genomic silencing effects, 
removing the complexities associated with lentiviral vector production and 
simplifying the cell culture process. This approach has seen great success in 
iPSCs (Oceguera-Yanez et al., 2016). Furthermore, genome editing allows for the 
creation of platelets with other biological benefits such as a lack of 
immunogenicity. Platelet transfusions often currently need to be matched for HLA 
immuno-compatibility with the recipient, which reduces the pool of suitable donors 
considerably. Patients with platelet transfusion refractoriness (the failure to 
achieve an acceptable increment in platelet count following transfusion) has been 
documented in 30-50% of patients who undergo regular platelet transfusions and 
has been described to be associated with the sensitisation against HLA antigens 
(Brand, 2001). As platelets only express HLA class I, through knockout of HLA 




Class I, it may be possible to generate ‘universal’ platelets at scale from a single 
stem cell line (Traherne, 2008). 
 
Figure 4.1. Schematic of cell culture and CRISPR applied to generate samples for whole-
genome sequencing 
A key component of the HLA Class I complex is β2-microglobulin (B2M) which 
forms the light chain not involved in antigen presentation but crucial in maintaining 
the overall structure of the complex (Arce-Gomez et al., 1978). Mutations in B2M 
in patient have been shown to result in significant immunodeficiencies due to the 
failure of intracellular antigen presentation (Wani et al., 2006). Mouse models with 
the gene knocked out showed a failure of CD8+ T cell development but otherwise 
generally healthy mice (Koller et al., 1990). Previously, Dr Amanda Evans 
modified two iPSC lines (MS3 and MS4) by using the double nickase technique 
to knockout B2M. The samples generated for sequencing were successfully 
cultured as outlined in Figure 4.1, with the knockout being confirmed by PCR 
genotyping. 




Alongside any off-target mutations introduced by the CRISPR technique, a 
confounding factor in any analysis is that other mutations have been reported to 
take place purely through the process of cell culture. This has been reported in 
iPSC culture, and is thought to be due to both adaptation to the conditions of cell 
culture, genetic drift as well as due to a lack of negative selection that would be 
present in vivo from a viable immune system (Thompson et al., 2020). 
Mutations broadly can be categorised into either single nucleotide variations 
(SNVs) that do not result in a frameshift, and insertion-deletions (indels) that may 
result in a frameshift. Many of the current techniques in the analysis of mutations 
come from the field of oncology. Different causes of mutation have been known 
to leave characteristic marks in the genome, for example, C:G>A:T transversions 
predominate in smoking-associated lung cancer, while C:G>T:A transversions 
are common in UV light-associated skin cancers (Hainaut and Pfeifer, 2001). A 
landmark paper looked at the profile of different types of single nucleotide 
polymorphisms and using unsupervised machine learning to cluster these for 
different drivers of mutational processes to obtain characteristic mutation 
signatures (Alexandrov et al., 2013). An indel classification system has remained 
more elusive due to the more complex nature of these mutations, but recent work 
has attempted to apply a similar analysis (Alexandrov et al., 2020). 
4.2 Aims 
Methods were developed to assess the off-target effects of genome editing in two 
stem cell lines both independently edited to be HLA-null using CRISPR with the 
double nickase system. Whole genome sequencing was used to identify any 
variation from the reference genome, with previously known variants filtered out 
to leave only the de novo mutations and compared between the control and 
knockout samples to remove the effect of the normal rate of mutation arising from 
the process of cell culture. Both SNP and indel frequencies were analysed, as 
well as the SNP mutation signature observed from these samples. The location 
of these mutations in the genome were also documented to assess their potential 
impact. 
4.3 The SNV mutation rate in both modified cell lines appeared 
reduced compared to controls 
All SNVs were called by comparing the control and knockout sequences to the 
reference genome, followed by filtering known single nucleotide polymorphisms 
(SNPs). As the cell culture period was known, the variants were quantified and 
measured as a rate of SNVs ocurring per day per base pair of DNA. In Figure 




4.2A, the average rate of mutation measured was lower in the knockout than the 
corresponding control sample in both bases. When split by chromosome for MS3 
in Figure 4.2B (control) and Figure 4.2C (knockout), the distribution of SNVs 
appear roughly similar, mostly distributed around the average, with a 
disproportionately large number of mutations ocurring in chromosome 21 and a 
disproportionately smaller number ocurring on the X chromosome. Similar results 
were observed in Figure 4.2D and Figure 4.2E for the MS4 line. 
The genomic location of SNVs is important as a SNV in an exonic region may 
alter the amino acid sequence of the resultant protein with consequences for its 
function, while those in intronic or intergenic regions may not have such a direct 
effect on function. In Figure 4.3 the subset of SNVs that were obtained by 
comparing the control line to the knockout lines (as opposed to all four to the 
reference genome) and the genomic location of these were plotted. In Figure 4.3A 
the MS3 comparison shows the vast majority of the SNVs detected occur in 
intergenic regions, followed closely by intronic regions. Only a very small fraction 
of all the SNVs detected occur in exonic regions. In Figure 4.3B a similar result is 
obtained for the MS4 comparison, with slightly more SNVs observed in exonic 
regions than with the MS3 line. 





Figure 4.2. Summarised SNV data from control and knockout samples from both cell 
lines. (A) The average mutation rate for each sample per day in cell culture per base pair. 
(B) The distribution of these mutations across each chromosome in the MS3 control 
sample (C) Chromosomal distribution of mutations in the MS3 knockout sample. (D) 
Chromosomal distribution of mutations in the MS4 control sample (E) Chromosomal 
distribution of mutations in the MS4 knockout sample. G – average across all 
chromosomes, plotted in (A). 











































































































































































































Figure 4.3. Comparing the difference between the knockout and control lines to show the 
genomic region where the SNVs are located. (A) From the MS3 control vs knockout lines. 
(B) From the MS4 control vs knockout lines. 
A 
B 




4.4 SNV mutation signatures from modified cell lines were 
quantified 
The mutational signatures of the SNVs observed in each of the four samples were 
also quantified to identify the process driving the formation of these mutations. In 
Figure 4.4, the main types of SNVs observed were C>T transitions followed by 
T>C transitions and this was consistent across all four samples and across the 
context of the surrounding two base pairs (e.g. ACA was likely to convert to ATA). 
No additional mutational signatures were observed in the knockout cells 
compared to the controls, indicating the same process was driving the acquisition 
of mutations independent of the CRISPR knockout modification. 
 
Figure 4.4. Results from quantifying the types of motifs and mutational signatures present in all four samples. 
Each column represents a different single nucleotide substitution, while the subcolumns indicate the context 
of the two bases surrounding the mutated base. Each bar represents the contribution of that mutation subtype 
to the overall mutational phenotype in the sample. Each row represents a different biological sample, either 
the control or knockout for MS3 and MS4. 




4.5 Indel frequency was also quantified in all samples 
Similar to the SNV data, the indel frequency was quantified and the knockouts of 
MS3 had a slightly lower rate of mutation than the corresponding control (Figure 
4.5A). MS4 had a higher rate of indels detected than its respective controls. On 
the chromosomal breakdown for MS3 (Figure 4.5B and Figure 4.5C), there 
appeared to not be any individual chromosome significantly contributing to the 
indel load on these cells; chromosome 17 and 19 appear to be consistently higher 
than the average, while chromosome 9, 22 and X appear to consistently be lower 
than the average. This pattern is repeated in the MS4 line (Figure 4.5D and Figure 
4.5E). This suggests that the distribution of indels may not be random and that 
certain chromosomes have features more amenable to indels than others, or that 
common factors have resulted in the detection of artefacts in both cell lines at 
similar locations. 
The types of indel occurring in these samples were also quantified in Figure 4.6. 
Variants were compared between knockout and control lines, and the types of the 
indels detected when performing this comparison were classified as complex, 
deletion or insertion. In both MS3 and MS4 comparisons, the vast majority of 
detected indels appear to be complex, consisting of both insertion and deletion of 
bases, followed by deletions. Although some purely insertion indels were detected 
in these samples, the proportion compared to the complex indels detected is very 
low. 
  





Figure 4.5. Summarised indel data from control and knockout samples from both cell 
lines. (A) The average mutation rate for each sample per day in cell culture per base pair. 
(B) The distribution of these mutations across each chromosome in the MS3 control 
sample (C) Chromosomal distribution of mutations in the MS3 knockout sample. (D) 
Chromosomal distribution of mutations in the MS4 control sample (E) Chromosomal 
distribution of mutations in the MS4 knockout sample. G – average across all 








































































































































































































Figure 4.6. The different types of indels seen in comparing the KO to the control line in 









4.6 Circos plots visualise all SNV and indel data laid across the 
genome 
By overlaying the SNV and indel data on top of one another, it becomes possible 
to identify areas rich in both; i.e. mutational hotspots. Circos plots were generated 
to visually identify such areas (Figure 4.7 and Figure 4.8); if a high incidence of 
indels and SNVs appeared at specific genomic loci in the knockouts but not the 
controls, this may indicate a mutational scar from on- or off-target effects of 
CRISPR. 
The large number of complex indels were observed as the blue band spanning a 
large proportion of the plots in all four samples. There is a visible deletion stripe 
on chromosome 15 in both Figure 4.7B and Figure 4.8B absent in the controls 
Figure 4.7A and Figure 4.8A, indicating the location of B2M (chr15:44711487-
44718877) thereby further confirming the success of the on-target effect of the 
CRISPR (Faber et al., 1976). 
Comparing Figure 4.7A and Figure 4.7B, a mutational hotspot identified in Figure 
4.2B and Figure 4.2C is visible as an area with insertion, deletion and complex 
indels and SNVs in chromosome 21, but is present in both control and knockouts. 
Another potential hotspot was observed in chromosome 2, with an increase in 
concentration of SNVs and indels in the knockouts compared to the controls in 
MS3 (Figure 4.7A and Figure 4.7B). 
The hotspot observed in chromosome 21 in MS3 is also present in the MS4 
knockout plot (Figure 4.8B) and yet absent from the corresponding control (Figure 
4.8A). The hotspot observed in chromosome 2 in MS3 is absent from the MS4 
plots. However, a hotspot was identified on chromosome 20 with additional 
mutations in the knockout than the control in the MS4 line (Figure 4.8B) that was 
not present in MS3. 





Figure 4.7. Circos plot of MS3 (A) control and (B) knockout cell lines.  The inner light blue 
ring represents the location of complex indels, with the red and green lines representing 
deletions and insertions respectively. The green dots represent the locations of the SNVs, 
with a position closer to the centre of the circle indicating a higher concentration of SNVs 
at that locus. 
A 
B 





Figure 4.8 Circos plot of MS4 (A) control and (B) knockout cell lines. The inner light blue 
ring represents the location of complex indels, with the red and green lines representing 
deletions and insertions respectively. The green dots represent the locations of the SNVs, 
with a position closer to the centre of the circle indicating a higher concentration of SNVs 












Notably, the findings from this analysis were from a single genome sequencing of 
each cell line at one point in time, ideally these would be repeated for biological 
replicates to allow for statistical analysis with a t-test to confirm the differences 
observed are not due to chance. The methodology, however, was established 
into a pipeline such that the analysis may be repeated on future samples. 
As this methodology relied on comparison with a reference sequence and filtering 
out known SNPs, it remains possible that SNPs that are common but unreported 
were classified as de novo mutations despite existing prior to the experiment. 
Ideally, the parent culture from which both the control and knockout cultures 
would also be sequenced to get a true mutation rate over a known time period; 
many variant calls seen from comparison with the reference genome are likely to 
be variants rather than true mutations, mixed with the true mutations that have 
been observed to take place over the duration of a cell culture (Thompson et al., 
2020). 
The many variants seen in common between the MS3 and MS4 lines is also of 
note as several studies have shown that pluripotent stem cells acquire mutations 
in cultures that confer a survival advantage to the stem cells so that within a few 
passages that whole culture is dominated by the mutant clone (Baker et al., 2016; 
Merkle et al., 2017). 
In Figure 4.2A, the SNV mutation rate was reduced in the knockouts compared 
to the controls. This is likely due to genetic bottleneck effects from the re-cloning 
involved in CRISPR as outlined in Figure 4.1. The act of re-cloning likely reduced 
the genetic variation present in the wider culture resulting in an observed lower 
rate of mutation. 
From the SNV data (Figure 4.2B,C,D and E), there were certain chromosomes 
(e.g. 21) predisposed to acquiring mutations than others and that this was not a 
random uniformly distributed process. This has been reported in the literature 
previously. Between 12.5% and 34% of all human pluripotent stem cell lines have 
been found to acquire specific non-random chromosomal abnormalities over time 
particularly in chromosome structure and number in chromosomes 1, 12, 17 and 
20 that were reminiscent of changes also observed in cancers (Na et al., 2014). 
In Figure 4.3, both MS3 and MS4 have the vast majority of their mutations in 
intergenic or intronic regions. SNVs in exonic regions are a very small percentage 
of the total SNVs, which implies that most of the detected SNVs have no effect 




on protein structure. However, intergenic regions are no longer thought of as ‘junk 
DNA’ and has been found to have an important role in gene regulation (Pennisi, 
2012). The impact of the SNVs detected will therefore likely not affect protein 
function, but may affect protein expression through effects on gene regulation. 
In Figure 4.3, the numbers of recorded mutations are much higher than those 
observed in Figure 4.2. This is likely because the comparisons in Figure 4.2 are 
with the reference genome, while in Figure 4.3 they are between the knockout 
and their matched controls. As the cultures have diverged over time, it is likely 
they have developed different sets of mutations independently, and this results in 
the inflated numbers seen here as both sets of mutations are included in the 
comparison in Figure 4.3 rather than one or the other seen in Figure 4.2. 
The same analysis performed for SNVs in Figure 4.3 was not repeated for indels 
as the effect of an indel can reach far beyond the location in which it is detected. 
For example, a frameshift can affect the entire length of the protein or intronic 
sequence despite only being a 2bp change. Furthermore, unlike SNVs, indels can 
be large and span several different types of genomic region. For these reasons, 
it is not an appropriate analysis to apply to elucidate what effects the presence of 
these mutations might have on overall gene expression. 
The mutation signature observed in Figure 4.4 has been designated SBS5 (of 
unknown origin) in the literature, and has been detected in most cell cultures, 
having been attributed to processes generating mutations throughout life at 
constant rates in all individuals (Alexandrov et al., 2015; Petljak et al., 2019). 
From Figure 4.5A, the rates of indel formation are two- to three-fold higher than 
the rates of SNV occurrence seen in Figure 4.2A. In all the chromosomal 
breakdowns of mutation rates, the X chromosome is consistently lower than the 
average across the genome. This is likely due to a low coverage of sequencing 
reads across the X chromosome due to its highly repetitive regions and therefore 
an artefact of the experimental setup than a true lower mutation rate (Ross et al., 
2005). 
From Figure 4.6, the vast majority of indels detected were complex (consisting of 
both insertion and deletion of elements). This may be another artefact of the 
sequencing technology used, as short read sequencing containing indels may not 
align with the genome at all or misalign with an incorrect part of the reference 
genome. There were very few insertions detected and this may reflect the 
tendency for NHEJ and HR to favour deletions in the DNA repair pathway (Mao 




et al., 2008). This may also reflect the inability of short read sequencing to detect 
the insertion of mobile genetic elements such as LINE-1 (Teissandier et al., 2019).  
The circus plots in Figure 4.7 and Figure 4.8 confirm the success of the targeted 
deletion of the B2M locus. The appearance of other genetic mutation hotspots 
was noted, but not consistent between the MS3 and MS4 lines. This may be 
interpreted as CRISPR not causing any repeated off-target effects at specific off-
target locations. This does not rule out the possibility of CRISPR causing random 
mutations throughout the genome, but Figure 4.2A and Figure 4.5A suggest that 
this is not the case either. 
Overall, from this analysis, despite the limitations mentioned above, the data 
suggests that the double nickase technique with the specific guides used to 
knockout HLA in these iPSC lines was successful, and that it posed no additional 
mutational burden on these cells. On the contrary, the re-cloning process 
appeared to have reduced the genetic diversity of the cell culture. 
Knowledge of the mutations present in these cells may provide an opportunity to 
spot harmful mutations that may occur by chance, for example in p53 as has been 
reported to have been acquired in certain stem cell lines previously (Merkle et al., 
2017). These issues become especially relevant when ensuring any transplant or 
transfusion of cells that have been designed to avoid immunogenicity (e.g. 
through B2M knockout) become tumorigenic. As iPSC-derived technologies such 
as forward-programming move to clinical translation, regulatory bodies will want 
to see evidence of safety and efficacy. These kinds of assays may provide further 
proof of the safety of genome-edited therapies as well as an opportunity for 
ongoing quality control as part of the manufacturing process. In one recent study, 
Ito and colleagues intend to translate the in vitro platelets they derived from 
immortalised MK cultures into human patients and techniques such as these may 
help to assure regulators that the resultant products will adhere to the Hippocratic 
principle of first doing no harm (Ito et al., 2018). 
This approach can be generalised and used as a pipeline for any other genome 
editing performed on iPSCs. For future work, ideally the direct parental cell culture 
from which both the control and edited cells were derived (Figure 4.1) would also 
be sequenced to accurately assess the effects of random mutations due to cell 
culture compared with those induced by the genome editing process. 
  




5 Passive absorption results in platelets 
loaded with rFVIIa that have an 
improved haemostatic effect in vitro 





As described in Figure 1.6, the two main routes by which proteins are present 
within the α-granules of megakaryocytes and subsequently platelets are through 
protein synthesis and endocytosis. Previous work has shown that both MKs and 
platelets are able to passively endocytose and pinocytose certain proteins such 
as fibrinogen and immunoglobulins (synthesised by hepatocytes and B cells 
respectively) into these granules which are then released upon stimulation by 
agonists (Handagama, George, et al., 1987). 
Mass spectrometry data has shown that the contents of the α-granules are wide-
ranging, a testament to the wide variety of roles that platelets play not just in 
thrombosis but also inflammation (Maynard et al., 2007).  Notably, not all proteins 
present in the plasma are endocytosed into the α-granules. For example, factor 
V is present in α-granules but not factor VII. This suggests that rather than being 
a passive process, endocytosis in this context is specific to certain proteins 
binding to specific receptors. 
Clathrin-coated membranes were first noted in platelets in 1982 (Morgenstern, 
1982). Clathrin-coated pits were shown to line the plasma membrane and open 
canalicular system (OCS), either existing by themselves or fused with secretory 
α-granules, shown to transfer plasma components to platelet granules (Behnke, 
1989). Other studies show that both clathrin dependent and independent 
endocytosis take place in platelets. The data suggests cargo is delivered to α-
granules and the endosomal-lysosome pathway respectively. These studies 
involve resting platelets with colloidal gold-tagged fibrinogen, now used as a 
marker for receptor-mediated endocytosis, and acid phosphatase, a marker for 
lysosomes (Behnke, 1992). 
The endocytosis of rFVIIa into granular structures within cells is not unique to 
megakaryocytes and platelets. Studies with rFVIIa tagged with a fluorophore 
revealed that it accumulates in hepatocytes, in zones of calcified cartilage in bone, 
and other extravascular spaces containing tissue factor-expressing cells 
(Gopalakrishnan et al., 2010). rFVIIa has also been shown to be endocytosed by 
endothelial cells through the endothelial cell protein C receptor (EPCR) (Ghosh 
et al., 2007). This binding has also been shown to reduce its pro-coagulant activity 
(López-Sagaseta et al., 2007). 
Some studies suggest that in vivo, sequestration within megakaryocytes and 
shielding from the normal proteolytic and excretion mechanisms acting on 
proteins present in the plasma may be a reason for the efficacy of once-daily 




rFVIIa injections for patients with haemophilia despite its plasma half-life of 2 
hours. One group have shown that MEG-01 cells, from a human 
megakaryoblastic leukaemia cell line, were able to take up rFVIIa passively 
through the endothelial protein C receptor (EPCR). The platelets produced from 
this appear to subsequently contain rFVIIa (Schut et al., 2017). 
Hoffman and colleagues demonstrated that rFVIIa is able to bind weakly to 
activated platelet membranes and locally enhance thrombin generation (Hoffman 
and Monroe, 2010). This association has been described to take place through  
binding to GPIb-IX-V (Weeterings et al., 2008). More recently, another group 
showed using intracellular flow cytometry that rFVIIa can be directly endocytosed 
by platelets of FVII-deficient patients, suggesting that this may also contribute to 
the prolonged half-life observed with rFVIIa (Lopez-Vilchez et al., 2011). 
5.2 Aims 
Although the endocytosis of rFVIIa into platelets and megakaryocytes has been 
described before in the context of explaining the prolonged efficacy of rFVIIa 
beyond its theoretical plasma half-life, it has not been explored as a method to 
deliver rFVIIa using platelets for haemostatic effect in normal individuals for the 
treatment of acute haemorrhage.  
To provide further evidence for the mechanisms described in the literature, ex 
vivo mouse megakaryocytes and human FoPMKs were used to investigate 
whether rFVIIa can be endocytosed outside of a transformed cell line, and 
whether these can then produce platelets that have loaded with rFVIIa in their 
granules. The preliminary results from Lopez-Vilchez and colleagues were also 
validated. Human donor platelets were also tested for their ability to directly 
endocytose rFVIIa into α-granules, not lysosomes, and maintain functional 
activity. This was performed in the context of augmenting a transfusion unit to 
improve its haemostatic effect. These resultant platelets were then assayed to 
see if they can then subsequently release this rFVIIa upon stimulation, and the 
effect of these loaded platelets in in vitro clotting assays were observed. 
  




5.3 Mouse megakaryocytes and their resultant platelets were 
evaluated for their ability to endocytose rFVIIa 
Mouse bone marrow-derived HSCs were harvested and differentiated into 
megakaryocytes in culture to evaluate their ability to endocytose rFVIIa (section 
2.3.7). In Figure 5.1, they were evaluated for the presence of intracellular FVII by 
flow cytometry. 
Gates were set up first by forward and side scatter and singlet events were gated 
for (Figure 5.1A). A Per/Cy7-only control was used to set up the gate for CD42d, 
a marker of mouse megakaryocytes. These gates were then used to set up the 
gating for FVII in Figure 5.1B, by using a control stained for CD42d but with only 
secondary antibody staining for FVII. 
Mouse MKs not incubated with rFVIIa in this experiment showed 7.79 ± 0.778% 
positive for FVII (Figure 5.1C) while mouse MKs incubated with FVII reported 8.01 
± 0.826% positive for FVII (Figure 5.1D) (mean ± SEM). The overall difference 
was not statistically significant when compared in a paired t-test (n=3 for each 
condition, p>0.05) (Figure 5.2B). 





Figure 5.1. Mouse MKs derived from bone marrow were incubated for 24 hours with or without recombinant 
FVII. They were washed to remove excess FVII and intracellular staining was performed defining MKs 
using the Ab against CD42d (A) Isotype control for CD42d. Gating strategy from FS/SS, to singlets to 
setting up the CD42d gate (B) Control for FVII staining. Gate setup for FVII with CD42d and secondary 









Although no statistically significant increase was seen in the MKs from Figure 
5.2B, platelets were collected from each of these experiments to evaluate whether 
any rFVIIa had already been produced and packaged into the platelets. 
For the experiments in Figure 5.3 and Figure 5.4, platelets from the MKs in Figure 
5.1 and Figure 5.2 were collected and analysed by intracellular flow cytometry. 
Gates were first set up from the isotype control for CD42 (Figure 5.3A) on size 
and the gate for CD42d was set up. On the secondary-only control for FVII (Figure 
5.3B), the gate for the FVII was set up after selecting the events positive for 
CD42d. On platelets from MKs not incubated with rFVIIa (Figure 5.3C) compared 
with platelets from MKs incubated with rFVIIa (Figure 5.3D), there was a slight 
increase in percentage of events staining positive for FVII (on average, from 
7.81% to 9.56%, from Figure 5.4B), but this was not statistically significant at a 
p<0.05 level. An overlay plot showing the FVII stainings for a representative 
















Figure 5.2. Statistics from several experiments incubating mouse MKs with rFVIIa. (A) The FVII 
stainings from isotype, -rFVIIa and +rFVIIa were overlaid on a single plot. (B) % gating positive for 
FVII staining were quantified from biological replicates. n=3, a two-tailed paired t-test was performed 
at the p < 0.05 significance level, data shown as mean ± SEM. 
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Figure 5.3. Representative intracellular flow cytometry plots of platelets from mouse MKs 
incubated with or without rFVIIa. Platelets were defined by size and presence of CD42d. 
(A) Isotype control for CD42d. Gating strategy from FS/SS to set up the CD42d gate. (B) 
Secondary antibody only control for FVII. This was used to set the gates for %FVII+ve. (C) 









5.4 Forward-programmed megakaryocytes were able to 
endocytose rFVIIa into granules 
Forward programmed megakaryocytes were first assessed for viability (DAPI 
negative) and megakaryocyte identity (through expression of both CD41 and 
CD42) before any experiments were performed (Figure 5.5) to ensure cells were 
at least >50% viable and >60% CD41+ and CD42+.  
FoPMKs incubated with or without rFVIIa for 24 hours at 37ºC were fixed, 
permeabilised and stained for FVII before being analysed by flow cytometry. They 
were first gated on size to exclude debris (Figure 5.6A), and gating for FVII was 
established on a secondary only control (Figure 5.6B). FoPMKs incubated without 
rFVIIa showed on average 5.29% positive for FVII, likely non-specific binding 
(representative plot in Figure 5.6C and average from three experiments in Figure 
5.6F), while those incubated with rFVIIa showed on average 45.5% positive, 
















Figure 5.4. Summary of statistics for intracellular staining of platelets from MKs incubated with or 
without rFVIIa. (A) Overlay plot showing secondary only control, platelets from MKs without rFVIIa 
and platelets from MKs with rFVIIa (B) Percentage of platelets staining positive for intracellular 
rFVIIa, n=3, two-tailed paired t-test at a significant level of p<0.05. Data shown as mean ± SEM. 
Figure 5.5. Flow cytometry data to assess the viability of the FoPMK population (DAPI) and 
expression of markers for megakaryocytes (CD41 and CD42) to confirm their identity. 



















Figure 5.6. Representative flow cytometry plots of FoPMKs incubated with and without rFVIIa for 24 
hours before being washed and stained. (A) Cells were gated on FS/SS and then for singlet events 
(B) Secondary only staining was used to set up FVII gating (C) FoPKs not incubated with rFVIIa (E) 
FoPMKs incubated with rFVIIa (F) Overlay plot for FVII staining in secondary only control, without 
and with rFVIIa. (G) Quantified percentage of events in percentage gating FVII+ve under both 









To verify that the rFVIIa was present intracellularly and not simply adsorbed to 
the surface of the megakaryocytes, flow staining was repeated with and without 
permeabilization and a marker for megakaryocytes (CD41) and viability (Zombie) 
(Figure 5.7). Gates were established first on FS/SS and then to select only singlet 
events. The gate for CD41 was established using an isotype control for this 
antibody (Figure 5.7A). Gating for Zombie was established on samples stained 
for CD41 but not Zombie (Figure 5.7B). Gating for FVII was then set up on 
samples stained for CD41 and Zombie but only the 647 secondary antibody  
(Figure 5.7C). FoPMKs were incubated with rFVIIa for 24 hours at 37ºC before 
being washed and stained for FVII either with or without permeabilization (Figure 
5.7D-G). All controls used to establish the gating strategy were unpermeabilised. 
This was summarised in overlay flow plots (Figure 5.8A) and quantified for three 
biological replicates (Figure 5.8B), which confirmed a significant (p<0.05) 
difference between the FoPMKs incubated with rFVIIa and permeabilised 
compared with all other samples. From this data, FVII was confirmed to be 
present intracellularly in live megakaryocytes, and not adsorbed to their surface 
nor attached to dead cells. 
Immunofluorescence data further confirmed the endocytosis of FVII into these 
cells. Secondary antibody staining established no granular objects seen without 
any primary antibodies and acted as a control for background fluorescence signal 
(Figure 5.9A). Confocal images showed the presence of granular objects staining 
for rFVIIa in the cytoplasm of these FoPMKs (Figure 5.9C) that were absent in 
FoPMKs not incubated with rFVIIa (Figure 5.9B). However, the granules did not 
appear to co-localise with thrombospondin, the marker used for α-granules in 
Figure 3.1. 
  





Figure 5.7. Representative intracellular flow staining for FoPMKs incubated with and without rFVIIa with and 
without permeabilization. (A) Gating strategy set up first for cells, on size to exclude debris, then singlets, and then 
the CD41 gate was set with the isotype control (B) Gating for Zombie was set up on cells stained for CD41 but not 
Zombie (C) Gating for both CD41+ and Zombie-, the FVII gate was set up with a 647-secondary-only control (D) 
FoPMKs without permeabilization or incubation with rFVIIa (E) FoPMKs without permeabilization but with rFVIIa 
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Figure 5.8. Summarised flow data for CD41+Zombie- gated FoPMK cells on the number of events positive 
for FVII staining with and without permeabilization. (A) Overlay flow plots summarising the data in Figure 5.7 
(B) Quantified percentages of cells staining positive for FVII; n=3, one-way ANOVA with Tukey’s correction 
for multiple testing, * p < 0.05; data shown as mean ± SEM. 
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Figure 5.9. Representative immunofluorescence photographs for forward programmed 
megakaryocytes incubated with and without rFVIIa. (A) Secondary only staining (B) Primary 
and secondary antibodies added, on cells not incubated with rFVIIa (C) Staining on cells 
incubate with rFVIIa for 24 hours at 37ºC. Staining was performed for FVII (red, ab97614, 
secondary A21244) and thrombospondin (THBS, green, ab1823, secondary A21121). n=3, on 










Intracellular flow cytometry was used to assess whether the subsequent platelets 
produced by these MKs contained rFVIIa or not. MKs incubated with rFVIIa for 24 
hours at 37ºC were then washed and cultured in RPMI for another 24 hours to 
elicit platelet release. Platelets were then collected from these cultures, fixed and 
stained for analysis. 
Gating was established using isotype controls for gating on CD41/42 to establish 
platelet identity (Figure 5.10A). A control omitting Zombie was used to set up the 
Zombie gate for live platelets (Figure 5.10B). A 647-secondary only control was 
used to set up the FVII positive gate (Figure 5.10C). Platelets from the MKs not 
incubated with rFVIIa were measured (Figure 5.10D) and compared to platelets 
from MKs incubated with rFVIIa (Figure 5.10E).  
Overlaid on top of each other, there was no observed difference between these 
two conditions (Figure 5.11A). Quantified from three biological replicates, 
platelets from MKs not incubated with rFVIIa showed an average of 9.36% 
positive for FVII, compared to 10.5% for platelets from MKs incubated with rFVIIa 
(Figure 5.11B). No significant increase was observed in FVII staining at the 
p<0.05 level. 





Figure 5.10. Intracellular flow data in platelets from FoPMKs incubated with and without rFVIIa.(A)  
Gating strategy to set up CD41/42 gates on isotype control samples. (B) Gating strategy to set up 
Zombie gate on samples stained with CD41/42 but not Zombie (C) Gating strategy to set up FVII 
positive gate on samples stained with CD41, CD42, Zombie and 647-secondary only. (D) 
Representative FVII staining on platelets from FoPMKs incubated without rFVIIa. (E) Representative 









5.5 Human platelets can directly endocytose rFVIIa 
Intracellular flow cytometry was used to test whether human platelets are able to 
directly endocytose rFVIIa. Human donor platelets were incubated at room 
temperature for 1 hour with rFVIIa before being washed and analysed. Controls 
used to establish gating were unpermeabilised and incubated with 647-secondary 
only (Figure 5.12A). After gating on size and for only singlet events, the FVII gate 
was set. On platelets not incubated with rFVIIa and unpermeabilised, there was 
no significant difference between the samples incubated but not permeabilised 
and not incubated with rFVIIa but permeabilised (Figure 5.12B-D). However, there 
was a significant (p<0.05) difference between all three of these groups and the 
samples incubated with rFVIIa and permeabilised (Figure 5.12E,G) and was 
visible as a whole population shift on an overlay plot (Figure 5.12F). This 
suggested that rFVIIa was absorbed by the platelets and was present 
intracellularly, not weakly attached to the surface. 
As there seemed to be evidence for endocytosis in the flow data, a FVII ELISA 
on platelet lysates were also performed to confirm this (Figure 5.13). Results from 
the samples show that the 10x106 platelets incubated with 10µg/ml rFVIIa 
contained 13.9ng/ml of FVII in their lysate compared to 0.4ng/ml for the platelet 















Figure 5.11. Summary of flow data on platelets from FoPMKs incubated with or without rFVIIa 
(A) Overlay plots of PLPs from secondary only control, without and with rFVIIa (B) Quantified 
data; data shown as mean ± SEM, paired t-test performed at the p<0.05 significance level. 
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Figure 5.12. Intracellular flow cytometry showing presence of intracellular rFVIIa in platelets incubated with rFVIIa for 1 
hour. (A) Gating was set up on FS/SS and on singlet events alone. FVII gate was set up on unpermeabilised platelets with 
647-secondary only (B) Platelets without rFVIIa incubation, without permeabilization (C) Platelets with rFVIIa incubation, 
without permeabilization (D) Platelets without rFVIIa incubation, with permeabilization (D) Platelets with rFVIIa incubation, 
with permeabilization (E) Overlay flow plots summarising this data (F) Quantified percentages across n=3 biological 







































Figure 5.13. Factor VII ELISA was performed to detect the presence of rFVIIa in the 
lysates of 10x106 platelets incubated with rFVIIa for 1 hour at room temperature and 
subsequently washed. n=3, data shown as mean ± SEM.(A) Standard curve for ELISA 
(B) ELISA results for lysates incubated with and without rFVIIa * p<0.05 from a two-tailed 
unpaired t-test 
5.6 These loaded platelets can release rFVIIa upon exposure to 
agonists 
In order to test whether these loaded human donor platelets were able to release 
this absorbed rFVIIa, a releasate assay was performed where these samples 
were incubated with or without agonist, and the supernatant collected for analysis 
by ELISA. In Figure 5.14, the lysates further replicate the previous result in Figure 
5.13 while acting as internal controls to verify that the platelets being used in this 
experiment were loaded with rFVIIa. The releasates from samples not incubated 
with rFVIIa did not show any detectable FVII, with or without agonist. The 
releasates of platelets incubated with rFVIIa showed a very small amount of 
rFVIIa not significantly different from those not incubated without agonist, while 
the releasate of platelets incubated with rFVIIa and agonist showed a significant 
(p<0.01) quantity of rFVIIa had been released. This shows that human platelets 
can absorb rFVIIa into their granules, and subsequently release this when 
challenged with an agonist. 
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Figure 5.14. Releasate assay performed on human donor platelets incubated with and 
without rFVIIa for 1 hour at room temperature.  Samples were then washed and then 
incubated with either TAP lysis buffer (section 2.1.1.4), 1U thrombin or Tyrode’s. A FVII 
ELISA was performed to quantify the presence of rFVIIa in each of these samples. N=3, 
error bars = SEM ** p<0.01 *** p < 0.001 
5.7 These platelets show improved haemostatic activity in a 
thrombin generation assay 
A thrombin generation assay was performed to measure the effect of this 
intracellular rFVIIa in donor platelets on thrombus formation, and representative 
plots of the thrombin generation over time were observed to be very different 
between loaded and unloaded platelets (Figure 5.15A). A dose-dependent 
relationship between the parameters of the thrombin generation plot and 
concentration of platelets used was observed under both conditions, trending to 
indicate a faster thrombus formation (reduced lag time, increased peak height, 
reduced peak time, increased area under curve) with increasing platelet 
concentration (Figure 5.15B-E). Platelets loaded with rFVIIa showed a more pro-
thrombotic phenotype compared to unloaded platelets at all concentrations, 
demonstrating a lower lag time, and time to peak, and a higher peak height and 
total area under the curve at both intermediate concentrations of platelets. The 
concentration curve for total thrombin generation (area under the thrombin 
generation curve) compared to the number of platelets was modelled using non-
linear regression to calculate the EC50 of the donor and loaded platelets, which 
were 3.43 (2.777 to 4.274) and 0.331 (0.09411 to 0.6773) respectively, reported 
as the mean (95% confidence interval) to 3 significant figures (Figure 5.15E). This 
shows that the EC50 of loaded platelets was significantly (p<0.05) reduced for total 
thrombin generation compared to donor platelets (Figure 5.16).  
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Figure 5.15. Thrombin generation assay on three concentrations of donor platelets incubated with or without 
10µg/ml rFVIIa for 1 hour at room temperature before being washed and analysed. Thrombin generation 
was performed in the presence of platelet and microparticle-free plasma (PMPP) in 100µl, triggered by the 
addition of RCLow (solution containing phospholipid micelles with rhTF) and measured for both conditions 
at three concentrations of platelets (PLTs) and repeated for n=3 biological replicates, data shown as mean 
± SEM. (A) Representative thrombin generation plots for donor platelets vs loaded platelets at 1x106 
platelets. (B) Lag time before onset of peak (C) Peak height (D) Time duration of peak in minutes (E) Area 






















































Figure 5.16. Confidence intervals for the EC50 for total thrombin generation, derived from 
non-linear regression applied to the concentration curves in Figure 5.15E. The EC50 here 
refers to concentration needed for half of the maximal signal from the assay. 
5.8 Discussion 
From Figure 5.1, there appeared to be a very slight increase in FVII staining in 
mouse megakaryocytes but this was not significant. Only one concentration of 
rFVIIa was used, for one incubation time which may not be sufficient for significant 
endocytosis. The number of mouse MKs cultured from bone marrow was small 
(Figure 5.1A) and the cells only survived for a short (<7 days) period of time, 
although other groups have reported cultures lasting for several weeks (Ho et al., 
2019). In Figure 5.4, there is a small increase in FVII staining (although not 
significant) from the platelets these MKs produce. One way to overcome some of 
these issues would be to combine this data with immunofluorescence, which 
would provide information on localisation of the rFVIIa. 
However, conclusions from the mouse MK model are of limited applicability to a 
human system. Other groups have reported that the composition of platelet α-
granules is species-specific and conclusions from the mouse system do not 
necessarily map onto human biology (Hoffman, 2005). The FoPMK system was 
adapted instead as it is likely more relevant for clinical translation and the 
numbers of megakaryocytes produced proved to be far greater than ex vivo 
mouse MK cultures (Figure 5.1A compared to Figure 5.6A). 




Intracellular flow staining in Figure 5.7 was used to show that rFVIIa was 
endocytosed by live FoPMKs, and not dead cells that may absorb protein non-
specifically. This data also confirmed that the rFVIIa was present inside of the 
cells, and not merely adsorbed to the surface. To do this experiment, a standard 
megakaryocyte marker (CD41) and dead cell marker (Zombie) was used as has 
been suggested in the literature to ensure all events seen were live MKs 
(Shepherd et al., 2018). Zombie was used in place of other more commonly used 
viability stains, for example Calcein-AM, which leak out of permeabilised cells. 
The disadvantage to this is that Zombie only stains dead cell membranes, and so 
is a ‘negative’ dye where those staining negative are gated for, as opposed to a 
‘positive’ dye like Calcein-AM which gives more confidence in the viability of its 
population. All controls were unpermeabilised to establish the assay gating 
strategy as permeabilization itself is likely to change the binding properties of the 
antibody due to more exposed non-specific binding sites. This perhaps explains 
the increase in percentage of events gating positive for the -rFVIIa condition 
between the unpermeabilized and permeabilized samples (Figure 5.8B). 
The platelets produced from these MKs did not have any significant staining for 
FVII (Figure 5.11). From looking at the IF data, this may not be entirely surprising. 
From Figure 5.9C, it can be noted that unlike the genetically engineered FVII in 
chapter 3 (Figure 3.20), the rFVIIa endocytosed is not distributed across many 
different granules but localised to only a small number (3 in Figure 5.9C, 
compared to >29 thrombospondin granules and >14 for the vWF-F7TF in Figure 
3.20C). This may indicate that the vast majority of the rFVIIa absorbed into the 
MKs are ending up in a small population of platelets, and most of the produced 
platelets remain unloaded. Like the FVII in chapter 3, the rFVIIa here did not co-
localise with thrombospondin. This may suggest it is also similarly in a VEGF-
positive granule. Alternatively, it may be possible that the rFVIIa taken up by these 
MKs ended up in granular structures unrelated to the α-granules, such as 
lysosomes or early endosomes, which were then not transferred to the resultant 
platelets from these MKs. 
A limitation of the FoPMK approach is that it remains difficult to scale up to 
produce enough PLPs necessary for an in vivo mouse transfusion experiment, to 
ask whether these loaded platelets have a superior haemostatic effect in vivo. For 
a cost-benefit analysis, clinical translation, this may represent the worst of both 
worlds, being expensive to scale-up, while requiring addition of an expensive drug 
(the work in genetically engineering FVII into the granules in chapter 3 simplifies 
this to just the issue of scaling up FoPMK platelet production). To address this, 
human donor platelets were assessed for their ability to directly endocytose 




rFVIIa, which would render the use of platelet loading far more accessible and 
easier to scale-up, despite requiring the use of an expensive drug. 
Gates were set up only on size as donor platelet preparations gating only on 
FS/SS have been shown previously to be highly positive for CD41/42 and viable 
(Vučetić et al., 2018). Unlike Hoffman and colleagues, flow cytometry data (Figure 
5.12G) here suggests that rFVIIa is able to be directly endocytosed into platelets, 
and not just weakly attached to the surface (Hoffman and Monroe, 2010). This is 
more in line with results reported by Lopez-Vilchez and colleagues (Lopez-Vilchez 
et al., 2011). However, these experiments do not rule out the weak attachment of 
rFVIIa in vivo from the plasma, as any excess rFVIIa was washed off in the 
experiments presented here. 
From the combination of intracellular flow data and ELISA data it can be 
concluded that rFVIIa is present inside of the platelets incubated with the drug. 
Intracellular flow cytometry is able to answer whether the rFVIIa is present inside 
of the platelets or not (with and without permeabilization) (Figure 5.12G), and 
ELISA data is able to quantify the exact amount of rFVIIa absorbed (Figure 5.13), 
with the two approaches complementing one another. The ELISA data suggests 
that the vast majority of the rFVIIa added was in excess and was not absorbed. It 
may be possible to load many more platelets with the same concentration of 
rFVIIa used here. 
The conclusions from one group suggest that the prolonged efficacy of rFVIIa lies 
due to its uptake by megakaryocytes and subsequent production of platelets  
(Schut et al., 2017). Data generated here suggest that direct uptake by platelets 
in circulation may play a more fast-acting, and therefore much larger role.  
From the releasate experiments (Figure 5.14), it can be quantified that 
approximately 40% of the absorbed rFVIIa was released in response to agonists, 
which may indicate why a dramatic difference was seen in the thrombin 
generation assay. The rFVIIa may exist as a dynamic equilibrium between the 
granules and the extracellular compartment, thus the FVII detected in the 
releasate of the no thrombin condition may be due to Le Chatelier’s principle. 
Alternatively, it is possible that the centrifugation or other mechanical stimulus 
may have triggered some platelet activation independent of the thrombin. 
The thrombin generation assay data (Figure 5.15) suggest that fewer loaded 
platelets are required for the same level of total thrombin generation due to the 
lowered EC50, suggesting that they are more readily able to form clots. This is 




likely to be of benefit both locally in thrombus formation. Intravital microscopy has 
previously established a small number of platelets being responsible for initiation 
of clotting after a laser injury, before recruiting others (Rosen et al., 2001). 
Clinically, this might be applicable in giving platelet transfusions. As patients 
indicated for a transfusion typically have a low platelet count, the transfusion of 
loaded platelets may provide significantly more benefit than transfusion in patients 
with a normal platelet count.  
The results of this are somewhat surprising given that FVII is present in large 
quantities in plasma but are not endocytosed by platelets in circulation as 
evidenced by mass spectrometry data from platelet α-granules (Maynard et al., 
2007). Meanwhile, these data show that FVIIa is readily taken up by donor 
platelets into their α-granules. This may be explained by the change in 
conformation in FVIIa compared to FVII, or some epitope created only when in 
complex with TF, that allows for binding to a receptor on platelets, perhaps EPCR. 
Speculatively, this might explain the ability of platelets to adsorb FVIIa on the 
surface of their cell membranes and not FVII in the cell-based model of 
haemostasis described in section 1.4.2. 
To conclude, FoPMKs can endocytose rFVIIa and package it into granules, but 
this is not present in the subsequently produced platelets to a noticeable degree.  
By contrast, human platelets directly from a donor can endocytose rFVIIa and 
subsequently release it when stimulated with agonist. This results in them having 
better characteristics at forming thrombi in the thrombin generation assay, 
especially at low concentrations where the differences are most apparent.




6 A novel thrombocytopaenic mouse 
model for measuring haemostasis after 
human platelet transfusion 
  





Previous work in establishing a model for human platelet transfusion in vivo has 
met with success. Early attempts introduced platelets into an immunodeficient 
NSG mouse with survival of human platelets for several days when injected 
intravenously (Newman, Aster R and Boylan B., 2007). Later work showed that 
platelet transfusion through the tail vein is equivalent to the retro-orbital route 
used previously and may increase the survival time of the platelets (56% 
detectable in the circulation when injected retro-orbitally after 5 hrs, versus 84% 
when injected via the tail vein) (Fuhrmann et al., 2016). However, these times 
remain far below the five to seven days seen with platelet transfusion into human 
recipients. 
Work involving transplantation of human CD34+ stem cells to reconstitute human 
megakaryopoiesis in mice resulted in poor engraftment, and this was discovered 
to be due to rapid clearance of human platelets by mouse macrophages (Hu and 
Yang, 2012). Macrophage depletion with clondronate-liposomes was able to 
reverse this effect. However, these models have significant differences compared 
to clinical platelet transfusion, where patients with a low platelet count are 
transfused with human donor platelets to treat acute haemorrhage. This is not 
modelled by irradiation and transplantation of CD34+ stem cells for a long-term 
engraftment.  By depleting the circulating mouse platelets, it would be possible to 
remove a major confounding factor in using a mouse model to assess the 
functionality of transfused human platelets, without requiring irradiation and 
subsequent transplantation of human stem cells into the mouse bone marrow 
niche. 
There are several different techniques used to induce thrombocytopaenia in mice. 
Chemical approaches include the use of busulfan, but this is also associated with 
an associated leukopaenia which is undesirable as this effect is not limited to 
platelets (Qi and Hardwick, 2007). Genetic knockout of the c-Mpl receptor leads 
to a 85-90% drop in platelet counts, but the remaining platelets are still functional, 
and this does not appear to be a specific cell-targeted approach as seen by 
defects in other parts of haematopoiesis (Alexander et al., 1996). More recent 
genetic approaches include using diphtheria toxin receptor under a platelet factor 
4 promoter to allow for a platelet depletion specific to an individual mouse that is 
still able to receive transfusion of murine platelets (Wuescher, Nishat and Worth, 
2019).  




The gold standard for inducing thrombocytopenia in mice has been antibody-
mediated depletion, mostly developed in a C57BL/6 background. Polyclonal 
antisera against mouse platelets have been used to cause a thrombocytopenia 
(Jenne et al., 2011; Salas-Perdomo et al., 2019). A specific monoclonal antibody 
targeting GPIIb/IIIa was shown to be effective in reducing platelet counts, but 
induced an anaphylactic response (Nieswandt et al., 2003), whilst one instead 
targeting GP1b has been shown to effectively induce a thrombocytopenia for up 
to 96 hours without an allergic response (Nieswandt et al., 2000). These models 
have been used to investigate bleeding disorder such as immune 
thrombocytopenic purpura (ITP), the role of platelets in immunity and 
neuroprotection. However, they have not been used with human platelet 
transfusion and it is unclear if these antibodies will cross-react with and clear 
human platelets. 
The group of Koji Eto (Kyoto University), also working on in vitro-derived platelets, 
used NSG mice with irradiation-induced thrombocytopaenia, and an intravital 
laser-induced injury model to assess the formation of thrombi (Nakamura et al., 
2014). This approach has the same major limitations as described with irradiation. 
Furthermore, although the laser injury model shows that in vitro platelets form 
stable thrombi under imaging, it lends no functional evidence that these stable 
thrombi contribute significantly to haemostasis. 
More recently, an antibody-mediated depletion model was published by the 
Bergmeier group, including a laser-induced injury and imaging of the resulting 
platelet recruitment (Paul and Bergmeier, 2020). This shows that it is possible for 
human donor platelets to be haemostatically active with the absence of 
endogenous mouse platelets. This shares the limitation of not directly measuring 
bleeding and has not been used with in vitro-derived platelets or platelets loaded 
with rFVIIa. 
6.2 Aims 
As described in the introduction, previous work has shown that human donor 
platelets can survive for several hours in the mouse circulation. In this chapter, 
thrombocytopaenia was induced through an antibody-mediated depletion of 
endogenous mouse platelets to limit the indirect effects of inducing a 
thrombocytopenia seen through other techniques. These mice then underwent a 
transfusion of human donor platelets and subsequently were subjected to a tail 
transection experiment to functionally measure haemostasis in the context of 
human platelet transfusion. This mouse model was then used to measure the 




haemostatic effect of donor platelets loaded with rFVIIa compared to only donor 
platelets. 
6.3 A polyclonal anti-mouse platelet antibody was able to lower 
mouse platelet counts, but showed cross-reactivity with 
human platelets 
Mice were rendered thrombocytopaenic with a polyclonal rabbit anti-mouse 
platelet antiserum (see section 2.1.1.15). This was originally raised by taking 
C57BL/6 platelets and using these as an antigen in rabbits, and subsequently 
collecting the serum. Previous work had shown that it was effective at fully 
rendering C57/BL6 mice thrombocytopaenic (Hilton, Kile and Alexander, 2009). 
However, it had not been tested in an immunocompromised NRG/J mouse, which 
comes from a BALB/c background. 




















Figure 6.1. NRG/J mice treated with anti-thrombocyte antiserum. NRG/J mice were given 
i.v. anti-thrombocyte antiserum or PBS and bled via the tail vein at -24, 4, 24 and 48 hours 
post-injection. n=3, results show mean+SEM, *** p=0.0006. A two-way repeated 
measures ANOVA was performed with a Geisser-Greenhouse correction. Comparisons 
were performed at each time-point and a Bonferroni correction was applied. 
The anti-mouse thrombocyte antiserum showed mixed results (Figure 6.1). Mice 
given the depletion antiserum had a reduction in their platelet count compared to 
baseline to 68% of the original level, eventually dropping to 56% by 24 hours, 
while control mice had an increase in platelet counts. Although the platelet count 
was lowered in the mice that received the antiserum intravenously, this was only 
to 68% of baseline compared with a 99% decrease seen in the literature (Salas-
Perdomo et al., 2019). For this model, the ultimate purpose was to reduce the 
mouse platelet count to be as low as possible to measure the effects of only the 
human platelets, for which a 68% reduction is unsuitable. Furthermore, the control 
mice platelet count increased over the course of the experiment. Alongside this, 




it was noted that by comparing other blood parameters between baseline and 48 
hours, the lymphocyte percentage had reduced in both experimental groups, with 
a corresponding increase in the granulocyte percentage (Table 6.1). The white 
blood count had also trended towards increasing, although this was not 
statistically significant. 
 Anti-Thrombocyte serum PBS 











WBC 2.97±3.74 4.50±1.91  1.97±1.84 3.65±0.30  
LYM% 49.93±12.61 29.33±0.74 * 52.50±13.88 32.20±2.60 * 
MON




GRA% 35.23±10.95 56.30±1.53 * 34.50±8.63 52.40±3.00 * 
EOS% 3.47±2.26 1.73±0.44  6.50±5.30 2.00±0.80  
RBC 6.03±1.81 8.83±2.55  3.77±1.94 8.58±1.64  
MCV 49.33±0.67 50.33±0.67  49.00±1.15 50.00±0.00  
MCH 16.37±0.29 16.33±0.07  16.83±0.68 16.35±0.10  
MCHC 33.13±0.64 32.50±0.53  34.20±1.81 32.60±0.00  
RDW 15.10±0.31 15.43±0.29  14.87±0.13 15.45±0.10  
MPV 5.20±0.35 5.67±0.24  5.10±0.12 4.95±0.10  
Table 6.1. Complete blood counts reported from mice of both groups compared at 
baseline (-24 hours) and 48 hours post-injection. Data shown as mean ± 95% CI. * 
p<0.05, two-way-ANOVA with Sidak’s multiple comparison tests. 
The anti-mouse thrombocyte antiserum was added to human donor platelets 
(Figure 6.2) in order to assess whether the polyclonal nature of this antiserum 
would cross-react with any human platelets given as a transfusion, which would 
diminish the utility of this approach. 





Figure 6.2. Flow cytometry data on the binding of anti-mouse thrombocyte serum onto 
human platelet samples. Representative flow plots are shown, n=1. (A) Serum was 
incubated with human donor platelets without a secondary antibody. (B) Secondary 
antibody A21244 (section 2.1.1.15) only with human donor platelets. (C) Serum with 
human donor platelets and secondary antibody.  (D) An overlay plot of all three conditions 
was created in Kaluza. 




From the flow cytometry data (Figure 6.2), it is clear that there is an observed 
difference from human platelets with this antiserum, from a 1% positive gating in 
the secondary antibody only staining to a 95.44% positive gating with the serum. 
In Figure 6.2A, with only the serum, no signal is seen from the platelets. This was 
used to set the platelet gate. In Figure 6.2B, with only the secondary antibody 
(section 2.1.1.15), no signal is seen from the platelets in the Alexa-647 channel. 
This was used to set the positive gate. In Figure 6.2C, with both the serum and 
the secondary antibodies, a significant shift is seen. Finally, in Figure 6.2D, an 
overlay plot shows the shift seen, indicating this polyclonal serum is able to cross-
react with human donor platelets. The gates were set using the serum-only and 
secondary-only as controls, and the platelets incubated with both the serum and 
the secondary antibody showed 91.3% of the platelets in the positive gate.  
6.4  Immunocompromised NRG/J mice were rendered 
thrombocytopaenic with a monoclonal anti-GP1b antibody 
that does not cross-react with human platelets 
Figure 6.3. A monoclonal anti-GP1b antibody does not bind to human platelets.  
Representative flow (n=1) overlay plots of anti-platelet antiserum (section 2.1.1.15) 
(green) binding to human platelets, used as a positive control. The secondary antibody-
only A21244 (section 2.1.1.15) was used as a negative control (blue). Results from the 
anti-GP1b antibody are shown in red. 




In contrast to the anti-thrombocyte serum, which here was used as a positive 
control, the anti-GP1b monoclonal antibody showed no cross-reactivity with 
human platelets (Figure 6.3). There was no detectable difference between the 
anti-GP1b signal compared with the secondary antibody only control.  
A time course experiment was performed to measure the scale of the 
thrombocytopenia that is was possible to induce in these mice, as well as the 
duration of this platelet depleted period (Figure 6.4A). When platelet counts were 
plotted over time, the non-depleted group showed a steady platelet count of 1467 
± 69 PLTx103/mm3, whereas the group given the antibody showed a rapid 
thrombocytopaenia to 68 ± 10 PLTx103/mm3 within 1hr of the injection. This 
depletion lasted for at least 48 hours post injection. After this period, a rapid rise 
in platelet count to pre-depletion levels was seen between 48 and 96 hours post 
injection, followed by a reactive thrombocytosis above the normal platelet count 
that was observed between 96 and 168 hours post injection. There was no steady 
increase in platelet count seen with the vehicle control in Figure 6.4A as was 
observed with the previous antiserum (Figure 6.1). 
From Figure 6.4B, flow data on blood taken from IVC of control and treated mice 
show that the platelets normally seen in the platelet gate are almost completely 
absent from the treated mouse blood, providing further evidence of platelet 
depletion. No evidence for any other blood parameter being altered was observed 
in either experimental group between the treatments or between baseline and 48 
hours (Table 6.2). 
























Figure 6.4. A monoclonal anti-GP1b antibody was able to induce a >99% 
thrombocytopaenia for 48 hours in NRG/J mice. (A) Time course data of platelet counts 
for the control and mice treated with anti-Gp1b antibody (section 2.1.1.15),  Tail vein 
bleeds were performed -24, 1, 24, 48, 72, 96 and 168 hrs post platelet depletion.  Results 
show mean + SEM, n=3, p<0.01 (B) Flow data on blood taken from IVC of control and 
treated mice with the platelet gate highlighted.  
  
PBS anti-GP1b antibody 
A 
B 




 Anti-GP1b antibody PBS 
Baseline 48 hours  Baseline 48 hours  
PLT 1,378.50±357.00 68.00±10.00 * 1,350.50±155.00 1,466.50±69.00  
MPV 5.00±0.20 9.30±1.40  4.90±0.00 4.85±0.10  
Hb 15.50±1.00 14.95±0.70  15.40±1.00 16.25±0.30  
WBC 2.60±0.00 3.00±0.80  2.20±0.40 2.35±0.30  
LYM% 36.80±8.80 37.00±2.40  33.45±7.10 36.10±5.40  
MON% 16.65±0.70 16.50±0.00  15.15±0.70 15.25±0.70  
GRA% 46.55±9.50 46.50±2.40  51.40±7.80 48.65±6.10  
EOS% 1.60±0.40 1.05±0.30  1.50±0.80 1.45±0.90  
LYM# 0.90±0.20 1.05±0.30  0.65±0.30 0.80±0.00  
MON# 0.40±0.00 0.45±0.10  0.25±0.10 0.30±0.00  
GRA# 1.30±0.20 1.50±0.40  1.30±0.00 1.25±0.30  
EOS# 0.04±0.01 0.03±0.00  0.03±0.02 0.03±0.02  
RBC 9.49±0.43 9.36±0.41  9.37±0.81 10.09±0.40  
HCT 47.65±2.70 47.05±2.50  47.30±4.60 51.00±1.80  
MCV 50.50±1.00 50.50±1.00  50.50±1.00 50.50±1.00  
MCH 16.30±0.40 16.00±0.00  16.45±0.30 16.15±0.30  
MCHC 32.45±0.30 31.80±0.20  32.55±0.90 31.95±0.50  
RDW 15.35±0.30 15.50±0.20  14.95±0.10 15.25±0.10  
Table 6.2. Complete blood counts reported from mice of both groups compared at 
baseline (-24 hours) and 48 hours post-injection. Data shown as mean ± 95% CI. * p<0.05, 
two-way-ANOVA with Sidak’s multiple comparison tests. 
  




6.5 Thrombocytopaenic mice were transfused with donor 
platelets and the haemostatic effect was measured through 
a tail transection 
Thrombocytopenic mice were then used for a tail transection experiment to 
measure haemostasis. The weight of the tail transected and haemoglobin 
concentration from the mice were examined to show no significant differences 
between the groups apart from the platelet count (Figure 6.5A,B,C). 
Next, the volume of blood loss in the first four minutes of the experiment showed 
the greatest difference between the three groups (Figure 6.6A). The undepleted 
group showed very little blood loss (10.4 ± 3.70 µL), while the depleted group 
showed a significant volume of blood loss (275 ± 38.1 µL), approximately a third 
of the estimated circulating volume of these mice). The depleted group that were 
transfused with human donor platelets showed a significant (p<0.05) reduction in 
the volume of blood lost compared to the depleted only group (71.8 ± 30.3 µL). 
A plot of the cumulative blood loss over time (Figure 6.6C) showed that this effect 
was sustained over the course of the twenty minute experiment, although the 
addition of the cumulative errors from each volume calculation compounded when 
summing them together, making it difficult to draw any statistically significant 
conclusions after the first four minutes. 
 

























Figure 6.5. Controls for the haemostasis tail transection experiment.  (A) The weight of 
tail transected (B) The weight of tail transected normalised to mouse body weight (C) The 
circulating blood haemoglobin concentrations as measured by a complete blood count, at 















































































































































Depleted + Human Platelets
 
Figure 6.6. Summary of haemostasis mouse model from mice that were undepleted, 
depleted of platelets and depleted and subsequently transfused with 100x106 human 
donor platelets. (A) The total blood volume lost in the first four minutes in all three groups. 
One way ANOVA, *p <0.05 **p<0.01 (B) The amount of cumulative blood volume loss 









6.6 Passively loaded platelets have a superior haemostatic 
effect to unloaded platelets in an in vivo mouse model 
Finally, this mouse model was used to evaluate the functionality of the human 
donor platelets loaded through endocytosis (chapter 5) in vivo. As the undepleted 
mice appeared to consistently show little to no bleeding in previous experiments 
(Figure 6.6B), this was omitted for the following experiment as it would be 
unethical to use more mice than necessary. Instead, the main controls in this 
experiment were platelet-depleted and given a PBS transfusion which was 
expected to show a significant blood loss, platelet-depleted and given a human 
donor platelet transfusion, expected to show a reduction, and platelet-depleted 
mice given a transfusion of rFVIIa loaded platelets. 
The weight of the tail transected and circulating haemoglobin concentration from 
the mice were examined to show no significant differences between the groups 
apart from the platelet count (Figure 6.7A,B,C). 
Next, the volume of blood loss in the first four minutes of the experiment showed 
significant (p<0.05) differences between the three groups (Figure 6.8A). The 
platelet-depleted group showed a large volume of blood loss (167 ± 19.5 µL). The 
depleted group that were transfused with human donor platelets showed a 
significant (p<0.05) reduction in the volume of blood lost compared to the depleted 
only group (66.6 ± 11.0 µL).  Finally, the group of mice transfused with the donor 
platelets loaded with rFVIIa showed a reduction from this (20.7± 2.64 µL). It was 
noted that there was no overlap between any of the three groups at this timepoint. 
A plot of the cumulative blood loss over time (Figure 6.8B) showed that this effect 
trended over the course of the twenty minute experiment, with the average blood 
loss from the loaded donor platelet group being consistently below the average 
blood loss from the donor platelet group at all time points, although the 
compounding error of the cumulative blood loss makes it difficult to draw 
statistically significant conclusions. 
The rate of blood loss appears to be steady at 11.4±4.08µL/min (mean±SEM) for 
the group transfused with donor platelets only, while the rate of blood loss 
appears to be biphasic with an inflection point at 12 minutes for the group 
transfused with loaded donor platelets with the first 12 minutes progressing at a 
rate of 5.72±0.676µL/min and the latter 12 minutes progressing at 
16.4±4.11µL/min (data from Figure 6.8B and Figure 6.9). The variability in blood 
loss was also noted to be lower in these first twelve minutes of loaded platelet 
transfusion compared to the latter 12 minutes or the donor platelets only.  



















































































































l) Depleted + PBS
Depleted + Donor Platelets





Figure 6.7. Controls for the haemostasis tail transection experiment. (A) The weight of tail transected (B) The 
weight of tail transected normalised to mouse body weight (C) The circulating blood haemoglobin 
concentrations as measured by a complete blood count, shortly before the transection (-1hr). n=3, ANOVA. 
Error bars represent SEM. 
 





































































L) Depleted + PBS
Depleted + Donor Platelets
Depleted + Donor Loaded Platelets
 
Figure 6.8. Summary of haemostasis mouse model from mice that were depleted of 
platelets and transfused with 100x106 human donor platelets, and depleted and  
transfused with 100x106 human donor platelets loaded with rFVIIa. (A) The total blood 
volume lost in the first four minutes in all three groups. One way ANOVA, *p <0.05 
**p<0.01 (B) The amount of cumulative blood volume loss over the full 20 minutes of the 






























Depleted + Donor Platelets
Depleted + Donor Loaded Platelets
 
Figure 6.9. Rate of blood loss for each individual timepoint (non-cumulative) plotted for 
the three groups of mice (n=3 in each group, all depleted of mouse platelets and then 
transfused with either PBS, donor platelets or donor loaded platelets). Data shown as 
mean±SEM. 
6.7 Discussion 
From Figure 6.6, although the platelet count was lowered in the mice that received 
the antiserum intravenously, this was only to a modest degree. Differences 
between the BALB/c background of the NRG/J mice and C56BL/6 mice the serum 
was raised from could be a reason why the same dose previously reported to 
result in a full depletion had a substandard effect in the NRG/J mice (Hilton, Kile 
and Alexander, 2009; Salas-Perdomo et al., 2019). This effect may be 
counteracted by increasing the dose of antiserum used and could be used to alter 
the magnitude of thrombocytopaenia. Furthermore, the control mice platelet count 
increased over the course of the experiment. This could be due to an inflammatory 
reaction, or perhaps a physiological response to the dilution of the platelet count 
through the intravenous injection of 100uL of fluid. From Table 6.1, it is possible 
that an inflammatory reaction is responsible for this effect as the percentage of 
granulocytes increased with a concordant decrease in the percentage of 
lymphocytes, suggesting an acute bacterial infection in both groups. Bacterial 
infection has been demonstrated to result in a rise in platelet counts in the 
literature (Bordin et al., 1995). 
From Figure 6.2, the signal from human platelets with this antiserum may be due 
either to non-specific binding, or binding to shared antigens present in both 
human and mouse platelets that the anti-thrombocyte serum is able to bind to. 
However, this feature renders this antiserum unsuitable for model development 
as it is likely to clear the human platelets from circulation as well as the mouse 




platelets. Mice given the depletion antiserum appear to have a reduction in their 
platelet count compared to baseline to around 68% of the original level before 
steadily recovering over 48 hours towards the baseline, while control mice appear 
to experience an increase in platelet counts above the baseline platelet count. 
Figure 6.4A shows clearly that the platelet count was depleted significantly (p < 
0.01) through use of the anti-GP1b antibody and this represented a superior 
choice compared with the anti-thrombocyte antiserum. The antibody may have 
opsonised the platelets both in circulation and those newly produced, leading to 
Fc-dependent clearance by macrophages as seen in immune thrombocytopenic 
purpura (ITP) (Harrington et al., 1951). The platelet-sized objects seen in the flow 
gates in Figure 6.4B may be very newly formed platelets, as evidenced by the 
increase in MPV; although no association has been found between steady-state 
platelet turnover and platelet size in humans (Mezzano et al., 1981), Burstein and 
colleagues found that larger platelets are released after administration of IL-6 
(Burstein et al., 1992). Alternatively, these could be platelets that do not express 
CD42b on their surface, reported to correlate with decreased responses to 
agonist (Blair, Michelson and Frelinger, 2018). The dose of the antibody as 
suggested by the manufacturer was reported to increase the length of the period 
of platelet-depletion and not to modulate the degree of platelet depletion, 
suggesting the dose affects the half-life of the antibody in the circulation, but that 
any dose used is far in excess of that needed to opsonise all platelets in the 
circulation owing to its specificity. The reactive thrombocytosis seen post 96 hours 
is likely mediated by increased TPO production as a homeostatic response to the 
low platelet count, which is perhaps why it occurs after three days (as TPO acts 
on the level of the stem cell to stimulate thrombopoiesis) (Dettke et al., 1998). 
This mouse model could therefore be also used as a model to discover novel 
factors involved in stimulation of reactive thrombopoiesis. 
The only parameter measured to demonstrate the antibody does not interact with 
human platelets was binding; the antibody may also stimulate other functionality 
without long-term binding, for example, platelet activation.  Interaction between 
vWF and GP1b is sufficient to promote platelet aggregation and similar effects 
have been previously reported by antibodies against GP1b through activating 
GP1b-IX in a shear-independent manner by inducing unfolding of the 
mechanosensory domain therein, leading to downstream platelet signalling 
(Quach, Chen and Li, 2018). 
There are many factors that might influence the level of blood loss from these 
mice and several measurements were taken in order to ensure that conditions 




that could affect the level of blood loss unrelated to the activity of platelets were 
kept as consistent as possible (Figure 6.5). Firstly, the weight of the tail that had 
been transected was collected and weighed (Figure 6.5A), and this showed no 
significant difference between the three groups. This indicates that the amount of 
tail transected and therefore the injury sustained was similar in all three groups. 
One confounder is the total body weight of the mice; 1g of tail to a 20g mouse is 
more significant an injury compared to a 30g mouse. For this reason, the ratio of 
transected tail to total body weight was also compared (Figure 6.5B) which again 
revealed no significant difference. Secondly, the circulating haemoglobin 
concentration were compared between all three groups (Figure 6.5C), both at the 
baseline bleeds taken 24 hours before the experiment and in the blood samples 
taken shortly before the experiment to confirm platelet depletion. A vastly different 
haemoglobin concentration may affect the calculations of volume of blood loss as 
it is based upon a haemoglobin assay of the saline that the mice bleed into. There 
was no significant difference between any of the groups at either timepoint, 
indicating that the platelet depletion had no significant effect on the haemoglobin 
levels in the mice. 
Other blood parameters measured in the complete blood counts from these mice 
also showed no difference between the experimental groups apart from in the 
platelet count (Table 6.2), suggesting that the antibody is able to specifically 
deplete platelets and not affect other cell types. This suggests that any significant 
difference is solely due to platelet-related haemostasis and not differences in the 
coagulation cascade. Platelets are known to be a source of cytokines, 
microparticles and other factors, however, so the possibility that there exist other 
indirect consequences of platelet depletion on haemostasis that were not 
measured here remains (Maynard et al., 2007).  
A time course of the remainder of the experiment (Figure 6.6) shows how the rate 
of blood loss slows in all three groups over the twenty minutes of the experiment. 
This may be due to the significant levels of blood loss experienced by the 
depletion only group, and that with a reduced circulating volume, other factors 
such as blood pressure became the primary driving factors behind the rate of 
blood loss. Other possible factors to explain this effect may be the formation of a 
thrombus in all three groups that slowed the rate of blood loss. 
The final experiment in Figure 6.8 shows that the loaded platelets described have 
a significantly (p<0.05) improved haemostatic response in vivo in the first four 
minutes of the experiment. This also appeared biphasic, with the trend being the 
rate of blood loss in the first 12 minutes being much lower in the loaded platelets, 




before speeding up in the latter half of the experiment. The dynamics of the effects 
of loaded platelets on blood loss also appear to be different to the donor platelets 
from the individual timepoint data (Figure 6.9). This might suggest that the loaded 
platelets are being used up in the first part of the experiment, while slowing blood 
loss and maintaining the mouse blood pressure. In the latter part of the 
experiment, this suggests that after having been used up, the mice were able to 
bleed more than the same timepoint of mice transfused with only donor platelets 
as the other group had already lost a large proportion of their circulating blood 
volume. The peak of blood loss present in the depleted mice at eight minutes is 
lessened in magnitude in the mice transfused with donor platelets, and is shifted 
8 minutes to the right in the mice transfused with loaded donor platelets (Figure 
6.9). 
However, it was also noted that the final cumulative blood loss was very similar 
between the unloaded donor platelet transfusion and the loaded platelet 
transfusion groups. This could be a feature of the relatively low number of 
platelets being transfused in this model. With an approximate pre-depletion 
platelet count of 1000x103 platelets/µL and a blood volume of 1mL, this 
represents about 109 platelets in circulation. Comparatively, with a transfusion of 
only 108 platelets, or 10% of the original platelet count, this may not be sufficient 
to restore full haemostasis. This low number of platelets was chosen to amplify 
any differences between the groups, while still being sufficient for some degree 
of haemostasis. It would be difficult to assess differences between the groups 
when all of them have little-to-no bleeding as observed with the undepleted 
controls (Figure 6.6A), or when all groups bleed profusely and was chosen as in 
humans a platelet count of 100x103/µl is clinically sufficient for haemostasis. This 
may mean however that all of the circulating platelets given by transfusion were 
used up in the first four minutes, or technical issues such as clots being dislodged 
when moving from one tube to another may have an effect on the later timepoints.  
Alternatively, the effect of rFVIIa being at the very initiation of the clotting cascade 
(Figure 1.11) may imply it is specifically this initial part of the clotting process that 
is being accelerated. Evidence of this is that the rate of blood loss appears to be 
steady for the group transfused with donor platelets only (Figure 6.8 and Figure 
6.9), while the rate of blood loss appears to be biphasic with an inflection point at 
12 minutes for the group transfused with loaded donor platelets with the first 12 
minutes progressing much more slowly and the latter 12 minutes increasing, 
suggesting that the loaded platelets are being used up in the first half of the 
experiment. 




Figure 5.14 suggests that perhaps a small amount of rFVIIa is released without 
agonist stimulation from these platelets. Although this would likely be diluted by 
the blood volume of the mouse compared to the targeted delivery of the rFVIIa to 
the site of bleeding and would not result in a therapeutic dose if administered at 
this level directly to the mice, it may be prudent to include this as another control 
group if this experiment were to be repeated with rFVIIa-loaded platelets. 
Overall, inducing a thrombocytopenia is possible, specifically depleting mouse 
platelets for 48 hours while not affecting any other blood parameters. The 
antibody used does not cross-react with human platelets. This creates a 
significant bleeding phenotype in these immunodeficient mice. Human platelets 
can be transfused into this model, survive in the circulation for the length of the 
experiment and have a significant effect on reducing bleeding in mice.




7 FINAL DISCUSSION 





Platelets, being small anucleate cells with granules that are released upon 
activation, have great potential as a novel drug delivery system. The benefits of 
this approach include the ability to potentially improve the safety profile and 
reducing the required dose of drugs that are already in clinical use, by only 
exposing the active drug in areas of platelet activation, to eventually provide 
significant improvements over currently available treatments. 
As platelets normally activate in areas of thrombus formation, rFVIIa was chosen 
as a candidate to augment the thrombotic potential of platelets selectively in areas 
of bleeding for the treatment of acute haemorrhage. This project aimed to develop 
tools to load platelet granules with rFVIIa, assess the success of this and their 
efficacy for the treatment of bleeding in vivo as a proof-of-concept for using 
platelets as a delivery system. This was done through exploring the two routes 
that proteins normally take for trafficking to platelet granules, synthesis and 
endocytosis. 
7.2 Loading platelet granules with non-endogenous proteins 
 Loading platelet granules through an expression cassette in a 
forward-programmed megakaryocyte system 
Firstly, a modified form of the FVII was designed, cloned and transduced into 
FoPMKs. The transduction of FoPMKs was shown to be successful through a 
variety of techniques including ELISA, flow cytometry, Western blot and IF. The 
modified FVII was then localised using IF into granules within these FoPMKs. 
ELISA data also suggested that the modified FVIIa was present in the resultant 
platelets in the supernatant and flow cytometry was used to demonstrate further 
that the platelets produced by these MKs in a liquid culture system contained this 
modified protein. 
The importance of these results lies in the generalisability of the targeting system 
used. Previous work had only showed that when fused to FVIII that the resultant 
fusion protein ended up in granules in ex vivo megakaryocytes from dogs (Du et 
al., 2013). Work by Dr Annett Mueller from the Ghevaert group showed that this, 
when fused to GFP could be used to load platelet granules more generally, and 
that this was not specific to only FVIII. 
Evidence in this thesis has shown that it is possible to load arbitrary clotting 
factors such as rFVIIa, but also that cleavage sequences such as a thrombin 
cleavage site can be inserted to result in the release of the original protein from 




the vWF-based targeting system upon activation. Finally, the data here has 
elucidated how this targeting strategy affects the subtype of α-granule that these 
proteins may be targeted to, which has previously not been investigated. 
 Validation of the functionality of the modified FVII 
After having verified the presence of the modified FVII structurally, it was then 
validated functionally. First, Western blots were used to show that the addition of 
exogenous enzyme was able to cleave the modified FVII at the appropriate 
inserted cleavage sequences. Thrombin alone was sufficient to cleave the full-
length protein into the heavy and light chain seen in the native rFVIIa, thought to 
be due to the presence of intracellular furin in the lysates. 
Next, thrombin generation assays showed a clear difference between the 
platelets produced by the FoPMKs transduced with the vWF-F7TF compared to 
donor platelets and those produced from untransduced FoPMKs. This was 
notable both in the raw thrombin generation graphs at intermediate 
concentrations of platelets, but also in the calculated EC50 values derived from 
the concentration curve of platelets when observing the total thrombin generation 
from this assay. 
The trends shown in all parameters of this assay suggest that the platelets 
produced from transduced FoPMKs are able to generate more thrombin, and 
therefore form clots more rapidly, than those from untransduced FoPMKs and 
donor platelets. However, this is an in vitro model system to recreate the process 
of clotting and so caution should be taken when interpreting this result for 
translation to in vivo models. 
Importantly, this also demonstrates that the proteins delivered using this system 
such as FVIIa do not undergo such irreversible structural changes due to the 
addition of the large (~40kDa) vWF SPD2 domain as to render them non-
functional. This suggests that, when scaled up in the future, this would create 
platelets containing a version of FVII that would convert into its native active 
enzymatic form upon platelet activation and subsequently have an effect on 
thrombin generation, as the Western blot data suggests that without thrombin this 
does not take place. This may then provide a further safety mechanism for this 
drug over the commercially available rFVIIa, in requiring thrombin to be present 
before the rFVIIa is enzymatically active in its native form. 




 Endocytosis as a technique to load platelet granules 
Platelets were shown to be able to directly endocytose rFVIIa into their granules 
through a short incubation at room temperature, and the efficacy of these loaded 
platelets was demonstrated in releasate assays and in thrombin generation 
assays (chapter 5). Flow cytometry was used to demonstrate that platelets are 
able to directly endocytose and internalise the protein, and ELISA was used to 
show that they are able to release it upon stimulation with thrombin. Thrombin 
generation assays showed similar results to those seen from the platelets loaded 
through the expression cassette, with a higher total thrombin generation observed 
at intermediate concentrations from the raw thrombin generation graph as well as 
a reduction in the EC50 for these loaded platelets compared to donor platelets. 
Difficulty remains in directly comparing the activity of the rFVIIa in these platelets 
loaded through endocytosis with those from the lentiviral transduction, as the 
amount of protein absorbed or synthesised per granule or platelet is likely subject 
to considerable variation between the two systems. However, despite this caveat, 
the reduction in EC50 values appears similar. 
Importantly, taken together with the results from the expression cassette, this 
shows that this effect on total thrombin generation is caused by the selective 
release of rFVIIa by platelets in response to thrombin, regardless of the very 
different techniques used to actually load the granules.  
 Demonstrating the in vivo potential of loaded platelets 
Finally, the most important finding of this work was that these loaded platelets 
demonstrate efficacy in an in vivo model of haemostasis. The platelets loaded by 
endocytosis might be predicted to result in a faster rate of clot formation from the 
faster, sharper peak seen from the thrombin generation assay. The result from 
this in vivo was demonstrated to result in a significant (p<0.05) reduction in blood 
volume loss in the first 4 minutes from a transfusion and tail transection model in 
vivo (chapter 6). 
This work builds on all the results of previous chapters in demonstrating that the 
effects seen from these loaded platelets from in vitro assays translate to an in 
vivo system, opening the door to encourage the development of even more 
sophisticated techniques to generate these platelet products at scale to address 
some of the current issues with platelet transfusion and rFVIIa administration. 




7.3 Further work 
 How much rFVIIa is present in loaded platelet granules? 
One question that remains relating to this work is in accurately quantifying how 
much of the protein is packaged into each granule or into each platelet. This would 
help to compare the effective doses of loaded platelets with the doses of rFVIIa 
used in the literature in clinical trials (Gill et al., 2009). This would also help in 
estimating the high local concentration of rFVIIa generated in areas of platelet 
activation and allow further mathematical modelling of this. 
The total amount may vary from platelet to platelet, and likely will need to be 
standardised for each preparation as some granules may contain more rFVIIa 
than others, and some platelets may contain more granules than others. The 
techniques used to load the platelets may also affect this, as suggested by the IF 
data in Figure 5.9 showing few granules in MKs loaded through endocytosis, 
compared to Figure 3.20 loaded through the expression cassette showing many 
more granules positive for rFVIIa per megakaryocyte. 
Finally, this could then be used to directly quantify the effective dose of rFVIIa 
required for efficacy compared to the current standard for treatment to test the 
hypothesis that the rFVIIa is delivered to create a high local concentration of the 
protein in areas of bleeding and that this has a similar effect in vivo to systemically 
dosed rFVIIa. This also raises the question of whether the FVIIa released by 
loaded platelets remains bound to the platelet surface or if it is released into the 
interstitial space. 
 Do loaded platelets continue to keep rFVIIa sequestered in vivo? 
The data in chapter 5 showed that even the no thrombin condition of loaded 
platelets, expected not to have any FVII in their releasate, did show a small 
amount of FVII detected. Questions that remain to be explored are whether this 
is significant in vivo, whether this matters for the safety of loaded platelets and 
whether the platelets are able to only release the rFVIIa at sites of bleeding or if 
they release the rFVIIa in other locations. 
This observed FVII in the supernatant may have been left over from an incomplete 
washing of the excess rFVIIa, or it may have been released from the loaded 
platelets themselves. The latter may occur due to accidental activation of the 
platelets, for example, through mechanical manipulation, or perhaps it may 
represent a situation where the contents of these granules are somewhat leaky 
to the extracellular compartment. This effect has been previously observed in the 




spontaneous release of neurotransmitters from synaptic granules in neurones 
(Fatt and Katz, 1950; Kavalali, 2018). Platelet granules, being similar to synaptic 
vesicles in many respects, may undergo similar processes. 
Theoretically, despite this apparent leakiness of the platelet granule contents, the 
efficacy of the loaded platelets should derive from a high local concentration of 
rFVIIa in areas of platelet activation, and a dilution to very low plasma 
concentrations in the general circulation. This would however require further work 
and different mouse models to address and to quantify its impact. 
 How are the different granule populations formed and do they 
undergo differential release? 
The immunofluorescence data from chapters 3 and 5 raise questions about the 
trafficking of proteins in megakaryocytes, and implies that the sorting of proteins 
in these cells is not as linear as has been previously assumed. For example, 
although the vWF-SPD2 fragment attached to GFP results in GFP expression 
from thrombospondin-containing granules (Figure 3.1), the same vWF-SPD2 
fragment attached to FVII does not (Figure 3.20). Instead, this appears to direct 
the fusion protein to an alternative subpopulation of granule that contains VEGF 
but not thrombospondin or endostatin. Some papers suggest that the different 
subpopulations serve antagonistic functions (pro- and anti-angiogenic), and are 
released in response to different agonists, although both appear to be released 
upon exposure to thrombin (Italiano et al., 2008). An open question remains as to 
how the FVII portion of the protein is able to partially override the vWF-SPD2 
portion of the domain, given the size of this fragment, and whether this may be 
differentially released in response to certain agonists. 
Although GFP was expressed in the cytoplasm when the SPD2 domain is 
removed, the same cannot be said for FVII without this domain. Despite being at 
a high titre when detected by qPCR in HCT116 cells (Figure 3.8), attempts to 
detect the resultant protein by Western blot and flow cytometry in FoPMKs failed. 
This may suggest that the protein is somehow being degraded and being taken 
directly to the proteosome, or that it is being misfolded and thus not binding to the 
antibody or that its expression is being silenced, which may be how in vivo, certain 
coagulation factors such as Factor V are expressed by MKs whereas others such 
as Factor VII are not (Maynard et al., 2007). 
The vWF-F7TF protein produced was also not present in every granule containing 
VEGF. There was a population containing both, as well as population of granules 




containing either one or the other. This might imply some stochasticity to the 
distribution and sorting of proteins into granules, with some granules ending up 
with more of certain proteins than others, and other studies have previously found 
little functional co-clustering of proteins within α-granules (Kamykowski et al., 
2011). Another explanation for this is that the expression of GFP was measured 
using direct fluorescence compared to the expression of vWF-F7TF, measured 
using immunofluorescence. The use of antibody staining may make the 
immunofluorescence technique more sensitive to the amount of protein present 
in a way that the direct fluorescence methodology is not. 
Finally, when comparing the synthesis route compared to the endocytosis route 
looking only at the MKs, the number of granules staining positive for FVII when 
the MKs are incubated for 24 hours with the protein remain small compared to the 
number detected when the vWF-F7TF is expressed through lentiviral 
transduction. There also appears to be some evidence of platelet heterogeneity 
in the literature (Kempton et al., 2005). Combined with the stochasticity of the 
vWF-F7TF produced through synthesis and the limited number of granules 
observed through endocytosis, there also appears to be some evidence of this 
heterogeneity from data in this thesis. 
7.4 Future perspectives and challenges 
 Genomic safe harbour integration 
The construct introduced in chapter 3 may be introduced into a genomic safe 
harbour site in the inducible FoPMKs to result in an inducible stem cell line that 
can be forward programmed to produce rFVIIa-loaded platelets.  
Challenges that remain with this approach include the need to discover novel safe 
harbour sites for this insertion to take place. The doxycycline inducible FoPMK 
system currently makes use of both well-characterised safe harbour sites, AAVS1 
and ROSA26. Insertion of a third sequence would require the discovery of another 
reliable safe harbour sequence that remains immune to silencing effects when 
the iPSCs are differentiated into FoPMKs, and this discovery could be attempted 
using a gene-trap approach or follow-up of predicted safe harbour sites from 
whole-genome sequencing studies (Pellenz et al., 2019). 
This approach could be combined with the work in chapter 4 to ensure the 
resultant cell lines remain absent of any known deleterious or dangerous 
mutations and CRISPR used to insert the vWF-F7TF construct into this genomic 
site. Combined with improvements in bioreactor technology and further scaling 




up, this alternative source of rFVIIa-loaded platelets could be evaluated with the 
mouse model established in chapter 6. If this occurs, it will also be necessary to 
explore whether the amount of vWF-F7TF being produced in this system per 
megakaryocyte and per granule is the same as that observed in the lentiviral 
system in order to make an accurate comparison between them. 
 Producing platelets on a larger scale 
This work complements studies looking at novel bioreactor technologies that 
might allow for in vitro-derived platelets to be extracted at a much larger scale 
than is currently possible. Current bioreactor technologies appear to result in 
approximately 10-100 platelets per input MK, even when incorporating 
microfluidic devices and turbulence to recreate the mechanical stresses of MKs 
in bone marrow. Compared to the thousands produced from MKs in bone marrow 
in vivo, this indicates an order of magnitude of improvement is still possible. 
This increase in thrombopoiesis would be necessary to offset the otherwise 
prohibitive costs involved in scaling up MK culture. For a standard human 
transfusion unit of 5x1010 platelets, roughly £200 (NHS Blood & Transplant, 2016), 
at present this would optimistically require the culture of approximately 5x108 
MKs, which when seeded at an optimal concentration of 0.5x106 MKs/mL would 
require approximately 1L of cell culture media, alone already £330 (CellGenix, 
2020), every two days along with associated cytokines. 
Improvements to in vitro thrombopoiesis technologies, e.g. new bioreactor 
designs or additional soluble factors to stimulate platelet release, may address 
some of these issues. From the work in chapter 3, if it is possible to achieve a 
similar haemostatic effect with fewer platelets in a transfusion unit, this may also 
independently bring in vitro derived platelets closer to clinical translation. Key 
considerations for clinical translation are ensuring stem cell-derived therapies are 
safe, effective and affordable, as defined by the International Society for Stem 
Cell Research guidelines from 2016 (Daley et al., 2016). 
The use of CRISPR to integrate these exogenous genetic sequences into the self-
renewing iPSC lines used for differentiation will eliminate the use of lentivirus. 
Lentiviral transduction, although a useful laboratory technique, is often expensive 
to produce and utilise on a large scale for platelet production as well as in a cGMP 
facility, and has safety issues when considering its random genomic integration 
leaves open the potential for a malignant transformation of the FoPMK culture, 
requiring constant screening for abnormal insertion and the presence of 
replication-competent viruses (Milone and O’Doherty, 2018). These have all been 




documented issues when other therapies such as with chimeric antigen receptor 
(CAR) T-cells in the field of cancer immunotherapy (Oldham, Berinstein and 
Medin, 2015). Elimination of lentivirus would simplify the culture process to be 
fully inline, allowing it to take place fully in a CL1 facility and render vWF-F7TF 
MK culture more scalable by reducing the costs and number of reagents required, 
complexity of cell culture, allowing it to more easily be translated into a cGMP 
facility and the quality assurance thereafter would be more straightforward. 
When combined with other work looking to knockout B2M and render platelets 
immuno-compatible with a large number of people, it is possible that in the future 
there will be one cGMP-compliant stem cell line engineered with all of the 
appropriate modifications to be able to produce platelets that do not require HLA-
matching and provide additional benefits such as rFVIIa delivery compared to 
platelets from donor blood. A similar approach has been taken with B2M 
knockouts to generate universally immuno-compatible CAR T cells (Ren et al., 
2017). 
 In vivo modelling of haemostasis 
One limitation of the work in this thesis is that much of the work is either with in 
vitro models that attempt to recreate the process of clotting (such as the thrombin 
generation assay) and in vivo work that takes place in a model system in mice 
that has limitations in its applicability to human platelet transfusion in a clinical 
context. For example, the main readout of the tail transection assay was the first 
four minutes of blood loss. The later time points appeared less informative due to 
three possible sources of experimental error. The significant percentage of 
circulating blood volume being lost is likely to have affected the blood pressure at 
later time points in the assay, which makes a direct comparison of blood volume 
lost between timepoints difficult. Any clot formed may have been dislodged by the 
movement of the tail from one tube to another. This makes later time points more 
unreliable, and measurement errors compound when measuring cumulative 
blood loss through this technique. Other mouse models may need to be explored 
to investigate these effects further, such as those looking at platelet survival 
(Fuhrmann et al., 2016). 
The purpose of the in vivo model explored here is very different to and does not 
attempt to model long-term safety due to technical limitations, not least being that 
the mice are terminated within twenty minutes of the transfusion. Even in an 
immunocompromised mouse model, human platelets are cleared within hours 
without the addition of other substances such as clodronate liposomes which 




deplete macrophages and may alter the physiology of the mice in other ways, 
which may alter the behaviour of these platelets compared to if they were 
transfused into a human patient (Newman, Aster R and Boylan B., 2007). These 
factors make it difficult to assess the incidence of increased thrombosis (e.g. in 
heart attacks and cerebrovascular accidents) with this form of therapy. As a key 
consideration of the use of rFVIIa in the clinic is the safety profile, especially when 
approaching regulatory agencies for these therapies. There is, however, a 
theoretical benefit of being able to use a lower overall dose of the drug and 
therefore reduce the incidence of adverse events. Future work may look at other 
in vivo models of haemostasis that also look at the safety aspects of these 
products. 
 Clinical trials 
As was previously described in the introduction (section 1.5), current treatments 
for acute haemorrhage involve blood products such as fresh frozen plasma, 
activated prothrombin complex concentrates, as well as platelet transfusion. The 
addition of donor platelets loaded through endocytosis as a therapeutic option 
may provide another product that could be derived from blood donors. This may 
allow for the transfusion of fewer platelets, resulting in less immune sensitisation 
of the recipient and allow the current limited platelet supply to treat more patients 
than is possible at present. 
Many of the surgical tools used for haemostasis also require a knowledge of 
where the bleeding is occurring from (Behrens, Sikorski and Kofinas, 2014). A 
targeted therapy that can be administered systemically could provide benefits 
over these current treatments for patients bleeding from an unknown source and 
as demonstrated in the in vivo model, where the tail transection was carried out 
immediately after transfusion, a significant difference was observed in the first 
four minutes of bleeding. 
For patients receiving rFVIIa in an acute setting for haemorrhage that likely will 
also require a transfusion at some point, the targeted delivery of this drug with the 
transfusion may result in a much lower dose of the drug being required to observe 
a benefit. The increased cost-effectiveness for rFVIIa that may justify its use more 
often clinically. This technique could also offer potential safety benefits through a 
reduction in thrombotic events as has been observed with the comparatively high 
doses of rFVIIa currently in clinical use.  
This could provide an ideal patient population with which to use this as an 
intervention in a clinical trial setting. Blood products are already common 




treatments for haemorrhage and so this may offer an opportunity to assess safety 
and efficacy of these products when compared to standard therapies that have 
known adverse events, allowing for the maintenance of clinical equipoise. 
The double-blinded control arm could be the current standard of trauma care with 
normal donor platelets used as a transfusion when required, while the 
experimental arm could be transfusion with these loaded platelets. The outcomes 
measured in such a trial would be the number of units of platelet transfusion 
required and quantity of blood loss as intermediate endpoints, as well as the 
percentage survival of these patients as an endpoint. Platelets have an advantage 
over other therapeutics in that they can also be removed quickly through 
plasmapheresis if any adverse events were detected with these loaded platelets. 
 Platelet granules as a drug delivery system beyond rFVIIa 
In this thesis, only rFVIIa was used as a payload for these platelets. This will 
however pave the way for further possible cargo proteins suitable for delivery. 
Example of some of these possibilities include the delivery of thymosin β4, shown 
in in vitro cultures to stimulate cardiomyocyte regeneration to areas of infarcted 
myocardium where platelets have been observed to accumulate (Shrivastava et 
al., 2010). Platelets might also be used to deliver anti-thrombotic agents to 
existing clots, such as tissue plasminogen activator (t-PA) (Greineder et al., 
2013). Due to their important immunomodulatory and angiogenic roles, platelets 
are often recruited by tumours and so there exist opportunities to deliver cytotoxic 
agents to certain cancers (Labelle, Begum and Hynes, 2014). Some of this has 
been attempted through covalent linkage of anti-PD1 antibodies to the surface of 
platelets, but it may be possible to further sequester these agents within platelet 
granules to further reduce their off-target effects (Zhang et al., 2018). 
This versatility is likely to provide a significant competitive advantage to in vitro-
derived platelets compared to other efforts to develop synthetic platelet 
alternatives based on nanoparticles which may not share the same biological 
interactions as real platelets and often depend on materials that, unlike stem cells, 
are not able to self-renew which may drive costs up (Shukla et al., 2017). 
Potential ways in which platelets could be used as a drug delivery system include 
being targeted to areas where platelets normally degranulate (Figure 7.1A), e.g. 
in coagulation or other instances where there is endothelial damage, such as 
myocardial infarction (Gidlöf et al., 2013).  Platelets could also be engineered to 
express receptors that bind proteins of interest from the blood preventing their 
action, and as they last for up to ten days, be more effective than antibodies  




(Figure 7.1B). Both of these could be coupled together to result in a targeted 
delivery system that could degranulate in response to a particular stimulus or 
context, such as in tumours using the Warberg effect, or at times of high sugar in 
diabetes  (Figure 7.1C). Finally, the platelets may simply be used to protect 
recombinant proteins from degrading in the blood, which might be especially 
useful in diseases where enzymes are missing from the blood, e.g. inborn errors 
of metabolism  (Figure 7.1D). 
 












Overall, this thesis demonstrates two methods for successfully loading platelet α-
granules with FVIIa, lentiviral transduction of their precursor megakaryocytes 
(with methods developed to assess off-target effects of CRISPR if integrated into 
a genomic safe harbour site) and direct endocytosis by platelets. Both techniques 
result in platelets that show improved haemostatic properties with in vitro assays. 
A novel mouse model for human platelet transfusion and subsequent 
haemostasis was established using immunocompromised thrombocytopenic 
NRG/J mice and this was subsequently used to show an improvement in 
haemostasis following transfusion of platelets loaded with rFVIIa.  
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